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Summary
Cardiovascular diseases remain the number one cause for morbidity and mortality
worldwide  with  an  estimated  half  of  cardiovascular  disease-related  deaths  being
attributed to cardiac arrhythmia. Despite this enormous importance for public health,
existing antiarrhythmic drugs are still far from being ideal as they display perilous
side effects and can not be administered over extended time periods. It is thus a
major endeavor of cardiovascular research to identify novel safer drug targets and
therapeutic strategies for the treatment of cardiac arrhythmia.
Since  cardiac  rhythmicity  is  directly  dependent  on  a  tight  regulation  of
intracellular Ca2+ and cardiac arrhythmia is  often associated with disturbances in
Ca2+ homeostasis,  we  used  an  unbiased  approach  to  identify  novel  regulators  of
cardiac  Ca2+ handling  and  modulators  thereof.  A  library  of  newly  synthesized,
organic-like  compounds was screened for  their  ability to restore rhythmic  cardiac
contractions  in  a  zebrafish  model  for  cardiac  fibrillation.  From  this  screen  we
identified the small ester compound efsevin, which binds to the voltage-dependent
anion channel 2 (VDAC2) in the outer mitochondrial membrane. We demonstrated
that treatment with efsevin enhances mitochondrial Ca2+ uptake and thereby prevents
propagation of spontaneous intracellular Ca2+ release events in cardiomyocytes, the
triggers for ectopic excitations and arrhythmia. Since this work presented a novel role
for  VDAC2  in  cardiomyocytes  we  analyzed  the  structure  of  VDAC2  by
crystallography  to  identify  elements  that  promote  specificity  of  this  isoform over
VDAC1 and VDAC3. Though we could not detect large structural differences, we
identified moieties that interact with regulatory proteins, which differ between the
isoforms, and could thus explain the distinct role of VDAC2 in cardiomyocytes. We
then used the crystal structure of VDAC2 to identify the binding site of efsevin by
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computational modeling and identified a binding pocket located between the wall of
the  VDAC2  pore  and  the  pore-lining  α  helix,  that  was  previously  suggested  to
promote  channel  gating.  In  planar  lipid  bilayers  we  demonstrated  that  efsevin
promotes gating of the channel from an anion-selective high conductance state into a
more  cation-selective  low  conductance  state,  thereby  explaining  the  enhanced
mitochondrial Ca2+ uptake induced by efsevin.
To analyze the translational potential of efsevin, we tested efsevin in experimental
models for the human cardiac arrhythmia catecholaminergic polymorphic ventricular
tachycardia (CPVT). Efsevin reduced spontaneous diastolic Ca2+ signals and action
potentials  in  cardiomyocytes  isolated  from CPVT  mice  and  significantly  reduced
episodes  of  ventricular  tachycardia  in  in  vivo.  Furthermore,  efsevin  reduced
spontaneous,  diastolic  Ca2+ signals  in  induced  pluripotent  stem  cell  derived
cardiomyocytes from a CPVT patient. Because efsevin lacks several features essential
for druggability like e.g. a nanomolar affinity to the target and key pharmacokinetic
properties like oral bioavailability, we then screened a library of clinically approved
compounds  for  additional  mitochondrial  Ca2+ uptake  enhancers.  We  identified
increased uptake of Ca2+ into mitochondria of cardiomyocytes upon treatment with
either the cholesterol uptake inhibitor ezetimbe or disulfiram, used for the treatment
of alcohol abuse. Both were active at significantly lower concentrations compared to
efsevin and showed efficacy experimental models for cardiac arrhythmia.
Taken together, this thesis (i) establishes the outer mitochondrial membrane as a
regulated  barrier  for  Ca2+,  (ii)  establishes  mitochondrial  Ca2+ uptake  as  a  novel
regulator of cardiac rhythmicity and (iii) provides a novel candidate structure and
lead substances for the development of a treatment for human cardiac arrhythmia.
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Introduction
Therapy of cardiac arrhythmia
Cardiovascular  diseases  (CVDs)  continue  to  dominate  mortality  and  morbidity
rates worldwide (Nichols et al., 2012; Benjamin et al., 2018). Despite a general decline
of CVD-associated deaths over the last years, mortality rates for cardiac arrhythmia
in particular are still increasing (Klawki et al., 2018). Almost half of all CVD related
deaths  are  attributed  to  sudden  cardiac  death  mainly  caused  by  ventricular
tachyarrythmias (Mehra, 2007). This is in part due to the insufficiency of currently
used antiarrhythmic drugs, which display perilous side effects and are thus difficult to
apply.
Cardiac  arrhythmias  originate  at  focal  areas  in  the  myocardium  induced  by
structural abnormalities, such as infarct wounds and anatomical obstructions, or as a
result  of  physiological  abnormalities  such  as  a  disturbed  cellular  ion  homeostasis
(Figure 1). The latter might be caused by maladaptations of  the mycardium to
preexisting conditions like heart failure, ion channel mutations, or drug intake. The
resulting  focal  activity  of  the  myocardium  gives  rise  to  a  propagating  ectopic
excitation  wave  along  the  heart  and  creates  a  reentry  circuit,  the  physiological
underpinning of tachycardias.
Commonly  used  antiarrhythmic  drugs  of  Vaughan  Williams  classes  I-IV  and
cardiac  glycosides  directly  or  indirectly  target  ion  channels  in  the  cardiomyocyte
membrane to modify the cardiac conduction system and thereby block expansion of
ectopic excitations along the myocardium (Figure 1). However, by blocking cardiac
de- or repolarization and thereby modulating cardiac conduction speed all of these
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drugs, with the exception of beta blockers, are prone to proarrhythmic and negative
inotropic side effects. It is thus a major focus of cardiovascular research to identify
novel targets and strategies for a safer treatment of cardiac arrhythmia.
A major line of research for the development of such therapies lies on intracellular
target  structures,  in  particular  the  cellular  Ca2+ handling  network,  but  not  only
because cardiac arrhythmias are often associated with disturbances in cellular Ca2+.
Also, by targeting intracellular structures the cardiac action potential is expected to
remain unaffected and therapies targeting intracellular structures could thus be less
prone to proarrhythmic side effects.
Figure 1. Cardiac arrhythmogenesis and treatment. Ca2+-associated arrhythmias
are triggered by the spontaneous release of Ca2+ during diastole (1). This spontaneous Ca2+
release triggers the influx of Na+ (2) through NCX and finally a spontaneous depolarization
of  the  cardiomyocyte  (3).  This  diastolic  excitation  is  propagated  along  the  electrical
syncytium  of  the  myocardium  and  triggers  an  ectopic  beat  (4).  Currently  used
antiarrhythmic drugs of Vaughan-Williams classes I,III, and IV target ion channels in the
myocardium  to  prevent  propagation  of  the  excitation  (3,4)  rather  then  targeting  the
intracellular origin of the arrhythmia (1).
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Cardiac Ca2+ cycling and arrhythmia
Cardiac rhythmicity and contractility critically depend on a tight regulation of
intracellular Ca2+ in the cells of the myocardium, the cardiomyocytes. During diastole
the concentration of resting Ca2+ inside the cell is in the low nanomolar range, while
the  cell  is  extracellularly  surrounded  by  approximately  2  mM Ca2+  (Bers,  2008;
Fearnley  et  al.,  2011).  In  this  phase  the cell  maintains  a  membrane  potential  of
approximately -80mV. During systolic excitation the cell is depolarized to roughly 20-
30 mV causing L-type Ca2+ channels to open and Ca2+ to passively enter the cell. The
L-type Ca2+ channels are located in clusters inside the t-tubuli, deep invaginations of
the cell membrane into the cellular lumen. The t-tubular membrane is tightly coupled
to the membrane of  the sarcoplasmic reticulum (SR),  the main Ca2+ store inside
cardiac muscle cell. Inside these couplons the L-type Ca2+ channel clusters in the t-
tubular membrane are closely juxtaposed to clusters of ryanodine receptors (RyRs)
on the surface of the SR. In a process called Ca2+-induced Ca2+ release (CICR) Ca2+
entering the cell through L-type channels binds to RyRs causing them to open and to
release large amounts of Ca2+ from the SR into the cytosol. The transient rise in
intracellular Ca2+ leads to activation of the myofilaments and consecutively muscle
contraction. Thereafter, Ca2+ is actively extruded from the cell by the sarcolemmal
Na+/Ca2+ exchanger NCX and pumped back into the SR by the sarco-/endoplasmatic
reticulum Ca2+ pump (SERCA) to return to resting conditions (for a review see Bers,
2002).
Certain  conditions  such  as  mutations  in  ion  channels,  imbalances  in  ion
homeostasis or defects in post-translational regulation can lead to uncontrolled Ca2+
fluxes in the cell. Erratic Ca2+ release during diastole induced by mutations in RyR or
due  to  elevated  cytosolic  Ca2+ levels  can  be  the  trigger  for  severe  arrhythmias
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(Figure  1).  Specifically,  individual  clusters  of  RyRs  on  the  surface  of  the  SR
spontaneously activate during diastole and release small quantities of Ca2+ from the
SR as  a  locally  restricted  event.  These  elementary  Ca2+ release  events  were  first
discovered by using Ca2+ sensitive dyes and were contiguously named Ca2+ sparks
(Cheng et al., 1993). Once the rate of Ca2+ sparks reaches a certain threshold, Ca2+
from one spark activates the neighboring cluster of RyRs and a saltatory expansion of
Ca2+ inside the cells occurs, called a Ca2+ wave. The elevated level of Ca2+ inside the
cell  drives NCX through which Na+ enters the cell  in a 1:3 Ca2+ over Na+ ratio,
yielding a net influx of positive charges, and thus depolarization of the cell (Allen et
al., 1984). If sufficiently large these delayed afterdepolarizations (DADs) can spread
along the myocardium and cause ectopic excitations and finally arrhythmia.
Regulation of cardiac Ca2+ cycling
 Apart from these main players, a plethora of regulatory proteins and pathways
fine  tune  intracellular  Ca2+ handling  to  guarantee  a  meticulously  regulated  Ca2+
homeostasis at rest and during adaption to higher workload.
These Ca2+ regulatory mechanisms range from post-translational modifications of
the key players such as the L-type Ca2+ channel or the RyR, to additional regulatory
proteins such as subunits of these channels or structural proteins, which anchor the
essential cell compartments together to finally entire organelles that interact with the
aforementioned cellular structures.  For  example,  lysosomes and mitochondria were
both described to form close contacts to the SR at Ca2+ release sites and to vividly
interact  with  the  SR  (Hajnóczky  et  al.,  2000;  Aston  et  al.,  2017).  Especially
mitochondria were shown to be capable of sequestering large amounts of Ca2+ into
their matrix (Hajnóczky et al., 2000).
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These regulatory mechanisms are still under intensive research and while some of
them are well  described, others were just  recently discovered and are still  poorly
understood. However, these intracellular regulatory mechanisms bare the potential to
serve as novel drug targets, since they have the power to modulate and regulate Ca2+
release and by this  to  suppress  erratic  Ca2+ release without  affecting the cardiac
conduction system.
The central thesis of the project
In  this  work  we  present  mitochondrial  Ca2+ uptake  as  a  novel  regulatory
mechanism of cardiac rhythmicity and a potential drug target.
By applying an unbiased screening approach we identified the novel compound
efsevin by its ability to restore rhythmic cardiac contractions in otherwise fibrillating
heart  of  a  zebrafish arrhythmia model  (Shimizu et  al.,  2015).  A pull-down assay
identified the voltage-dependent anion channel 2 (VDAC2) to be the target of efsevin.
VDAC2 is a large pore forming protein in the outer mitochondrial membrane, which
in cardiomyocytes is positioned in close proximity to the Ca2+ release sites of the SR.
It is composed of a β-sheet barrel and a pore-lining α-helix that was proposed to be
responsible for channel gating (Schredelseker et al., 2014). Efsevin binds to the hinge
region of this helix and facilitates gating of VDAC2 from the open state into less
anion selective gated states and thereby enhances influx of Ca2+ into mitochondria
(Wilting et al., 2020).
With this data, we formulated the following central hypothesis: Arrhythmogenic
signals in cardiomyocytes are generated by erratic diastolic Ca2+ release starting with
a Ca2+ spark, the spontaneous opening of a single cluster of RyRs (Figure 2). Under
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pathological conditions Ca2+ released from this elementary event triggers opening of
neighboring  Ca2+ release  sites  to  initiate  an  arrhythmogenic  Ca2+ wave,  which
propagates  along  the  cardiomyocyte.  Mitochondria,  which  are  located  in  close
proximity to the Ca2+ release sites of the SR, have the ability to take up Ca2+ and
thereby provide a Ca2+ buffering compartment to shape cellular Ca2+ signals. When
mitochondrial Ca2+ uptake is pharmacological activated a fraction of the released Ca2+
is  buffered into mitochondria leading to a spacial  and temporal restriction of the
spark.  By this mechanism the cell  can tolerate a higher spark frequency without
generation of arrhythmogenic Ca2+ waves (Figure 2).
Figure  2.  Model  for  mitochondrial  Ca2+ uptake  mediated  suppression  of
arrhythmia. Ca2+ released by the spontaneous opening of a cluster of ryanodine receptors
(RyR)  during  diastole  diffuse  laterally  inside  the  cytoplasm  and  induces  saltatoric
propagation of a Ca2+ wave by activating neighboring Ca2+ release units (orange arrow).
Upon activation of mitochondrial Ca2+ uptake the Ca2+ signal is buffered into mitochondria
and the saltatoric propagation is interrupted (green arrow).
To prove this hypothesis we evaluated the effect of efsevin on Ca2+ sparks and
waves  in  ventricular  cardiomyocytes.  Indeed,  efsevin  enhanced  cytosolic  Ca2+
clearance and thus led to a spatial and temporal restriction of individual Ca2+ sparks
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(Shimizu et al., 2015; Schweitzer et al., 2017). Thereby it suppressed the generation of
Ca2+ waves and finally arrhythmogenic action potentials in these cells. This effect was
blocked in the presence of the mitochondrial Ca2+ uptake inhibitor Ru360. To prove
the general validity of this hypothesis we identified and tested distinct enhancers of
mitochondrial  Ca2+ uptake  (MiCUps)  acting  on  different  proteins  within  the
mitochodrial Ca2+ uptake complex (Schweitzer et al., 2017, Sander et al., submitted).
Independent of the molecular target all of these enhancers suppressed arrhythmogenic
Ca2+ waves in cardiomyocytes.
This  mechanism  was  potent  enough  to  suppress  arrhythmogenesis  also  in
translational models for human cardiac arrhythmias (Schweitzer et al., 2017, Sander
et al., submitted). In catecholaminergic polymorphic ventricular tachycardia (CPVT)
a increased propensity of spontaneous SR Ca2+ release induced by mutations in RyR
leads to the occurrence of episodes of life-threatening ventricular tachycardia under
physical or emotional stress. In cardiomyocytes from a CPVT mouse model MiCUps
significantly suppressed arrhythmogenic Ca2+ waves and action potentials. MiCUps
also reduced episodes of ventricular tachycardia in CPVT mice in-vivo and efficiently
suppressed  arrhythmogenic  Ca2+ waves  in  induced  pluripotent  stem  cell  derived
cardiomyocytes from a CPVT patient.
Taken  together,  this  thesis  presents  a  novel  regulatory  mechanism  in
cardiomyocytes  which  can  be  pharmacologically  activated  to  suppress
arrhythmogenesis.  It  is  potent  enough  to  suppress  arrhythmia  in  translational
arrhythmia  models  and is  thus  a  promising  candidate  for  future  pre-clininal  and
clinical studies.
In the following chapter the key steps leading to the success of the project are
discussed coherently.
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Coherent discussion of individual project related 
publications
Identification  of  VDAC2  as  a  novel  regulator  of  cardiac
rhythmicity
Shimizu, H.*, Schredelseker, J.*, Huang, J.*, Lu, K.*, Naghdi, S., Lu, F., Franklin, S., Fiji, H.
D.,  Wang, K.,  Zhu, H., Tian, C.,  Lin,  B.,  Nakano, H.,  Ehrlich, A., Nakai,  J., Stieg, A. Z.,
Gimzewski, J. K., Nakano, A., Goldhaber, J. I., Vondriska, T. M., Hajnóczky, G., Kwon, O., and
Chen,  J.-N.  (2015)  Mitochondrial  Ca2+ uptake  by  the  voltage-dependent  anion  channel  2
regulates cardiac rhythmicity. Elife. 4, e04801 (*...shared first authorship)
With the aim to identify novel  candidate structures  for a safer  antiarrhythmic
therapy, we set out to screen for novel cellular regulators of cardiac rhythmicity and
chemical modulators thereof through an unbiased approach. To this aim we used the
zebrafish cardiac fibrillation model  tremblor (tretc318). Homozygous  tremblor embryos
carry a null-mutation for a cardiac specific isoform of the Na+/Ca2+ exchanger NCX
(Ebert et al.,  2005; Langenbacher et al.,  2005) and are characterized by a hyper-
contracted myocardium with only chaotic contractions. We used these embryos to
screen a diversity-oriented library of approximately 200 newly synthesized organic-like
compounds.  One  compound,  hereafter  called  efsevin,  potently  restored  rhythmic
cardiac contractions in  tremblor hearts. Using a pull-down assay with immobilized
efsevin on embryonic protein lysate we identified the voltage-dependent anion channel
2  (VDAC2)  as  the  protein  target  of  efsevin.  Transient  knockdown of  VDAC2 in
tremblor embryos  abolished the efsevin  induced  phenotype  rescue,  while  transient
VDAC2 overexpression phenocopied it, confirming VDAC2 as the effective target of
efsevin.
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VDACs  are  the most  abundant  proteins  in  the outer  mitochondrial  membrane
(OMM).  They are  large  pore-forming  channels  that  mediate  the  transfer  of
metabolites  and  ions  over  the  OMM. Although  they  are  often  considered  freely
permeable due to their large pore diameter an increasing number of reports present
VDACs as regulated barrier in the OMM (Rapizzi et al., 2002; Báthori et al., 2006).
In  cardiomyocytes  the  OMM is  in  close  contact  with  the  SR and  and  intensive
crosstalk between the two organelles exist (Hajnóczky et al., 2000; Ruiz-Meana et al.,
2010). Molecular tethers link mitochondria to the SR (García-Pérez et al., 2008) in
close  vicinity  to  the  SR  Ca2+ release  units  (De  la  Fuente  et  al.,  2016) and
mitochondria express several distinct transporters and channels for Ca2+ uptake and
release. A gradual rise in mitochondrial matrix Ca2+ was reported to enhance enzymes
of the TCA cycle under higher workload (Brandes and Bers, 1997), however, the role
of an observed rapid beat-to-beat Ca2+ uptake remains elusive.
We therefore rationalized that the Ca2+ uptake of mitochondria could be altered by
efsevin  binding  and  that  this  could  explain  the  antiarrhythmic  effect  of  efsevin.
Indeed  efsevin  as  well  as  overexpression  of  VDAC2 enhanced  mitochondrial  Ca2+
uptake in HeLa cells. To investigate the effect of the enhanced mitochondrial Ca2+
uptake on mechanisms of arrhythmogenesis in cardiomyocytes we recorded cytosolic
Ca2+ signals in isolated murine cardiomyocytes. The elementary Ca2+ release event in
cardiomyocytes is the Ca2+ spark that is induced by the opening of one cluster of
RyRs (Cheng et al., 1993). We found that in murine cardiomyocytes efsevin had no
influence on the frequency or amplitude of Ca2+ sparks indicating no effect on SR
Ca2+ release. Most strikingly however, the decay of the Ca2+ spark was significantly
accelerated  leading  to  shorter  and  narrower  sparks.  To  test  if  this  spacial  and
temporal restriction of Ca2+ sparks could prevent saltatory expansion of Ca2+ release
inside the cardiomyocyte we induced spontaneous Ca2+ waves in cardiomyocytes by
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raising  extracellular  Ca2+.  We  found  a  significant,  dose-dependent  reduction  in
spontaneous  Ca2+ waves  with  efsevin.  Since  Ca2+ waves  underlie  delayed
afterdepolarizations and thus arrhythmia this effect explains the antiarrhythmic effect
of efsevin.
Based on our results we formulated the following research hypothesis: Fast uptake
of Ca2+ into mitochondria represents a buffering compartment adjacent to the Ca2+
release sites of the sarcoplasmic reticulum, which can be enhanced by pharmacological
activation of VDAC2 as a molecular compartment of the mitochondrial Ca2+ uptake
complex. Arrhythmogenic signals in cardiomyocytes are generated under conditions
where  RyRs  become leaky,  e.g.  by  elevated  intracelluar  Ca2+ levels.  Under  these
conditions the spark frequency raises until a certain threshold is reached after which
Ca2+ released  from a  spark  triggers  opening  of  neighboring  Ca2+ release  sites  to
initiate a Ca2+ wave. By activating mitochodrial Ca2+ uptake in close vicinity to the
spark, a fraction of the released Ca2+ is transported into mitochondria leading to a
spacial and temporal restriction of the spark. By this mechanism the cell can tolerate
a higher spark frequency without generation of arrhythmogenic Ca2+ waves.
This study identified VDAC2 and mitochondrial Ca2+ uptake in general as a potent
regulator of cardiac rhythmicity and a potential drug target for arrhythmia. Against
the common perception that VDAC constitutes freely permeable pores in the OMM,
we present evidence that the uptake of Ca2+ into mitochondria is already regulated at
the OMM. Furthermore, this study suggests an isoform-specific role for VDAC2 in
cardiomyocytes. We therefore set out to investigate VDAC2 on a structural level with
the aim to identify differences between VDAC2 and VDAC1 that could explain its
specific role in Ca2+ transport.
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The structure of VDAC2
Schredelseker, J., Paz, A., López, C. J., Altenbach, C., Leung, C. S., Drexler, M. K., Chen, J.-
N., Hubbell, W. L., and Abramson, J. (2014) High-Resolution Structure and Double Electron-
Electron Resonance of the Zebrafish Voltage Dependent Anion Channel 2 Reveal an Oligomeric
Population. J. Biol. Chem. 289, 12566–77
After our discovery of VDAC2 as a regulator of cardiomyocyte Ca2+ handling and
cardiac rhythmicity, we set out to investigate the molecular basis for the cardiac-
specific role of VDAC2. Three isoforms of VDAC are expressed in higher animals and
expression patterns between cell types vary. Although the distinct physiological roles
of the three isoforms are not fully understood, evidence points towards considerable
differences between the three isoforms. Especially VDAC2 was repeatedly described
to fulfill several strictly isoform-specific roles: most strikingly, VDAC2 knock-out mice
are embryonic  lethal  (Cheng et  al.,  2003),  while  knock-out  mice for  VDAC1 and
VDAC3 display relatively mild  phenotypes  (Anflous et  al.,  2001;  Sampson et  al.,
2001). Furthermore, VDAC2 was shown to exclusively mediate mitochondrial import
of pro-apoptotic Bcl-2 family members thereby inhibiting apoptosis  (Naghdi et al.,
2015). Most relevant for us was the finding that VDAC2 specifically mediates transfer
of Ca2+ from the sarcoplasmic reticulum into mitochondrial in cardiomyocytes by us
and others (Subedi et al., 2011; Min et al., 2012; Shimizu et al., 2015).
We therefore set out to investigate the molecular structure of VDAC2 with the aim
to identify structural elements that could explain the unique physiological features of
VDAC2 compared to isoforms 1 and 3. Using X-ray crystallography we resolved the
structure of zebrafish VDAC2 at a 2.8 Å resolution. Comparable to VDAC1, VDAC2
forms a β-barrel composed from 19 antiparralel β-sheets, exept for sheets 1 and 19
which align parallel, and an N-terminal α-helix lining the pore. However, we did not
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find major structural differences between VDAC1 and VDAC2, which could explain
the different physiological behavior of the channel. Recent studies however propose
that isoform differences could be attributed to differences in molecular interaction
partners  (Caterino et al., 2017) such as Bcl2 family members  (Cheng et al., 2003).
Indeed, we identified several structural elements that could serve as docking sites for
molecular interactions partners which vary between the isoforms, mainly the loop
connecting β-sheets 1 and 2 which is displaced by ~12 Å compared to VDAC1 and an
electropositive cluster within the same loop which is electronegative in VDAC1.
In an effort to identify the efsevin binding site we also set out to co-crystallize
VDAC2 together with efsevin. However, the limited solubility of efsevin did not allow
us to achieve a molar amount of efsevin in the experimental setup high enough to
efficiently bind one efsevin molecule to each molecule of VDAC2. Consistently the
structure of efsevin could not be resolved in the co-crystallization attempts.
However, this work set the basis for a follow-up study in which we used purified
VDAC2, generated with the protocol established here, and the determined VDAC2
structure  to  characterize  the  efsevin-VDAC2  interaction  on  a  biophysical  and
structural level.
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The VDAC2-efsevin interaction
Wilting F., Kopp R., Gurnev P.A., Schedel A., Dupper N. J., Kwon O., Nicke A., Gudermann T.,
and Schredelseker J. (2020) The antiarrhythmic compound efsevin directly modulates voltage-
dependent anion channel 2 by binding to its inner wall and enhancing mitochondrial Ca 2+ uptake,
Br J Pharmacol. doi: 10.1111/bph.15022
After identifying efsevin as a potent suppressor of cardiac arrhythmia in zebrafish
and isolated murine cardiomyocytes  and subsequent determination of  the VDAC2
structure we set out to investigate the efsevin mode-of-action on a molecular level.
Therefore we inserted purified recombinant VDAC2 into planar lipid bilayers and
measured single channel currents in response to 10s voltage steps from -60 to +60
mV. In line with previous reports on other VDAC isoforms, VDAC2 showed a single
channel conductance of approx. 4 ns in the open state in 1M KCl (Colombini, 1989;
Ujwal et al., 2008). At low potentials between -20 and +20 mV the channel almost
exclusively resided in this  4  nS-open state,  but displays vigorous gating behavior
between the open state and two distinct gated states with conductances of 2 and 1 nS
respectively  at  intermediate  potentials  around  ±30  mV.  At  very  low  or  high
potentials below -40 mV or above +40 the channel is mostly gated and only scarcely
opens into the open state.  This translates  into a bell-shaped conductance-voltage
relationship that is typical for VDAC and is consistent with previous observations on
other VDAC isoforms. Strikingly addition of efsevin strongly facilitated gating and
significantly reduced the open probability of the channel. Even at the physiologically
relevant low potentials the channel mainly shifts between the two gated states. We
then measured ion selectivity of the open state and the efsevin-induced gated state
and  found  that  anion  selectivity  is  reduced  upon  efsevin  binding  explaining  the
enhanced mitochondrial Ca2+ uptake observed previously.
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To identify potential efsevin binding sites we used the previously solved molecular
structure  of  VDAC2  (Schredelseker  et  al.,  2014) for  computational  docking
experiments and identified a pocket formed between the barrel wall and the hinge
region of the N-terminal pore-lining helix. Since the N-terminal helix was repeatedly
proposed to be involved in channel gating and since this would be in line with our
electrophysiological  data,  we  further  validated  this  potential  binding  site  by  a
mutagenesis approach. By mutating three key residues from the identified pocket to
alanines,  we  completely  eliminated  efsevin-sensitivity  of  VDAC2  in  planar  lipid
bilayer recordings.
To finally proof the hypothesis that efsevin enhances mitochondrial Ca2+ uptake by
binding to this pocket and changing the ion selectivity of the channel, we established
a heterologous expression system in cultured HL-1 cardiomyocytes. Therefore we first
knocked down expression of the endogenous mVDAC2 by shRNA. Knock-down of
mVDAC2  completely  abolished  SR-mitochondria  Ca2+ transfer  as  analyzed  by
recording the intra-mitochondrial Ca2+ level during caffeine-induced SR Ca2+ release.
Strikingly subsequent  heterologous expression of  VDAC2 or  the efsevin-insensitive
mutant zVDAC2AAA completely restored SR-mitochondria Ca2+ transfer but only wild-
type zVDAC2 was sensitive to efsevin.
Taken together, this study describes the efsevin-VDAC2 interaction on a molecular
level. We show that efsevin binds through a pocket located inside the channel pore
and shifts the channel into a more cation selective state leading to enhanced transfer
of Ca2+ from the SR into mitochondria.  This supports our initial  hypothesis  that
efsevin activates a mitochondrial buffering system to blunt cytosolic Ca2+ signals and
to suppress arrhythmia.
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The translational potential of enhancing mitochondrial Ca2+
uptake for the treatment of arrhythmia
Schweitzer, M. K., Wilting, F., Sedej, S., Dreizehnter, L., Dupper, N. J., Tian, Q., Moretti, A.,
My, I.,  Kwon, O.,  Priori,  S.  G., Laugwitz, K.-L., Storch, U.,  Lipp, P., Breit, A., Mederos y
Schnitzler, M., Gudermann, T., and  Schredelseker, J. (2017) Suppression of Arrhythmia by
Enhancing Mitochondrial  Ca2+ Uptake  in  Catecholaminergic  Ventricular  Tachycardia  Models.
JACC Basic to Transl. Sci. 2, 737–746
After  we  had  identified  the  mode  of  action  of  efsevin  on  a  physiological  and
structural  level,  we  next  evaluated  the  translational  potential  of  this  novel
pharmacological concept in experimental models for a human cardiac arrhythmia. To
this  aim  we  used  two  models  for  catecholaminergic  polymorphic  ventricular
tachycardia (CPVT) as an example for a Ca2+-triggered arrhythmia (Cerrone et al.,
2009). CPVT is characterized by episodes of ventricular tachycardia in response to
catecholaminergic  stimulation  induced  by  physical  or  emotional  stress  and  is
associated with mutations in cardiac Ca2+ handling proteins, predominantly RyR2
(CPVT1) or calsequestrin (CPVT2).
Mice heterozygous for a R4496C conversion in RyR2 (RyR2R4496C/WT), a homolog to
the human R4497C mutation associated with CPVT, recapitulate the human CPVT
phenotype  and  show  episodes  of  bidirectional  ventricular  tachycardia  upon
catecholaminergic stimulation  (Cerrone et al., 2005). We recorded intracellular Ca2+
in freshly isolated cardiomyocytes of RyR2R4496C/WT mice and analyzed diastolic Ca2+
activity immediately after stopping rhythmic electrical stimulation of the cells. In line
with the CPVT phenotype, isoproterenol induced the occurrence of spontaneous Ca2+
waves, the molecular basis for arrhythmogenesis within this diastolic phase. Strikingly
efsevin  completely  abolished  isoproterenol-induced  diastolic  Ca2+ waves  without
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affecting systolic Ca2+ transients. The diastolic Ca2+ waves are considered to trigger a
transient sodium influx through the Na+/Ca2+ exchanger initiating depolarization of
the  cell  and  thus  spontaneous  activity  in  form  of  a  delayed  afterdepolarization
(DAD). To evaluate if efsevin can suppress DADs, we patch-clamped RyR2R4496C/WT
cardiomyocytes  and  found  a  significant  reduction  of  spontaneous  diastolic  action
potentials  after  superfusion  with  efsevin.  To evaluate  our  hypothesis  that  efsevin
exerts its therapeutic effect by enhancing mitochondrial Ca2+ uptake we applied both,
a loss-of-function and a gain-of-function approach. For the loss-of-function approach
we repeated the above experiment in the presence of Ru360 a specific blocker of the
mitochondrial Ca2+ uniporter (MCU) in the inner mitochondrial membrane. Indeed,
in  the  presence  of  Ru360  efsevin  was  unable  to  suppress  isoproterenol-induced
diastolic Ca2+ waves. Vice-versa, we used a previously described enhancer of MCU, to
prove the general concept that pharmacological enhancement of mitochondrial Ca2+
uptake could suppress arrhythmogenesis. Kaempferol, a naturally occurring flavonoid,
was reported to enhance mitochondrial Ca2+ uptake in HeLa cells  (Montero et al.,
2004). After confirming that kaempferol enhances transfer of Ca2+ from the SR into
mitochondria  using  our  HL-1  cardiomyocyte mitochondrial  Ca2+ uptake  assay,  we
tested  it  on  RyR2R4496C/WT cardiomyocytes  and  found  that  kaempferol  suppresses
diastolic Ca2+ waves comparable to efsevin. These results demonstrate that enhancing
mitochondrial Ca2+ uptake could serve as a general pharmacological concept for the
treatment of arrhythmia and is independent of the molecular target, which is VDAC2
for efsevin and MCU for kaempferol.
We then used both mitochondrial Ca2+ uptake enhancers (MiCUps), efsevin and
kaempferol,  in-vivo in  RyR2R4496C/WT mice.  Mice  were  implanted  with  an  osmotic
minipump releasing a constant  dose  of  drug into the blood flow 3 days prior  to
undergoing an ECG recording. During the ECG recording mice were injected with a
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bolus of epinephrine and caffeine to induce catecholaminergic stress and the ECG was
evaluated for the occurrence of bidirectional ventricular tachycardia. Strikingly, all
mice receiving vehicle control but only half of the mice treated with either efsevin or
kaempferol developed ventricular tachyarrhythmia.
To finally prove efficacy of efsevin in human tissue we used pluripotent stem cell-
derived cardiomyocytes from a CPVT patient (Jung et al., 2012) and again recorded
spontaneous Ca2+ activity as a measure for arrhythmogenesis. Comparable to the data
obtained  from  RyR2R4496C/WT mice,  we  found  that  both  MiCUps,  efsevin  and
kaempferol, significantly reduced spontaneous diastolic Ca2+ waves.
Taken together, our data from this study highlights the translational potential of
enhancing mitochondrial Ca2+ uptake as a therapeutic concept for the treatment and
prevention  of  Ca2+-triggered  cardiac  arrhythmias.  Through  targeting  different
components of the mitochondrial Ca2+ uptake complex, both MiCUps, efsevin and
kaempferol, significantly suppressed arrhythmia in a murine and a human model for
cardiac arrhythmia. However,  both substances are still  very experimental and not
optimized  for  the  use  in  human.  For  example,  basic  pharmacokinetic  and
pharmacodynamic parameters are largely undetermined or suggest impracticality for
the use as drugs in human. We therefore set out to identify additional substances
which activate mitochondrial Ca2+ uptake in a follow-up study.
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Novel mitochondrial Ca2+ uptake enhancers 
Sander P., Arduino D., Schweitzer M. K., Wilting F., Gutenthaler S., Dreizehnter L., Moretti A.,
Gudermann  T.,  Perocchi  F.,  and  Schredelseker  J. (2020)  Approved  drugs  ezetimibe  and
disulfiram enhance mitochondrial Ca2+ uptake and suppress cardiac arrhythmogenesis, submitted
After we demonstrated that the two MiCUps efsevin and kaempferol significantly
reduce arrhythmogenesis  in translational  models  for  human Ca2+-triggered cardiac
arrhythmia,  we  questioned  if  these  substances  are  druggable  for  pre-clinical  and
clinical  studies and finally the use as therapeutics.  Analysis  of  the dose response
curves of efsevin and kaempferol revealed an EC50 of approximately 2-5 µM for both
drugs in our SR-mitochondria Ca2+ transfer assay, which is relatively high for the use
as therapeutics since it makes binding of the drugs to unspecific targets likely. In this
regard  very  little  is  known  about  efsevin.  Though  we  identified  VDAC2  as  the
primary target of efsevin relevant for the reduction of arrhythmogenesis, selectivity of
the drug was never systematically addressed. Kaempferol was suggested to act on
different targets including the NF-кB B (Kadioglu et al., 2015), the fibroblast growth
factor (Lee et al., 2018), and other signaling pathways (Yao et al., 2014; Kim et al.,
2015; Wu et al., 2017).
To  circumvent  problems  associated  with  the  high  EC50 of  these  drugs,  we
selectively screened a library of FDA and EMA approved drugs for their ability to
enhance  mitochondrial  Ca2+ uptake  using  a  HeLa  based  high-throughput  assay
(Arduino et al., 2017). From this screen we identified four substances, which enhanced
mitochondrial Ca2+ uptake greater then 2.5-fold compared to control and have never
been  associated  with mitochondrial  Ca2+ before.  We then validated  these  hits  at
different  concentrations in  HeLa cells  and excluded cefatrizine as  a  false-positive.
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Since we previously identified cardiac SR-mitochondria Ca2+ transfer as the molecular
foundation  for  the  antiarrhythmogenic  activity  of  MiCUPs  we  evaluated  the
remaining three substances in our HL-1 cardiomyocyte Ca2+ transfer assay. In this
assay two substances,  namely ezetimibe,  used to lower  cholesterol  and disulfiram,
used for the treatment of alcohol abuse, significantly enhanced SR-mitochondria Ca2+
transfer at significantly lower concentrations compared to our previously established
MiCUps efsevin and kaempferol. Interestingly, the natural compound honokiol, which
scored highest in the HeLa assay failed to enhance SR-mitochondria Ca2+ transfer in
cardiomyocytes, which might be explained by differences in the subunit composition
(Raffaello et al., 2013; Patron et al., 2019) or subcellar localization (De la Fuente et
al., 2016) of the mitochondrial Ca2+ uptake complex in this cell type.
We then tested ezetimbe and disulfiram for their antiarrhythmogenic activity in
different arrhythmia models. As a first assay we tested both substances in  tremblor
zebrafish embryos as an  in-vivo model for Ca2+ overload induced arrhythmia. Both
significantly restored rhythmic cardiac contractions in tremblor comparable to efsevin
(Shimizu et al., 2015) but at significantly lower concentrations. As a next step we
tested  ezetimibe  and  disulfiram  for  their  potential  to  suppress  arrhythmogenic
diastolic  Ca2+ waves  in  CPVT cardiomyocytes  of  RyR2R4496C/WT mice  and  human
iPSC-derived cardiomyocytes (Schweitzer et al., 2017). Both significantly suppressed
isoproterenol-induced  diastolic  Ca2+ waves  dose-dependently  and  again  at  lower
concentrations then efsevin  and kaempferol.  Interestingly,  disulfiram induced  side-
effects in all tested models. Fish displayed severe malformations and cells displayed
elevated cytosolic baseline Ca2+ concentrations and increased spontaneous activity,
indicating that although effective, care has to be taking when disulfiram is used in
pre-clinical and clinical applications.
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This study presents two FDA and EMA approved drugs as novel enhancers of
mitochondrial  Ca2+ uptake.  Both  substances  effectively  suppress  arrhythmia  in
experimental models for human arrhythmia, however disulfiram shows indications of
severe side effects. Both substances are promising candidates for future pre-clinical
and clinical studies to evaluate the therapeutic potential of MiCUps for arrhythmia
therapy.
Relevance of the work for the scientific field
Mitochondrial  Ca2+ uptake  as  a  regulator  of  cardiac
rhythmicity
Already in the early 60s researchers noted that mitochondria can take up vast
amounts of Ca2+ inside the mitochondrial matrix (DeLuca and Engstrom, 1961) but
the  physiological  role  of  this  uptake  was  discussed  ever  since.  In  principle,  two
mechanisms,  a  high affinity low conductance pathway for gradual  Ca2+ uptake in
response to changes in basal cytosolic Ca2+ levels and a low affinity high conductance
pathway  for  the  rapid  uptake  of  Ca2+ were  discussed  (Waldeck-Weiermair  et  al.,
2013). Today, it is widely appreciated that a slow and gradual uptake of Ca2+ into
mitochondria stimulates enzymes of  the TCA cycle to enhance energy production
(McCormack and Denton, 1989; Brandes and Bers, 1997), while the role of the fast
mitochondrial  Ca2+ uptake  remains  elusive.  Several  reports  suggest  that  the  fast
mitochondrial  Ca2+ uptake  represents  a  local  buffering  mechanism  to  shape
intracellular Ca2+ signals (Hoth et al., 2000; Montero et al., 2000).
Rapid mitochondrial Ca2+ uptake was particularly investigated in cardiomyocytes,
which constantly undergo rapid and large changes in intracellular Ca2+ levels and
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where  Ca2+ signaling  represents  a  central  part  of  the  cell’s  physiology.  In
cardiomyocytes mitochondria  comprise approximately 30% of the total cell volume
(Barth et al., 1992; Kim et al., 1994) primarily to cover the high energy demand of
the working  myocardium. Conspicuously  often however,  they are located  in  close
proximity to the Ca2+ release sites of the SR, and are tightly tethered to the SR
membrane (Boncompagni et al., 2009; Hayashi et al., 2009). An extensive cross-talk
between the two organelles  exists  (García-Pérez et  al.,  2008;  Dorn and Scorrano,
2010) and  mitochondria  were  reported  to  play  an  essential  role  in  shaping
intracellular Ca2+ signals (Parekh, 2003).
In this thesis we identified an immediate physiological role for rapid mitochondrial
Ca2+ uptake  in  cardiomyocytes  as  a  so  far  unappreciated  important  regulator  of
cardiac  rhythmicity.  We  propose  a  mechanism  in  which  spatially  defined
mitochondrial Ca2+ uptake in close vicinity to the cardiac Ca2+ release sites spatially
and temporally restricts erratic diastolic Ca2+ sparks and thereby inhibits saltatory
expansion of the signal in form of a Ca2+ wave. This hypothesis is supported by a
previous  report  in  which  inhibition  of  mitochondrial  Ca2+ uptake  increased  the
propensity for propagating Ca2+ waves in cardiomyocytes (Seguchi et al., 2005) and
the finding that VDAC2 closely interacts with the RyR (Subedi et al., 2011; Min et
al., 2012). Our data thus supports the notion that rapid mitochondrial Ca2+ uptake is
used  to  shape  intracellular  Ca2+ signals.  Moreover,  our  study  adds  additional
relevance to this mechanism, since we present this mechanism to be relevant for the
pathogenesis and treatment of a human disease.
Surprisingly, in our experiments activation of mitochondrial Ca2+ uptake activates
a mechanism to protect the cell during diastole while it has limited effects on systolic
Ca2+ signals. This poses the question why mitochondrial Ca2+ uptake is limited under
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physiological conditions. Future experiments are needed to address this question in
long-term experiments and a detailed analysis of systolic Ca2+ transients at rest and
under higher workload.
The  mitochondrial  outer  membrane  as  a  regulated  Ca2+
barrier
Ever since mitochondrial Ca2+ uptake was first described in the 1960s (DeLuca and
Engstrom, 1961) various studies speculated on the molecular entities mediating this
large  and  highly  selective  current described  as  MCU (Kirichok  et  al.,  2004).
Numerous targets in the inner mitochondrial membrane were suggested to be involved
in  mitochondrial  Ca2+ uptake  including  mitochondrial  uncoupling  proteins  2/3,
Letm1, and RyR (Trenker et al., 2007; Waldeck-Weiermair et al., 2011). The picture
changed  in  2011  when  the  molecular  identity  of  MCU  was  reported  by  two
independent  groups  (Baughman  et  al.,  2011;  De Stefani  et  al.,  2011).  After  this
discovery, research on mitochondrial Ca2+ uptake has experienced a revival and new
research tools, like gene-modified mice (Pan et al., 2013), became available. Numerous
regulatory subunits of MCU were identified and intensively investigated.
However, on its way into mitochondria, Ca2+ has to pass two membranes, the outer
and  inner  mitochondrial  membrane.  The  transfer  route  of  Ca2+ over  the  outer
mitochondrial membrane is generally believed to be constituted by VDACs. Because
of  their  large  pore  diameter  of  approx.  15  Å  and  their  conductivity  for  large
metabolites such as ATP and NADPH they were often depicted as unselective pores
leading to the assumption that the outer mitochondrial membrane would be freely
permeable for ions. However, several observations challenge this general belief and
establish VDAC in the OMM as a second regulated barrier for Ca2+ in addition to
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MCU: (i) VDAC was shown to be localized in close proximity to ER/SR Ca2+ release
sites and even a direct link to Ca2+ release channels was proposed (Szabadkai et al.,
2006; Min et al., 2012). (ii) Overexpression of VDAC1 enhanced transfer of Ca2+ from
microdomains  into  mitochondria (Rapizzi  et  al.,  2002).  (iii)  VDAC  gating  is
modulated by Ca2+ (Báthori et al.,  2006) and (iv) Ca2+ permeability through the
VDAC pore depends on the the open state of the channel (Tan and Colombini, 2007).
In  this  thesis  we  demonstrate  that  pharmacological  modulation  of  the  outer
mitochondrial membrane channel VDAC2 by efsevin enhances transfer of Ca2+ into
mitochondria. This data supports the idea that uptake of Ca2+ into mitochondria is
regulated already at the outer mitochondrial membrane, specifically through VDAC.
Moreover, we present evidence that this regulatory step is  highly relevant for the
physiological regulation of the cell. In cardiomyocytes VDAC2 limits uptake of Ca2+
into mitochondria. Enhancement of VDAC2 Ca2+ conductance by efsevin enhances
mitochondrial  Ca2+ uptake  and  thereby  creates  an  additional  Ca2+ buffering
compartment that protects the cell from arrhythmogenic diastolic Ca2+ signals. 
Against the common belief that MCU is the sole regulator of mitochondrial Ca2+
uptake, we propose a situation in which VDAC2 works together with MCU in the
inner mitochondrial  membrane as  a mitochondrial  Ca2+ uptake supercomplex.  We
present  evidence  that  overexpression  of  VDAC2 just  like  overexpression  of  MCU
restores rhythmic cardiac contractions in tremblor embryos, while knockdown of MCU
abolishes the rescuing effect of VDAC2 overexpression and vice-versa (Shimizu et al.,
2015).  This  demonstrates  that  both  channel  depend  on  each  other  and  regulate
mitochondrial Ca2+ uptake in form of a two membrane tunnel. This idea is further
supported by a  recently  identified  physical  interaction  between  VDAC and MCU
(Liao et al., 2015). 
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Beyond this interaction, several studies suggest that the mitochondrial Ca2+ uptake
complex  is  part  of  a  bigger  complex  involving  the  Ca2+ release  channel  of  the
sarcoplasmic reticulum, i.e. the IP3 receptor in non-excitable cells and the RyR in
cardiomyocytes  respectively  (Rizzuto et  al.,  1998;  Marchi  et  al.,  2018;  Xu et  al.,
2018). This is supported by the notion that due to the low-affinity of the MCU for
Ca2+ , a threshold of approximately 1 µM - 3 µM Ca2+ is required for opening of the
channel (Csordás et al., 2013), which is not reached by bulk cytosolic Ca2+ but only
within nandomains in close proximity to the Ca2+ release sites of the ER/SR. Within
these contact sites the outer mitochondrial membrane VDAC is tethered to the ER
presumably through the anchoring protein GRP75 (Szabadkai et al., 2006), to form
the center of the complex.
Taken together, this thesis together with other reports provides evidence that not
MCU alone, but a macromolecular complex between the SR Ca2+ release channel,
VDAC  in  the  outer  membrane,  and  MCU  in  the  inner  membrane  regulates
mitochondrial Ca2+ uptake. Therefore, care should be taken when investigating effects
of mitochondrial Ca2+ uptake on cellular physiology solely by genetic or physiological
manipulation of MCU under the assumption that the outer mitochondrial membrane
is freely permeable to Ca2+. Instead, VDAC and MCU should be treated as a complex
spanning both membranes to regulate Ca2+ uptake in two consecutive steps. Future
studies  are  needed however  to investigate the nature of  this  complex in different
tissues and the relative contribution of the outer and inner mitochondrial membrane
to the regulation of mitochondrial Ca2+ uptake.
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Mitochondrial Ca2+ uptake as a therapeutic strategy
By  describing  mitochondrial  Ca2+ uptake  as  a  pharmacologically  targetable
mechanism for the regulation of cardiac rhythmicity, this thesis presents an entirely
new candidate structure for the development of novel antiarrhythmic therapies. We
present four different candidate substances,  out of which two are FDA and EMA
approved drugs, which could serve as lead compounds for the generation of novel
drugs.  Furthermore,  we  show  efficacy  of  this  approach  in  models  for  cardiac
arrhythmias including a Ca2+ overload model and models for inherited arrhythmias
and  including  several  species,  namely  in-vivo experiments  on  fish  and  mice  and
experiments on human cells.
Common antiarrhythmic therapies using Na+, K+, and Ca2+ channel blockers aim
at  inhibiting  the  propagation  of  an  ectopic  excitation  along  the  myocardium by
blocking channels of the cardiac conduction system. As such they influence cardiac
de-  or  repolarization  and  are  thus  prone  to  proarrhythmic  side  effects.  Because
MiCUps  target  intracellular  structures  to  suppress  the  generation  of  ectopic
depolarizations and do not influence the cardiac action potential, they are expected
be less prone to these proarrhythmic effects.
However, several further studies must be conducted before MiCUps can be used for
clinical  testing.  Efsevin  the  first  substance  identified  in  our  studies  is  a  newly
synthesized compound and basic pharmacokinetic parameters like oral bioavailability,
plasma  half-life  time  or  volume  of  distribution  are  not  known  and  need  to  be
determined.  While  most  of  these  parameters  are  known  for  kaempferol,  both
substances, efsevin and kaempferol, showed fairly high EC50 values in the low µM
range in our mitochondrial Ca2+ uptake assay suggesting that fairly high amounts of
the drugs need to be administered to achieve a therapeutic effect.  At these high
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concentrations binding of the drug to other targets becomes likely. While specificity of
efsevin to other targets has never been assessed, kaempferol was suggested to interact
with numerous proteins including the NF-кB B (Kadioglu et al., 2015), the fibroblast
growth factor (Lee et al., 2018), and other signaling pathways (Yao et al., 2014; Kim
et al.,  2015; Wu et al.,  2017), suggesting that side effects are to be expected. In
contrast,  ezetimibe  and  disulfiram  are  clinically  approved  and  EC50 values  of
mitochondrial Ca2+ uptake in our assay are in the low nM range, a range that is well
suitable for their use as therapeutics. However, both substances have been approved
for other indications based on their effect on their primary targets, i.e. the cholesterol
transporter Niemann-Pick C1-like 1 (NPC1L1) for ezetimibe and the acetaldehyde
dehydrogenase for disulfiram. Affinity of the drug for the mitochondrial Ca2+ uptake
complex versus their primary targets has to be determined.
Furthermore  it  should  be  noted  that  mitochondrial  Ca2+ uptake  is  a  process
presumably taking place in every cell of the body and not limited to cardiomyocytes.
Though  we  assume  that  a  special  situation  exists  in  cardiomyocytes  due  to  the
specific subcellular localization of the mitochondrial Ca2+ uptake complex in these
cells  (De  la  Fuente  et  al.,  2016;  De  La  Fuente  et  al.,  2018) and  the  subunit
composition of MCU (Raffaello et al., 2013; Lambert et al., 2019; Patron et al., 2019),
effects of enhanced mitochondrial Ca2+ uptake in other tissues need to be excluded
prior to clinical experiments.
For the above reasons, the identified drugs might need to be optimized through
chemical modification. Our study identified the binding site for efsevin on the VDAC2
protein and thus provides a structural basis for the optimization of efsevin through
structure-aided  drug  design.  The  protein  target  of  kaempferol,  ezetimbe  and
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disulfiram within the mitochondrial Ca2+ uptake complex still need to be determined,
however, our work provides the tools to successfully address this question.
Taken  together,  this  thesis  provides  the  basis  for  the  development  of  a  novel
generation of antiarrhythmic drugs, but also opens the door for a number of studies
before clinical experiments can be started.
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Abstract Tightly regulated Ca2+ homeostasis is a prerequisite for proper cardiac function.  
To dissect the regulatory network of cardiac Ca2+ handling, we performed a chemical suppressor 
screen on zebrafish tremblor embryos, which suffer from Ca2+ extrusion defects. Efsevin was 
identified based on its potent activity to restore coordinated contractions in tremblor. We  
show that efsevin binds to VDAC2, potentiates mitochondrial Ca2+ uptake and accelerates the 
transfer of Ca2+ from intracellular stores into mitochondria. In cardiomyocytes, efsevin restricts 
the temporal and spatial boundaries of Ca2+ sparks and thereby inhibits Ca2+ overload-induced 
erratic Ca2+ waves and irregular contractions. We further show that overexpression of VDAC2 
recapitulates the suppressive effect of efsevin on tremblor embryos whereas VDAC2 deficiency 
attenuates efsevin's rescue effect and that VDAC2 functions synergistically with MCU to 
suppress cardiac fibrillation in tremblor. Together, these findings demonstrate a critical 
modulatory role for VDAC2-dependent mitochondrial Ca2+ uptake in the regulation of cardiac 
rhythmicity.
DOI: 10.7554/eLife.04801.001
Introduction
During development, well-orchestrated cellular processes guide cells from diverse lineages to 
integrate into the primitive heart tube and establish rhythmic and coordinated contractions. While 
many genes and pathways important for cardiac morphogenesis have been identified, molecular 
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mechanisms governing embryonic cardiac rhythmicity are poorly understood. The findings that Ca2+ 
waves traveling across the heart soon after the formation of the primitive heart tube (Chi et al., 
2008) and that loss of function of key Ca2+ regulatory proteins, such as the L-type Ca2+ channel, 
Na/K−ATPase and sodium-calcium exchanger 1 (NCX1), severely impairs normal cardiac function 
(Rottbauer et al., 2001; Shu et al., 2003; Ebert et al., 2005; Langenbacher et al., 2005), indicate 
an essential role for Ca2+ handling in the regulation of embryonic cardiac function.
Ca2+ homoeostasis in cardiac muscle cells is tightly regulated at the temporal and spatial level by 
a subcellular network involving multiple proteins, pathways, and organelles. The release and reup-
take of Ca2+ by the sarcoplasmic reticulum (SR), the largest Ca2+ store in cardiomyocytes, constitutes 
the primary mechanism governing the contraction and relaxation of the heart. Ca2+ influx after acti-
vation of the L-type Ca2+ channel in the plasma membrane induces the release of Ca2+ from the SR 
via ryanodine receptor (RyR) channels, which leads to an increase of the intracellular Ca2+ concentra-
tion and cardiac contraction. During diastolic relaxation, Ca2+ is transferred back into the SR by the 
SR Ca2+ pump or extruded from the cell through NCX1. Defects in cardiac Ca2+ handling and Ca2+ 
overload, for example during cardiac ischemia/reperfusion or in long QT syndrome, are well known 
causes of contractile dysfunction and many types of arrhythmias including early and delayed after-
depolarizations and Torsade des pointes (Bers, 2002; Choi et al., 2002; Yano et al., 2008; Greiser 
et al., 2011).
Ca2+ crosstalk between mitochondria and ER/SR has been noted in many cell types and the voltage-
dependent anion channel (VDAC) and the mitochondrial Ca2+ uniporter (MCU) serve as primary routes 
for Ca2+ entry through the outer and inner mitochondrial membranes, respectively (Rapizzi et al., 
2002; Bathori et al., 2006; Shoshan-Barmatz et al., 2010; Baughman et al., 2011; De Stefani et al., 
2011). In the heart, mitochondria are tethered to the SR and are located in close proximity to Ca2+ 
release sites (García-Pérez et al., 2008; Boncompagni et al., 2009; Hayashi et al., 2009). This subcel-
lular architecture exposes the mitochondria near the Ca2+ release sites to a high local Ca2+ concentration 
eLife digest The heart is a large muscle that pumps blood around the body by maintaining a 
regular rhythm of contraction and relaxation. If the heart loses this regular rhythm it works less 
efficiently, which can lead to life-threatening conditions.
Regular heart rhythms are maintained by changes in the concentration of calcium ions in the 
cytoplasm of the heart muscle cells. These changes are synchronised so that the heart cells contract 
in a controlled manner. In each cell, a contraction begins when calcium ions from outside the cell 
enter the cytoplasm by passing through a channel protein in the membrane that surrounds the 
cell. This triggers the release of even more calcium ions into the cytoplasm from stores within the 
cell. For the cells to relax, the calcium ions must then be pumped out of the cytoplasm to lower 
the calcium ion concentration back to the original level.
Shimizu et al. studied a zebrafish mutant—called tremblor—that has irregular heart rhythms 
because its heart muscle cells are unable to efficiently remove calcium ions from the cytoplasm. 
Embryos of the tremblor mutant were treated with a wide variety of chemical compounds with the 
aim of finding some that could correct the heart defect.
A compound called efsevin restores regular heart rhythms in tremblor mutants. Efsevin binds to 
a pump protein called VDAC2, which is found in compartments called mitochondria within the cell. 
Although mitochondria are best known for their role in supplying energy for the cell, they also act 
as internal stores for calcium. By binding to VDAC2, efsevin increases the rate at which calcium ions 
are pumped from the cytoplasm into the mitochondria. This restores rhythmic calcium ion cycling in 
the cytoplasm and enables the heart muscle cells to develop regular rhythms of contraction and 
relaxation. Increasing the levels of VDAC2 or another similar calcium ion pump protein in the heart 
cells can also restore a regular heart rhythm.
Efsevin can also correct irregular heart rhythms in human and mouse heart muscle cells, therefore 
the new role for mitochondria in controlling heart rhythms found by Shimizu et al. appears to be 
shared in other animals. The experiments have also identified the VDAC family of proteins as 
potential new targets for drug therapies to treat people with irregular heart rhythms.
DOI: 10.7554/eLife.04801.002
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that is sufficient to overcome the low Ca2+ affinity of MCU and facilitates Ca2+ crosstalk between SR 
and mitochondria (García-Pérez et al., 2008; Dorn and Scorrano, 2010; Kohlhaas and Maack, 2013). 
Increase of the mitochondrial Ca2+ concentration enhances energy production during higher workload and 
dysregulation of SR-mitochondrial Ca2+ signaling results in energetic deficits and oxidative stress in the 
heart and may trigger programmed cell death (Brandes and Bers, 1997; Maack et al., 2006; Kohlhaas 
and Maack, 2013). However, whether SR-mitochondrial Ca2+ crosstalk also contributes significantly to 
cardiac Ca2+ signaling during excitation-contraction coupling requires further investigation.
In zebrafish, the tremblor (tre) locus encodes a cardiac-specific isoform of the Na+/Ca2+ exchanger 1, 
NCX1h (also known as slc8a1a) (Ebert et al., 2005; Langenbacher et al., 2005). The tre mutant hearts 
Figure 1. Efsevin restores rhythmic cardiac contractions in zebrafish tremblor embryos. (A) Line scans across the atria of Tg(myl7:GFP) embryonic hearts 
at 48 hpf. Rhythmically alternating systoles and diastoles are recorded from vehicle- (upper left) or efsevin- treated wild type (upper right) and efsevin-
treated tre (lower right) embryos, while only sporadic unsynchronized contractions are recorded from vehicle-treated tre embryos (lower left). (B, C) 
Fractional shortening (FS) deduced from the line-scan traces. While cardiac contraction was not observed in tre, efsevin-treated wild type and tre hearts 
have similar levels of FS to those observed in control hearts. Ventricular FS of wild type v.s. wild type + efsevin vs tre + efsevin: 39 ± 0.6%, n = 8 vs 39 ± 1%,  
n = 10 vs 35 ± 3%, n = 6; and Atrial FS: 37 ± 1%, n = 11 vs 35 ± 2%, n = 11 vs 33 ± 2%, n = 15. (D) While efsevin restored a heart rate of 46 ± 2 beats 
per minute (bpm) in tre embryos, same treatment does not affect the heart rate in wild type embryos (126 ± 2 bpm in vehicle-treated embryos vs  
123 ± 3 bpm in efsevin-treated wild-type embryos). ***, p < 0.001 by one-way ANOVA. (E) Dose-dependence curve for efsevin. The tre embryos were 
treated with various concentrations of efsevin from 24 hpf and cardiac contractions were analyzed at 48 hpf. (F–H) Representative time traces of local 
field potentials for wild type (F), tre (G) and efsevin-treated tre (H) embryos clearly display periods of regular, irregular, and restored periodic electrical 
activity. (I) In vivo optical maps of Ca2+ activation represented by isochronal lines every 33 ms recorded from 36 hpf wild type (left), tre (center) and 
efsevin-treated tre (right) embryos.
DOI: 10.7554/eLife.04801.003
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lack rhythmic Ca2+ transients and display chaotic 
Ca2+ signals in the myocardium leading to unsyn-
chronized contractions resembling cardiac fibril-
lation (Langenbacher et al., 2005). In this study, 
we used tre as an animal model for aberrant Ca2+ 
handling-induced cardiac dysfunction and took 
a chemical genetic approach to dissect the Ca2+ 
regulatory network important for maintaining car-
diac rhythmicity. A synthetic compound named 
efsevin was identified from a suppressor screen 
due to its potent ability to restore coordinated 
contractions in tre. Using biochemical and genetic 
approaches we show that efsevin interacts with 
VDAC2 and potentiates its mitochondrial Ca2+ 
transporting activity and spatially and tempo-
rally modulates cytosolic Ca2+ signals in cardio-
myocytes. The important role of mitochondrial 
Ca2+ uptake in regulating cardiac rhythmicity is 
further supported by the suppressive effect of 
VDAC2 and MCU overexpression on cardiac fibril-
lation in tre.
Results and discussion
Identification of a chemical 
suppressor of tre cardiac 
dysfunction
Homozygous tre mutant embryos suffer from Ca2+ 
extrusion defects and manifest chaotic cardiac 
contractions resembling fibrillation (Ebert et al., 
2005; Langenbacher et al., 2005). To dissect 
the regulatory network of Ca2+ handling in car-
diomyocytes and to identify mechanisms control-
ling embryonic cardiac rhythmicity, we screened 
the BioMol library and a collection of synthetic 
compounds for chemicals that are capable of 
restoring heartbeat either completely or partially 
in tre embryos. A dihydropyrrole carboxylic ester 
compound named efsevin was identified based 
on its ability to restore persistent and rhythmic 
cardiac contractions in tre mutant embryos in 
a dose-dependent manner (Figure 1A,E, and 
Videos 1–4). To validate the effect of efsevin, we 
assessed cardiac performance of wild type, tre 
and efsevin-treated tre embryos (Nguyen et al., 
2009). Fractional shortening of efsevin treated 
tre mutant hearts was comparable to that of their 
wild type siblings and heart rate was restored 
to approximately 40% of that observed in con-
trols (Figure 1B–D). Periodic local field potentials 
accompanying each heartbeat were detected in 
wild type and efsevin-treated tre embryos using a microelectrode array (Figure 1F–H). Furthermore, 
while only sporadic Ca2+ signals were detected in tre hearts, in vivo Ca2+ imaging revealed steady 
Ca2+ waves propagating through efsevin-treated tre hearts (Figure 1I, Videos 5–7), demonstrating 
that cardiomyocytes are functionally coupled and that efsevin treatment restores regular Ca2+ tran-
sients in tre hearts.
Video 1. The video shows a heart of a wild-type 
zebrafish embryo at 2 dpf. Robust rhythmic contractions 
can be observed in atrium and ventricle.
DOI: 10.7554/eLife.04801.004
Video 2. This video shows a heart of a tremblor embryo 
at 2 dpf. Embryos of the mutant line tremblor display 
only local, unsynchronized contractions, comparable to 
cardiac fibrillation.
DOI: 10.7554/eLife.04801.005
Video 3. This video shows a heart of a tremblor embryo 
at 2 dpf treated with efsevin. Treatment of tremblor 
embryos with efsevin restores rhythmic contractions 
with comparable atrial fractional shortening compared 
to wild-type embryos and approximately 40% of 
wild-type heart rate.
DOI: 10.7554/eLife.04801.006
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Efsevin suppresses Ca2+  
overload-induced irregular 
contraction
We next examined whether efsevin could suppress 
aberrant Ca2+ homeostasis-induced arrhythmic 
responses in mammalian cardiomyocytes. Mouse 
embryonic stem cell-derived cardiomyocytes 
(mESC-CMs) establish a regular contraction pattern 
with rhythmic Ca2+ transients (Figure 2A,B,E,F). 
Mimicking Ca2+ overload by increasing extracel-
lular Ca2+ levels was sufficient to disrupt normal 
Ca2+ cycling and induce irregular contractions in 
mESC-CMs (Figure 2C,E,F). Remarkably, efsevin 
treatment restored rhythmic Ca2+ transients and 
cardiac contractions in these cells (Figure 2D–F). 
Similar effect was observed in human embryonic 
stem cell-derived cardiomyocytes (hESC-CMs) 
(Figure 2G). Together, these findings suggest 
that efsevin targets a conserved Ca2+ regulatory 
mechanism critical for maintaining rhythmic car-
diac contraction in fish, mice and humans.
VDAC2 mediates the suppressive 
effect of efsevin on tre
To identify the protein target of efsevin, we gen-
erated a N-Boc-protected 2-aminoethoxyeth-
oxyethylamine linker-attached efsevin (efsevinL) 
(Figure 3A,C). This modified compound retained 
the activity of efsevin to restore cardiac contrac-
tions in ncx1h deficient embryos (Figure 3B,D) and 
was used to create efsevin-conjugated agarose 
beads (efsevinLB). A 32kD protein species was 
detected from zebrafish lysate due to its binding 
ability to efsevinLB and OK-C125LB, an active efsevin 
derivative conjugated to beads, but not to beads 
capped with ethanolamine alone or beads conju-
gated with an inactive efsevin analog (OK-C19LB) 
(Figure 3A–E). Furthermore, preincubation of 
zebrafish lysate with excess efsevin prevented 
the 32kD protein from binding to efsevinLB or 
OK-C125LB (Figure 3E). Mass spectrometry anal-
ysis revealed that this 32kD band represents a 
zebrafish homologue of the mitochondrial voltage-dependent anion channel 2 (VDAC2) (Figure 3F 
and Figure 3—figure supplement 1).
VDAC2 is expressed in the developing zebrafish heart (Figure 4A), making it a good candidate for 
mediating efsevin’s effect on cardiac Ca2+ handling. To examine this possibility, we injected in vitro 
synthesized VDAC2 RNA into tre embryos and found that the majority of these embryos had coordi-
nated cardiac contractions similar to those subjected to efsevin treatment (Figure 4B, Videos 8–11). 
In addition, we generated myl7:VDAC2 transgenic fish in which VDAC2 expression can be induced in 
the heart by tebufenozide (TBF) (Figure 4C). Knocking down NCX1h in myl7:VDAC2 embryos results 
in chaotic cardiac movement similar to tre. Like efsevin treatment, induction of VDAC2 expression by 
TBF treatment restored coordinated and rhythmic contractions in myl7:VDAC2;NCX1h MO hearts 
(Figure 4D, Videos 12,13). Conversely, knocking down VDAC2 in tre hearts attenuated the suppres-
sive effect of efsevin (Figure 4E, Videos 14–16). Furthermore, we generated VDAC2 null embryos by 
the Zinc Finger Nuclease gene targeting approach (Figure 4G). Similar to that observed in morpholino 
knockdown embryos, homozygous VDAC2LA2256 embryos do not exhibit noticeable morphological 
Video 4. The video shows a heart of a wild-type 
zebrafish embryo at 2 dpf treated with efsevin. 
Treatment of wild-type embryos with efsevin did not 
affect cardiac performance, indicated by robust, 
rhythmic contractions comparable to untreated 
wild-type embryos.
DOI: 10.7554/eLife.04801.007
Video 5. Heat map of Ca2+ transients recorded in 1 day 
old wild type heart. 
DOI: 10.7554/eLife.04801.008
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defects, but the suppressive effect of efsevin was 
attenuated in homozygous VDAC2LA2256; NCX1MO 
embryos (Figure 4F). These findings demonstrate 
that VDAC2 is a major mediator for efsevin’s effect 
on ncx1h deficient hearts.
VDAC2-dependent effect of 
efsevin on mitochondrial Ca2+ 
uptake
VDAC is an abundant channel located on the 
outer mitochondrial membrane serving as a primary 
passageway for metabolites and ions (Figure 5A) 
(Rapizzi et al., 2002; Bathori et al., 2006; 
Shoshan-Barmatz et al., 2010). At its close state, 
VDAC favours Ca2+ flux (Tan and Colombini, 2007). 
To examine whether efsevin would modulate mito-
chondrial Ca2+ uptake via VDAC2, we transfected 
HeLa cells with VDAC2. We noted increased mito-
chondrial Ca2+ uptake in permeabilized VDAC2 
transfected and efsevin-treated cells after the addi-
tion of Ca2+ and the combined treatment further 
enhanced mitochondrial Ca2+ levels (Figure 5B).
Mitochondria are located in close proximity 
to Ca2+ release sites of the ER/SR and an exten-
sive crosstalk between the two organelles exists 
(García-Pérez et al., 2008; Hayashi et al., 2009; 
Brown and O'Rourke, 2010; Dorn and Scorrano, 
2010; Kohlhaas and Maack, 2013). We examined 
whether Ca2+ released from intracellular stores 
could be locally transported into mitochondria 
through VDAC2 in VDAC1/VDAC3 double knock-
out (V1/V3DKO) MEFs where VDAC2 is the 
only VDAC isoform being expressed (Roy et al., 
2009a). While treatments with ATP, an IP3-linked 
agonist, and thapsigargin, a SERCA inhibitor, 
stimulated similar global cytoplasmic [Ca2+] ele-
vation in intact cells, only ATP induced a rapid 
mitochondrial matrix [Ca2+] rise (Figure 5—figure 
supplement 1). This finding is consistent with 
observations obtained in other cell types (Rizzuto 
et al., 1994; Hajnóczky et al., 1995) and sug-
gests that Ca2+ was locally transferred from IP3 
receptors to mitochondria through VDAC2 at 
the close ER-mitochondrial associations. We next 
investigated whether this process could be mod-
ulated by efsevin. In permeabilized V1/V3DKO 
MEFs, treatment with efsevin increased the 
amount of Ca2+ transferred into mitochondria 
during IP3-induced Ca2+ release (Figure 5C). Also, in intact V1/V3 DKO MEFs, efsevin accelerated 
the transfer of Ca2+ released from intracellular stores into mitochondria during stimulation with ATP 
(Figure 5D,E).
Efsevin modulates Ca2+ sparks and suppresses erratic Ca2+ waves in 
cardiomyocytes
We next examined the effect of efsevin on cytosolic Ca2+ signals in isolated adult murine cardiomyo-
cytes. We found that efsevin treatment induced faster inactivation kinetics without affecting the 
Video 6. Heat map of Ca2+ transients recorded in 1 day 
old tremblor heart. 
DOI: 10.7554/eLife.04801.009
Video 7. Heat map of Ca2+ transients recorded in 1 day 
old efsevin treated tremblor heart. 
DOI: 10.7554/eLife.04801.010
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amplitude or time to peak of paced Ca2+ transients (Figure 6A). Similarly, efsevin treatment did not signif-
icantly alter the frequency, amplitude or Ca2+ release flux of spontaneous Ca2+ sparks, local Ca2+ release 
events, but accelerated the decay phase resulting in sparks with a shorter duration and a narrower 
width (Figure 6B). These results indicate that by activating mitochondrial Ca2+ uptake, efsevin acceler-
ates Ca2+ removal from the cytosol in cardiomyocytes and thereby restricts local cytosolic Ca2+ sparks 
to a narrower domain for a shorter period of time without affecting SR Ca2+ load or RyR Ca2+ release. 
Under conditions of Ca2+ overload, single Ca2+ sparks can trigger opening of neighbouring Ca2+ release 
units and thus induce the formation of erratic Ca2+ waves (Figure 6C). Efsevin treatment significantly 
reduced the number of propagating Ca2+ waves in a dosage-dependent manner (Figure 6C,D), demon-
strating a potent suppressive effect of efsevin on the propagation of Ca2+ overload-induced Ca2+ waves 
and suggesting that efsevin could serve as a pharmacological tool to manipulate local Ca2+ signals.
Figure 2. Efsevin reduces arrhythmogenic events in ES cell-derived cardiomyocytes. (A) Line-scan analysis of 
Ca2+ transients in mESC-CMs after 10 days of differentiation. (B–D) Representative graph of Ca2+ transients 
detected in mESC-CMs (B). After treatment with 10 mM Ca2+ for 10 min, the EB showed an irregular pattern of 
Ca2+ transients (C). Efsevin treatment restores regular Ca2+ transients under Ca2+ overload conditions in mESC-CMs  
(D). (E) Plotted intervals between peaks of Ca2+ signals detected in mESC-CMs prior to treatment (control), in  
10 mM Ca2+ext (Ca2+) and in 10 mM Ca2+ext+10 éM efsevin (Ca2++efsevin). (F, G) Plotted intervals of contractions 
detected in EBs prior to treatment (control), in 10 mM Ca2+ext (Ca2+) and in 10 mM Ca2+ext + 10 éM efsevin  
(Ca2+ + efsevin) for mouse ESC-CMs (F) and 5 mM Ca2+ext (Ca2+) and in 5 mM Ca2+ext + 5 éM efsevin (Ca2+ + efsevin) 
for human ESC-CMs (G). ***, p < 0.001 by F-test.
DOI: 10.7554/eLife.04801.011
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Mitochondrial Ca2+ uptake modulates embryonic cardiac rhythmicity
We hypothesize that efsevin treatment/VDAC2 overexpression suppresses aberrant Ca2+ handling-
associated arrhythmic cardiac contractions by buffering excess Ca2+ into mitochondria. This hypo-
thesis predicts that activating other mitochondrial Ca2+ uptake molecules would likewise restore 
coordinated contractions in tre. To test this model, we cloned zebrafish MCU and MICU1, an inner 
mitochondrial membrane Ca2+ transporter and its regulator (Perocchi et al., 2010; Baughman et al., 
2011; De Stefani et al., 2011; Mallilankaraman et al., 2012; Csordas et al., 2013). In situ hybrid-
ization showed that MCU and MICU1 were expressed in the developing zebrafish heart (Figure 7A) 
and their expression levels were comparable between the wild type and tre hearts (Figure 7—figure 
supplement 1). Overexpression of MCU restored coordinated contractions in tre, akin to what was 
observed with VDAC2 (Figure 7B). In addition, tre embryos injected with suboptimal concentra-
tions of MCU or VDAC2 had a fibrillating heart, but embryos receiving both VDAC2 and MCU at 
the suboptimal concentration manifested coordinated contractions (Figure 7C), demonstrating a 
synergistic effect of these proteins. Furthermore, overexpression of MCU failed to suppress the tre 
phenotype in the absence of VDAC2 activity and VDAC2 could not restore coordinated contrac-
tions in tre without functional MCU (Figure 7B,D). Similar results were observed by manipulating 
MICU1 activity (Figure 7E,F). Together, these findings indicate that mitochondrial Ca2+ uptake 
mechanisms on outer and inner mitochondrial membranes act cooperatively to regulate cardiac 
rhythmicity.
Conclusion
In summary, we conducted a chemical suppressor screen in zebrafish to dissect the regulatory network 
critical for maintaining rhythmic cardiac contractions and to identify mechanisms underlying aberrant 
Figure 3. VDAC2 is a protein target of efsevin. (A) Structures of efsevin and two derivatives, OK-C125 and OK-C19. (B) Efsevin and OK-C125 restored 
rhythmic contractions in the majority of tremblor embryos, whereas OK-C19 failed to rescue the tremblor phenotype. (C) Structures of linker-attached 
compounds (indicated by superscript L). (D) Compounds efsevinL and OK-C125L retained their ability to restore rhythmic contractions in NCX1hMO 
injected embryos, while the inactive derivative OK-C19L was still unable to induce rhythmic contraction. (E) Affinity agarose beads covalently linked  
with efsevin (efsevinLB) or OK-C125 (OK-C125LB) pulled down 2 protein species from zebrafish embryonic lysate, whereof one, the 32 kD upper band, was 
sensitive to competition with a 100-fold excess free efsevinL. The 32 kD band was not detected in proteins eluted from beads capped with ethanolamine 
alone (beadsC) or beads linked to OK-C19 (OK-C19LB). Arrowheads point to the 32kD bands. (F) Mass Spectrometry identifies the 32kD band as VDAC2. 
Peptides identified by mass spectrometry (underlined) account for 30% of the total sequence.
DOI: 10.7554/eLife.04801.012
The following figure supplement is available for figure 3:
Figure supplement 1. Mass Spectometry identifies VDAC2 as the target of efsevin. 
DOI: 10.7554/eLife.04801.013
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Ca2+ handling-induced cardiac dysfunction. We 
show that activation of VDAC2 through overex-
pression or efsevin treatment potently restores 
rhythmic contractions in NCX1h deficient zebrafish 
hearts and effectively suppresses Ca2+ over-
load-induced arrhythmogenic Ca2+ events and 
irregular contractions in mouse and human cardi-
omyocytes. We provide evidence that potentiat-
ing VDAC2 activity enhances mitochondrial Ca2+ 
uptake, accelerates Ca2+ transfer from intracel-
lular stores into mitochondria and spatially and 
temporally restricts single Ca2+ sparks in cardio-
myocytes. The crucial role of mitochondria in the 
regulation of cardiac rhythmicity is further sup-
ported by the findings that VDAC2 functions in 
concert with MCU; these genes have a strong synergistic effect on suppressing cardiac fibrillation and 
loss of function of either gene abrogates the rescue effect of the other in tre.
Figure 4. VDAC2 restores rhythmic cardiac contractions in tre. (A) In situ hybridization analysis showed that VDAC2 is expressed in embryonic hearts at 
36 hpf (upper image) and 48 hpf (lower image). (B) Injection of 25 pg in vitro synthesized VDAC2 mRNA restored cardiac contractions in 52.9 ± 12.1%  
(n = 78) of 1-day-old tre embryos, compared to 21.8 ± 5.1% in uninjected siblings (n = 111). (C) Schematic diagram of myl7:VDAC2 construct (top). In situ 
hybridization analysis showed that TBF treatment induces VDAC2 expression in the heart (lower panel). (D) While only 20% of myl7:VDAC2;NCX1hMO 
embryos have coordinated contractions (n = 116), 52.3 ± 2.4% of these embryos established persistent, rhythmic contractions after TBF induction of 
VDAC2 (n = 154). (E) On average, 71.2 ± 8.8% efsevin treated embryos have coordinated cardiac contractions (n = 131). Morpholino antisense oligonu-
cleotide knockdown of VDAC2 (MOVDAC2) attenuates the ability of efsevin to suppress cardiac fibrillation in tre embryos (45.3 ± 7.4% embryos with 
coordinated contractions, n = 94). (F) Efsevin treatment restores coordinated cardiac contractions in 76.2 ± 8.7% NCX1MO embryos, only 54.1 ± 3.6% 
VDAC2zfn/zfn;NCX1MO embryos have coordinated contractions (n = 250). (G) Diagram of Zinc finger target sites. VDAC2zfn/zfn carries a 34 bp deletion in 
exon 3 which results in a premature stop codon (red asterisk). In situ hybridization analysis showing loss of VDAC2 transcripts in VDAC2zfn/zfn embryos. 
White arrowheads point to the developing heart.
DOI: 10.7554/eLife.04801.014
Video 8. This video shows a heart of a wild-type 
zebrafish embryo at 1 dpf. Robust rhythmic contractions 
can be observed in atrium and ventricle.
DOI: 10.7554/eLife.04801.015
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The regulatory roles of mitochondrial Ca2+ in 
cardiac metabolism, cell survival and fate have 
been studied extensively (Brown and O'Rourke, 
2010; Dorn and Scorrano, 2010; Doenst et al., 
2013; Kasahara et al., 2013; Kohlhaas and 
Maack, 2013; Luo and Anderson, 2013). Our 
study provides genetic and physiologic evidence 
supporting an additional role for mitochondria in 
regulating cardiac rhythmicity and reveals VDAC2 
as a modulator of Ca2+ handling in cardiomyo-
cytes. Our findings, together with recent reports 
of the physical interaction between VDAC2 and 
RyR2 (Min et al., 2012) and the close proximity 
of outer and inner mitochondrial membranes at 
the contact sites between the mitochondria and 
the SR (García-Pérez et al., 2011), suggest an 
intriguing model. We propose that mitochondria 
facilitate an efficient clearance mechanism in the 
Ca2+ microdomain, which modulates Ca2+ hand-
ling without affecting global Ca2+ signals in car-
diomyocytes. In this model, VDAC facilitates 
mitochondrial Ca2+ uptake via MCU complex and 
thereby controls the duration and the diffusion 
of cytosolic Ca2+ near the Ca2+ release sites to 
ensure rhythmic cardiac contractions. This model 
is consistent with our observation that efsevin 
treatment induces faster inactivation kinetics of 
cytosolic Ca2+ transients without affecting the 
amplitude or the time to peak in cardiomyocytes 
and the reports that blocking mitochondrial Ca2+ 
uptake has little impact on cytosolic Ca2+ tran-
sients (Maack et al., 2006; Kohlhaas et al., 
2010). Further support for this model comes from 
the observation of the Ca2+ peaks on the OMM 
(Drago et al., 2012) and the finding that down-
regulating VDAC2 extends Ca2+ sparks (Subedi 
et al., 2011; Min et al., 2012) and that blocking 
mitochondrial Ca2+ uptake by Ru360 leads to an 
increased number of spontaneous propagating 
Ca2+ waves (Seguchi et al., 2005). Future studies 
on the kinetics of VDAC2-dependent mitochon-
drial Ca2+ uptake and exploring potential regula-
tory molecules for VDAC2 activity will provide 
insights into how the crosstalk between SR and 
mitochondria contributes to Ca2+ handling and 
cardiac rhythmicity.
Aberrant Ca2+ handling is associated with 
many cardiac dysfunctions including arrhythmia. 
Establishing animal models to study molecular 
mechanisms and develop new therapeutic strategies are therefore major preclinical needs. Our chem-
ical suppressor screen identified a potent effect of efsevin and its biological target VDAC2 on manipu-
lating cardiac Ca2+ handling and restoring regular cardiac contractions in fish and mouse and human 
cardiomyocytes. This success indicates that fundamental mechanisms regulating cardiac function are 
conserved among vertebrates despite the existence of species-specific features and suggests a new 
paradigm of using zebrafish cardiac disease models for the dissection of critical genetic pathways and 
the discovery of new therapeutic approaches. Future studies examining the effects of efsevin on other 
Video 9. This video shows a heart of a wild-type 
zebrafish embryo injected with zebrafish VDAC2 mRNA 
at 1 dpf. Robust rhythmic contractions can be observed 
in atrium and ventricle.
DOI: 10.7554/eLife.04801.016
Video 10. This video shows a heart of a tremblor 
embryo at 1 dpf. Tremblor embryos display only local, 
unsynchronized contractions, comparable to cardiac 
fibrillation.
DOI: 10.7554/eLife.04801.017
Video 11. This video shows a heart of a tremblor 
embryo injected with zebrafish VDAC2 mRNA at 1 dpf. 
Overexpression of zebrafish VDAC2 mRNA restores 
rhythmic contractions in tremblor embryos.
DOI: 10.7554/eLife.04801.018
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arrhythmia models would further elucidate the 
potential for efsevin as a pharmacological tool to 
treat cardiac arrhythmia associated with aberrant 
Ca2+ handling.
Materials and methods
Zebrafish husbandry and 
transgenic lines
Zebrafish of the mutant line tremblor (tretc318) 
were maintained and bred as described previ-
ously (Langenbacher et al., 2005). Transgenic 
lines, myl7:gCaMP4.1LA2124 and myl7:VDAC2LA2309 
were created using the Tol2kit (Esengil et al., 
2007; Kwan et al., 2007; Shindo et al., 2010). 
The VDAC2LA2256 was created using the zinc fin-
ger array OZ523 and OZ524 generated by the 
zebrafish Zinc Finger Consortium (Foley et al., 
2009a, 2009b).
Molecular Biology
Full length VDAC2 cDNA was purchased from 
Open Biosystems (Huntsville, AL) and cloned into 
pCS2+ or pCS2+3XFLAG. Full length cDNA 
fragments of zebrafish MCU (Accession number: 
JX424822) and MICU1 (JX42823) were amplified 
from 2 dpf embryos and cloned into pCS2+. For 
mRNA synthesis, plasmids were linearized and 
mRNA was synthesized using the SP6 mMES-
SAGE mMachine kit according to the manufac-
turers manual (Ambion, Austin, TX.).
Zebrafish injections
VDAC2 mRNA and morpholino antisense oligos 
(5 ¿-GGGAACGGCCATTTTATCTGTTAAA-3 ¿) 
(Genetools, Philomath, OR) were injected into 
one-cell stage embryos collected from crosses of 
tretc318 heterozygotes. Cardiac performance was 
analyzed by visual inspection on 1 dpf. The tre 
mutant embryos were identified either by observ-
ing the fibrillation phenotype at 2–3 dpf or by 
genotyping as previously described (Langenbacher 
et al., 2005).
Chemical screen
Chemicals from a synthetic library (Castellano 
et al., 2007; Choi et al., 2011; Cruz et al., 2011) 
and from Biomol International LP (Farmingdale, 
NY) were screened for their ability to partially 
or completely restore persistent heartbeat in tre 
embryos. 12 embryos collected from crosses of 
tretc318 heterozygotes were raised in the presence of individual compounds at a concentration of 10 µM 
from 4 hpf (Choi et al., 2011). Cardiac function was analyzed by visual inspection at 1 and 2 dpf. The 
hearts of tretc318 embryos manifest a chaotic movement resembling cardiac fibrillation with intermittent 
contractions in rare occasion (Ebert et al., 2005; Langenbacher et al., 2005). Compounds that elicit 
persistent coordinated cardiac contractions were validated on large number of tre mutant embryos 
and NCX1h morphants (>500 embryos).
Video 12. This video shows a heart of a 2 dpf  
Tg-VDAC2 embryo injected with a morpholino 
targeting NCX1h. Morpholino knock-down of  
NCX1h results in a fibrillating heart.
DOI: 10.7554/eLife.04801.019
Video 13. This video shows a heart of a 2 dpf NCX1h 
morphant in the Tg-VDAC2 genetic background. TBF 
treatment induces VDAC2 expression and restores 
coordinated cardiac contractions.
DOI: 10.7554/eLife.04801.020
Video 14. This video shows a heart of a 2 dpf wild type 
zebrafish embryo injected with a morpholino targeting 
VDAC2. Morpholino knockdown of VDAC2 did not have 
obvious effects on cardiac performance.
DOI: 10.7554/eLife.04801.021
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Zebrafish cardiac imaging
Videos of GFP-labelled myl7:GFP hearts were 
taken at 30 frames per second. Line-scan anal-
ysis was performed along a line through the atria 
or the ventricles of these hearts (Nguyen et al., 
2009). Fraction of shortening was deduced from 
the ratio of diastolic and systolic width and heart 
rate was determined by beats per minute. Cardiac 
parameters were analyzed in tremblortc318 and 
VDAC2LA2256 at 2 dpf.
Zebrafish optical mapping
36 hpf myl7:gCaMP4.1 embryos were imaged at 
a frame rate of 30 ms/frame. Electromechanical 
isolation was achieved by tnnt2MO (Milan et al., 
2006). The fluorescence intensity of each pixel 
in a 2D map was normalize to generate heat 
maps and isochronal lines at 33 ms intervals were 
obtained by identifying the maximal spatial gra-
dient for a given time point (Chi et al., 2008).
Mouse and human embryonic  
stem cells
The mouse E14Tg2a ESC and human H9 ESC line 
were cultured and differentiated as previously 
described (Blin et al., 2010; Arshi et al., 2013). 
At day 10 of differentiation, beating mouse EBs 
were exposed to external solution containing 
10 mM CaCl2 for 10 min before DMSO or efsevin 
(10 éM) treatment. Human EBs were differenti-
ated for 15 days and treated with 5 mM CaCl2 
for 10 min before DMSO or efsevin (5 éM) treat-
ment. Images of beating EBs were acquired at a 
rate of 30 frames/s and analyzed by motion-detection software. For calcium recording, the EBs were 
loaded with 10 éM fluo-4 AM in culture media for 30 min at 37°C. Line-scan analysis was performed 
and fluorescent signals were acquired by a Zeiss LSM510 confocal microscope.
Microelectrode array measurements
2-day-old wild type, tre, and efsevin-treated tre embryos were placed on uncoated, microelectrode 
arrays (MEAs) containing 120 integrated TiN electrodes (30 ém diameter, 200 ém interelectrode spac-
ing). Local field potentials (LFPs) at each electrode were collected for three trials per embryo type over 
a period of three minutes at a sampling rate of 1 kHz using the MEA2100-HS120 system (Multichannel 
Systems, Reutiligen, Germany). Raw data was low-pass filtered at a cutoff frequency of 10 Hz using a 
third-order Butterworth filter. Data analysis was carried out using the MC_DataTool (Multichannel 
Systems) and Matlab (MathWorks).
Ca2+ imaging
Murine ventricular cardiomyocytes were isolated as previously described (Reuter et al., 2004). Cells 
were loaded with 5 µM fluo-4 AM in external solution containing: 138.2 mM NaCl, 4.6 mM KCl, 1.2 mM 
MgCl, 15 mM glucose, 20 mM HEPES for 1 hr and imaged in external solution supplemented with 
2, 5 or 10 mM CaCl2. For the recording of Ca2+ sparks and transients, the external solution contained 
2 mM CaCl2. For Ca2+ transients, cells were field stimulated at 0.5 Hz with a 5 ms pulse at a voltage 
of 20% above contraction threshold. For all measurements, efsevin was added 2 hr prior to the actual 
experiment. Images were recorded on a Zeiss LSM 5 Pascal confocal microscope. Data analysis was 
carried out using the Zeiss LSM Image Browser and ImageJ with the SparkMaster plugin (Picht et al., 
2007). Cells were visually inspected prior to and after each recording. Only those recordings from 
Video 15. This video shows a heart of a 2 dpf tremblor 
mutant embryo injected with a morpholino targeting 
VDAC2. 
DOI: 10.7554/eLife.04801.022
Video 16. This video shows a heart of a 2 dpf tremblor 
mutant embryo injected with a morpholino targeting 
VDAC2. Efsevin treatment cannot restore coordinated 
cardiac contractions in the absence of VDAC2.
DOI: 10.7554/eLife.04801.023
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Figure 5. Efsevin enhances mitochondrial Ca2+ uptake. (A) HeLa cells were transfected with a flag-tagged zebrafish 
VDAC2 (VDAC2flag), immunostained against the flag epitope and counterstained for mitochondria with MitoTracker 
Orange and for nuclei with DAPI. (B) Representative traces of mitochondrial matrix [Ca2+] ([Ca2+]m) detected by 
Figure 5. Continued on next page
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Rhod2. Arrows denote the addition of Ca2+. Mitochondrial Ca2+ uptake was assessed when VDAC2 was overex-
pressed (left), cells were treated with 1 µM efsevin (middle) and combination of both at suboptimal doses (right). 
Control-traces with ruthenium red (RuRed) show mitochondrial specificity of the signal. (C) Representative traces  
of cytosolic [Ca2+] ([Ca2+]c) changes upon the application of 7.5 µM IP3 in the presence (+) or absence (−) of RuRed. 
Mitochondrial Ca2+ uptake was assessed by the difference of the – and + RuRed conditions normalized to the 
total release (n = 4; mean ± SE). (D) MEFs overexpressing zebrafish VDAC2 (polycistronic with mCherry) were 
stimulated with 1 éM ATP in a nominally Ca2+ free buffer. Changes in [Ca2+]c and [Ca2+]m were imaged using fura2 
and mitochondria-targeted inverse pericam, respectively. Black and gray traces show the [Ca2+]c (in nM) and [Ca2+]m 
(F0/F mtpericam) time courses in the absence (left) or present (right) of efsevin. (E) Bar charts: Cell population 
averages for the peak [Ca2+]c (left), the corresponding [Ca2+]m (middle), and the coupling time (time interval between 
the maximal [Ca2+]c and [Ca2+]m responses) in the presence (black, n = 24) or absence (gray, n = 28) of efsevin.
DOI: 10.7554/eLife.04801.024
The following figure supplement is available for figure 5:
Figure supplement 1. Local Ca2+ delivery between IP3 receptors and VDAC2. 
DOI: 10.7554/eLife.04801.025
Figure 5. Continued
healthy looking cells with distinct borders, uniform striations and no membrane blebs or granularity 
were included in the analysis.
Biochemistry
For pull down assays mono-N-Boc protected 2,2'-(ethylenedioxy)bis(ethylamine) was attached to the 
carboxylic ester of efsevin and its derivatives through the amide bond. After removal of the Boc group 
using TFA, the primary amine was coupled to the carboxylic acid of Affi-Gel 10 Gel (Biorad, Hercules, 
CA). 2-day-old zebrafish embryos were deyolked by centrifugation before being lysed with Rubinfeld's 
lysis buffer (Rubinfeld et al., 1993). The lysate was precleaned by incubation with Affi-Gel 10 Gel to 
eliminate non-specific binding. Precleaned lysate was incubated with affinity beads overnight. 
Proteins were eluted from the affinity beads and separated on SDS-PAGE. Protein bands of interest 
were excised. Gel plugs were dehydrated in acetonitrile (ACN) and dried completely in a Speedvac. 
Samples were reduced and alkylated with 10 mM dithiotreitol and 10 mM TCEP solution in 50 mM 
NH4HCO3 (30 min at 56°C) and 100 mM iodoacetamide (45 min in dark), respectively. Gel plugs were 
washed with 50 mM NH4HCO3, dehydrated with ACN, and dried down in a Speedvac. Gel pieces were 
then swollen in digestion buffer containing 50 mM NH4HCO3, and 20.0 ng/él of chymotrypsin (25°C, 
overnight). Peptides were extracted with 0.1% TFA in 50% ACN solution, dried down and resus-
pended in LC buffer A (0.1% formic acid, 2% ACN).
Mass spectrometry analyses and database searching
Extracted peptides were analyzed by nano-flow LC/MS/MS on a Thermo Orbitrap with dedicated 
Eksigent nanopump using a reversed phase column (New Objective, Woburn, MA). The flow rate 
was 200 nl/min for separation: mobile phase A contained 0.1% formic acid, 2% ACN in water, and 
mobile phase B contained 0.1% formic acid, 20% water in ACN. The gradient used for analyses was 
linear from 5% B to 50% B over 60 min, then to 95% B over 15 min, and finally keeping constant 
95% B for 10 min. Spectra were acquired in data-dependent mode with dynamic exclusion where 
the instrument selects the top six most abundant ions in the parent spectra for fragmentation. Data 
were searched against the Danio rerio IPI database v3.45 using the SEQUEST algorithm in the BioWorks 
software program version 3.3.1 SP1. All spectra used for identification had deltaCN>0.1 and met 
the following Xcorr criteria: >2 (+1), >3 (+2), >4 (+3), and >5 (+4). Searches required full cleavage with 
the enzyme, <4 missed cleavages and were performed with the differential modifications of carbami-
domethylation on cysteine and methionine oxidation.
In situ hybridization
In situ hybridization was performed as previously described (Chen and Fishman, 1996). DIG-labeled 
RNA probe was synthesized using the DIG RNA labeling kit (Roche, Indianapolis, IN).
Immunostaining
HeLa cells were transfected with a C-terminally flag-tagged zebrafish VDAC1 or VDAC2 in plasmid 
pCS2+ using Lipofectamine 2000 (Invitrogen). After staining with MitoTracker Orange (Invitrogen) 
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cells were fixed in 3.7% formaldehyde and permeabilized with acetone. Immunostaining was per-
formed using primary antibody ANTI-FLAG M2 (Sigma Aldrich, St. Luis, MO) at 1:100 and secondary 
antibody Anti-Mouse IgG1-FITC (Southern Biotechnology Associates, Birmingham, AL) at 1:200. Cells 
were mounted and counterstained using Vectashield Hard Set with DAPI (Vector Laboratories, UK).
Mitochondria Ca2+ uptake assay in HeLa cells
HeLa cells were transfected with zebrafish VDAC2 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). 
36 hrs after transfection, cells were loaded with 5 µM Rhod2-AM (Invitrogen), a Ca2+ indicator preferen-
tially localized in mitochondria, for 1 hr at 15°C followed by a 30 min de-esterification period at 37°C. 
Subsequently, cells were permeabilized with 100 µM digitonin for 1 min at room temperature. 
Figure 6. Effects of efsevin on isolated cardiomyocytes. (A) Electrically paced Ca2+ transients at 0.5 Hz (top). 
Normalized quantification of Ca2+ transient parameters reveals no difference for transient amplitude (efsevin-treated 
at 98.6 ± 4.5% of vehicle-treated) and time to peak (95 ± 3.9%), but a significant decrease for the rate of decay  
(82.8 ± 4% of vehicle- for efsevin-treated) (lower panel). (B) Representation of typical Ca2+ sparks of vehicle- and 
efsevin treated cardiomyocytes (top). No differences were observed for spark frequency (101.1 ± 7.7% for efsevin- 
compared to vehicle-treated), maximum spark amplitude (101.6 ± 2.5%) and Ca2+ release flux (98.7 ± 2.8%). In 
contrast, the decay phase of the single spark was significantly faster in efsevin treated cells (82.5 ± 2.1% of 
vehicle-treated). Consequently, total duration of the spark was reduced to 85.7 ± 2% and the total width was 
reduced to 89.5 ± 1.4% of vehicle-treated cells. *, p < 0.05; ***, p < 0.001. (C) Increasing concentrations of 
extracellular Ca2+ induced a higher frequency of spontaneous propagating Ca2+ waves in isolated adult murine 
ventricular cardiomyocytes. Efsevin treatment reduced Ca2+ waves in a dose-dependent manner. (D) Quantitative 
analysis of spontaneous Ca2+ waves spanning more than half of the entire cell. Addition of 1 µM efsevin reduced 
Ca2+ waves to approximately half. Increasing the concentration of efsevin to 10 µM further reduced the number  
of spontaneous Ca2+ waves and 25 µM efsevin almost entirely blocked the formation of Ca2+ waves.
DOI: 10.7554/eLife.04801.026
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Figure 7. Mitochondria regulate cardiac rhythmicity through a VDAC2-dependent mechanism. (A) MCU and 
MICU1 are expressed in the developing zebrafish hearts (arrowhead). (B) Overexpression of MCU is sufficient to 
restore coordinated cardiac contractions in tre embryos (47.1 ± 1.6% embryos, n = 112 as opposed to 18.3 ± 5.3% 
of uninjected siblings, n = 64) while this effect is significantly attenuated when co-injected with morpholino antisense 
oligonucleotide targeted to VDAC2 (27.1 ± 1.9% embryos, n = 135). (C) Suboptimal overexpression of MCU (MCUS) 
and VDAC2 (VDAC2S) in combination is able to suppress cardiac fibrillation in tre embryos (42.9 ± 2.6% embryos,  
n = 129). (D) The ability of VDAC2 to restore rhythmic contractions in tre embryos (48.5 ± 3.5% embryos, n = 111) is 
significantly attenuated when MCU is knocked down by antisense oligonucleotide (MOMCU) (25.6 ± 2.4% embryos,  
n = 115). (E) Overexpression of MICU1 is sufficient to restore rhythmic cardiac contractions in tre embryos  
(49.3 ± 3.4% embryos, n = 127 compared to 16.8 ± 1.4% of uninjected siblings, n = 150). This effect is abrogated  
by VDAC2 knockdown (MOVDAC2, 25.3 ± 5.5% embryos, n = 97). (F) Suboptimal overexpression of MICU1 (MICU1S) 
and VDAC2 (VDAC2S) in combination is able to restore rhythmic cardiac contractions in tre embryos (48.6 ± 6.0%,  
n = 106). Error bars represent s.d.; *p < 0.05; ***p < 0.001.
DOI: 10.7554/eLife.04801.027
The following figure supplement is available for figure 7:
Figure supplement 1. Expression of MCU, MICU1 and VDAC2. 
DOI: 10.7554/eLife.04801.028
Fluorescence changes in Rhod2 (ex: 544 nm, em: 590 nm) immediately after the addition of Ca2+ (final 
free Ca2+ concentration is calculated to be approximately 10 µM using WEBMAXC at http://web.
stanford.edu/cpatton/webmaxcS.htm) were monitored in internal buffer (5 mM K-EGTA, 20 mM 
HEPES, 100 mM K-aspartate, 40 mM KCl, 1 mM MgCl2, 2 mM maleic acid, 2 mM glutamic acid, 
5 mM pyruvic acid, 0.5 mM KH2PO4, 5 mM MgATP, pH adjusted to 7.2 with Trizma base) using a 
FLUOSTAR plate reader (BMG Labtech, Germany).
Mitochondria Ca2+ uptake assay in VDAC1/VDAC3 double knockout 
(V1/V3 DKO) MEFs
V1/V3 DKO MEFs were cultured as previously described (Roy et al., 2009a). Efsevin-treated (15 éM 
for 30 min) or mock-treated MEFs were used for measurements of [Ca2+]c in suspensions of permeabi-
lized cells or imaging of [Ca2+]m simultaneously with [Ca2+]c in intact single cells. Permeabilization of the 
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plasma membrane was performed by digitonin (40 éM/ml). Changes in [Ca2+] in the cytoplasmic buffer 
upon IP3 (7.5 éM) addition in the presence or absence of ruthenium red (3 éM) was measured by fura2 in 
a fluorometer (Csordás et al., 2006; Roy et al., 2009b). To avoid endoplasmic reticulum Ca2+ uptake 
2 éM thapsigargin was added before IP3. For imaging of [Ca2+]m and [Ca2+]c, MEFs were co-transfected 
with plasmids encoding polycistronic zebrafish VDAC2 with mCherry and mitochondria-targeted inverse 
pericam for 40 hr. Cells were sorted to enrich the transfected cells and attached to glass coverslips. In 
the final 10 min, of the efsevin or mock-treatment, the cells were also loaded with fura2AM (2.5 éM) and 
subsequently transferred to the microscope stage. Stimulation with 1 éM ATP was carried out in a normi-
nally Ca2+ free buffer. Changes in [Ca2+]c and [Ca2+]m were imaged using fura2 (ratio of ex:340 nm–380 nm) 
and mitochondria-targeted inverse pericam (ex: 495 nm), respectively (Csordas et al., 2010).
Statistics
All values are expressed as mean ± SEM, unless otherwise specified. Significance values are calculated 
by unpaired student's t-test unless noted otherwise.
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Background: Biochemical characterization of voltage-dependent anion channel 2 (VDAC2) is limited due to an inability to
obtain functional protein.
Results:The crystal structure of VDAC2 suggests a dimer interface that is confirmed by double electron-electron resonance and
cross-linking.
Conclusion: zfVDAC2 has a fractional dimeric population.
Significance: VDAC isoforms are structurally similar, but this study has identified a number of hot spots that require further
exploration.
In recent years, there has been a vast increase in structural and
functional understanding of VDAC1, but VDAC2 and -3 have
been understudied despite having many unique phenotypes.
One reason for the paucity of structural and biochemical charac-
terizationof theVDAC2and-3 isoformsstemsfromthe inabilityof
obtaining purified, functional protein. Here we demonstrate the
expression, isolation, and basic characterization of zebrafish VDAC2
(zfVDAC2).Further,weresolved thestructureofzfVDAC2at2.8 Å
resolution, revealing a crystallographic dimer. The dimer orienta-
tion was confirmed in solution by double electron-electron reso-
nance spectroscopy and by cross-linking experiments disclosing a
dimer population of 20% in lauryldimethine amine oxide deter-
gent micelles, whereas in lipidic bicelles a higher population of
dimeric and higher order oligomers species were observed. The
present study allows for a more accurate structural comparison
between VDAC2 and its better-studied counterpart VDAC1.
Mitochondria are often depicted as the cell’s “powerhouse”
because they generate ATP fromADP and inorganic phosphate
through the oxidative phosphorylation process. It is now firmly
established thatmitochondria have a farmore expansive role in
cellular function, including signaling, cell death/survival, and
differentiation (1–3). As such, mitochondria are central to nor-
mal human physiology as well as disease. The most abundant
proteins in the outermitochondrial membrane, the voltage-de-
pendent anion channels (VDACs),5 are large pore-forming pro-
teins that mediate the efficient exchange of metabolites and
ions between the cytosol and the mitochondrial intermem-
brane space (IMS). In mammals, there are three VDAC iso-
forms (VDAC1–3), which have a high degree of sequence
homology, yet their relative ratios and distribution between cell
types are varied.
The sequence identity/similarity between human VDAC1
(hVDAC1), hVDAC2 and hVDAC3 is 75%/91% and 67%/85%,
respectively (Fig. 1). Undoubtedly, VDAC1 is the best charac-
terized isoform. After decades of struggle, three groups inde-
pendently resolved the high resolution structure of VDAC1
(4–6). Using the lipidic bicelle crystallization technique (6–8),
we solved a high resolution x-ray structure of mouse VDAC1
(mVDAC1) at a resolution of 2.3Å.All reported high resolution
structures of VDAC1 revealed a novel fold of a 19-stranded
-barrel with an N-terminal -helix lying inside the pore. This
helix is aligned nearly parallel to themembrane plane, causing a
partial narrowing of the pore. Numerous studies have estab-
lished the functional importance of the N-terminal -helix in
regulating the flux of metabolites through the channel (9, 10),
and the observation that it is localized within the pore makes it
* This work was supported, in whole or in part, by National Institutes of Health
Grants RO1 GM078844 (to J. A.) and 5R01 EY005216 (to C. J. L.). This work was
also supported by Austrian Science Fund FWF Erwin-Schrödinger Fellowship
J3065-B11 (to J. S.), Jules Stein Eye Institute Training Grant 2T32EY007026-
36A1 (to C. J. L.), and the Jules Stein Professor Endowment (to W. L. H.).
This work is dedicated to the memory of Armand S. Vartanian, a colleague and
friend.
The atomic coordinates and structure factors (code 4BUM) have been deposited
in the Protein Data Bank (http://wwpdb.org/).
1 These authors contributed equally to this work.
2 To whom correspondence may be addressed. E-mail: chenjn@mcdb.ucla.
edu.
3 To whom correspondence may be addressed. E-mail: hubbellw@jsei.ucla.
edu.
4 To whom correspondence may be addressed. E-mail: jabramson@
mednet.ucla.edu.
5 The abbreviations used are: VDAC, voltage-dependent anion channel;
hVDAC, zfVDAC, and mVDAC, human, zebrafish, and mouse VDAC, respec-
tively; CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-
propanesulfonic acid; IMS, intermembrane space; DEER, double electron-
electron resonance; LDAO, lauryldimethyl amine oxide; CW, continuous
wave; DEF, dipolar evolution function.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 18, pp. 12566 –12577, May 2, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
12566 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289 • NUMBER 18 • MAY 2, 2014
 at U
B
M
 B
ib
lio
th
ek
 G
ro
ssh
ad
ern
 o
n
 A
p
ril 8
, 2
0
2
0
h
ttp
://w
w
w
.jb
c.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
ideally suited to regulate the passage of ions and metabolites
through the pore. Based on molecular dynamics simulations
and a series of cross-linking studies, the structure is believed to
reside in the “open” conformation, facilitating the passage of
ATP and other nucleotides (11, 12).
In contrast toVDAC1, structural and biochemical character-
ization of VDAC2 and -3 is rather limited, yet these isoforms
have distinct physiological functions. In particular, VDAC2
null mice are embryonic lethal (13), whereas null mice of
VDAC1 and -3 isoforms display mild phenotypes (14, 15). Fur-
thermore, VDAC2 has been shown to interact and inhibit the
proapoptotic protein BAK, thereby hampering mitochondrial
apoptosis (13). In cardiomyocytes, VDAC2 specifically inter-
acts with the ryanodine receptor and mediates Ca2 transfer
from the sarcoplasmic reticulum intomitochondria (16), impli-
cating a role for VDAC2 in cardiac Ca2 homeostasis. Addi-
tionally, the small quinazolinone agent erastin, an anti-tumor
compound, interactswithVDAC2 to induce cell death in tumor
cells expressing mutant RAS (17, 18). In total, there is signifi-
cant evidence that despite the high sequence identity in this
family, VDAC2 has a specific phenotype, which is distinct from
those of the other two VDAC isoforms.
To gain insight into the structure and function ofVDAC2,we
expressed and purified zfVDAC2. The purified protein forms
active channels in lipid planar bilayers, and we were able to
determine the structure at 2.8 Å resolution. The overall struc-
ture is very similar to VDAC1, revealing a dimer interface
between 17, 18, 19, 1, and 3. Using double electron-
electron resonance (DEER) measurements and cross-linking
experiments, we confirmed the dimer topology in solution and
found a fractional dimer content of20% in detergent micelles
and 40% in lipidic bicelles.
EXPERIMENTAL PROCEDURES
Cloning of pQE60-zfVDAC2C127A and Single-cysteine Mutants—
The full-length zfVDAC2 ORF was purchased from Open Bio-
systems and PCR-amplified. PCR primers were used to add an
NcoI site (5) and a His6 tag followed by a HindIII site (3) for
subsequent NcoI/HindIII cloning into the pQE60 expression
plasmid. For DEER experiments, we created construct pQE60-
zfVDAC2C127A/S232C. Three individual PCRs were used to cre-
ate three overlapping fragments of the zfVDAC2 ORF and to
introduce the C127A and S232C mutations, respectively, by
mutagenesis primers. Individual PCR fragments were fused by
FIGURE 1. Sequence alignment between VDAC1 and -2. A select set of VDAC1 and -2 sequences are aligned. For reference, the secondary structure elements
are represented as two-dimensional schematics above sequences.
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splicing by overlap extension-PCR, and the resulting product
was ligated into the pQE60 backbone using NcoI/HindIII. All
PCR-amplified products were fidelity-checked by sequencing
(Laragen, Inc., Culver City, CA).
Tocreate single-Cysmutants for cross-linking experiments, the
Cys-less backbone pQE60-zfVDAC2C127A was created by fusion
of base pairs 427–870 of the ORF from pQE60-zfVDAC2 into
pQE60-zfVDAC2C127A/S232C using PstI and HindIII, thereby
eliminating the S232C mutation. Single-cysteine mutants were
subsequently generated in the pQE60-zfVDAC2C127A backbone
by mutagenesis PCR. For pQE60-zfVDAC2C127A/V27C, pQE60-
zfVDAC2C127A/D50C, pQE60-zfVDAC2C127A/S52C, and pQE60-
zfVDAC2C127A/T83C mutation primers were used to introduce
the respective mutations in two independent PCRs, which
were then fused in a splice overlap extension PCR. Final PCR
products were ligated into pQE60-zfVDAC2C127A using
XhoI and PstI. For pQE60-zfVDAC2C127A/Q196C, pQE60-
zfVDAC2C127A/L251C, pQE60-zfVDAC2C127A/I255C, and pQE60-
zfVDAC2C127A/I257C mutagenesis PCR was performed as
described above, but PCR products were ligated into pQE60-
zfVDAC2C127A using PstI and NheI. All PCR-amplified prod-
ucts were fidelity-checked by sequencing (Eurofins MWG
Operon, Ebersberg, Germany).
Expression and Purification of zfVDAC2—Cloning, expres-
sion, and purification of zfVDAC2 followed the previously
reported protocol for mVDAC1 (6). In short, M15 Escherichia
coli cells carrying pQE60-zfVDAC2 were grown in Luria broth
with agitation at 37 °C, induced at an OD of 1 with 0.4 mM
isopropyl-1-thio--D-galactopyranoside and grown for an addi-
tional 4–5 h. Cells were harvested by centrifugation and resus-
pended in 50 mM TrisHCl (pH 8.0), 2 mM EDTA, 20% sucrose.
The cell slurry was lysed by consecutive incubation with 12.5
g/ml lysozyme and 0.6% Triton X-100 followed by sonication.
Inclusion bodies were obtained through centrifugation at
12,000  g for 15 min, washed, and solubilized in 20 mM
TrisHCl (pH 8.0), 300 mM NaCl, 6 M guanidinium hydrochlo-
ride. zfVDAC2 proteinwas purified using a Talonmetal affinity
column and refolded in a three-step dialysis at 10 mg/ml. Dial-
ysis buffers were as follows: 1) 20mMTrisHCl (pH8.0), 300mM
NaCl, 1 mM DTT, 3 M guanidinium hydrochloride; 2) 20 mM
TrisHCl (pH 8.0), 300 mM NaCl, 1 mM DTT, 0.1% LDAO; and
3) 20 mM TrisHCl (pH 8.0), 50 mM NaCl, 1 mM DTT, 0.1%
LDAO. 2%LDAOwas added to the protein solution prior to the
second dialysis step. Refolded protein was concentrated, ultra-
centrifuged (355,000  g, 30 min) to remove aggregated pro-
tein, and passed over a Superdex 200 column in 150 mM NaCl,
0.1% LDAO, 20 mM TrisHCl (pH 8.0) to obtain a homogenous
protein population (Fig. 2, A and B). For crystallization, frac-
tions containing the non-aggregated zfVDAC2 peak were col-
lected, concentrated, and buffer changed to 50 mM NaCl, 0.1%
LDAO, 20 mM TrisHCl (pH 8.0) using an Amicon Ultra-30k
(Millipore) concentrator.
Crystallization—Crystals of 0.6  0.2  0.1 mm were
grown by the hanging drop vapor diffusion method using the
Mosquito crystallization robot. A 12 mg/ml protein solution
was mixed (1:1) with a well solution of 100 mM TrisHCl (pH
8.0), 100 mM KCl, and PEG 2000 ranging between 19 and 24%.
Subsequent optimization was performed by the addition of
n-undecyl--D-thiomaltopyranoside at its critical micelle con-
centration (0.011%). Crystals were cryoprotected by transfer-
ring them for 10 s into a solution containing 100 mM TrisHCl
(pH 8.0), 100 mM KCl, 50% PEG 2000, 0.011% n-undecyl--D-
thiomaltopyranoside prior to flash freezing in liquid nitrogen.
Lipid Planar Bilayer—Lipid bilayer experiments were per-
formed as described previously (6). In brief, recordings were
performed in diphytanoyl phosphatidylcholine bilayers across a
0.1-mm hole in 10 mM TrisHCl (pH 7.4), 1 MKCl, 5 mMCaCl2.
After channel insertion, currents were recorded in response to
test pulses between 50 and 50 mV. Total point histograms
at each applied voltage were plotted to calculate the conduc-
tance (G) of open and closed states (Fig. 2C).
X-rayDataCollection andProcessing—X-ray diffraction data
were collected to 2.7 Å on flash-frozen crystals (180 °C) at the
Advanced Light Source (Berkeley, CA) (beam line 5.0.2). Index-
ing and integration were performed with XDS (19), using data
up to 2.8 Å, and the space group was determined to be P3221
with the following unit cell dimensions: a  72.47 Å, b  72.47
Å, and c  177.95 Å (    90° and   120°). One molecule
is present per asymmetric unit with an estimated solvent con-
tent of 70.4% (Vm  4.15 Å
3/Da) based on the Matthews prob-
ability calculator (20, 21). The structure was solved by molecu-
lar replacement using themurine VDAC1 coordinates (Protein
Data Bank code 3EMN) as the search model in PHENIX (21).
After generation of the initial model, it was manually rebuilt
using Coot (22), followed by iterative rounds of refinement in
PHENIX (21). The finalmodel (ProteinData Bank code 4BUM)
contained 283 amino acids, sixwatermolecules, and one LDAO
molecule with a final R-factor and R-free of 0.246 and 0.282,
respectively. Data collection and refinement statistics are listed
in Table 1. All figures containing structures were generated
using PyMOL (23) or Chimera (24).
Spin Labeling, Continuous Wave (CW) EPR Spectroscopy,
and DEER Experiments—For CW and DEER experiments,
DTT was removed during the size exclusion chromatography
step, and the protein was incubated with a 5-fold molar excess
of 1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl methanethio-
sulfonate for 16 h at 4 °C to generate the R1 side chain (25).
Excess spin label was removed by repeated washes using an
Amicon Ultra-30k (Millipore) concentrator in 20 mM TrisHCl
(pH 8.0), 50 mM NaCl, 0.1% LDAO, 20% glycerol. For
zfVDAC2C127A/S232C, the fraction of spin-labeled protein was
98% as estimated from a 4,4-dithiodipyridine titration for
free thiol after the spin labeling reaction (26). A fraction of the
spin-labeled zfVDAC2C127A/S232C was reconstituted in bicelles
by mixing the protein with bicelles in a 4:1 ratio with a 35%
(2.8:1) L--dimyristoylphosphatidylcholine/CHAPSO bicellar
solution.
The CW EPR spectra of zfVDAC2 232R1 in LDAO and
bicelles were recorded at room temperature on a Varian E-109
spectrometer fitted with a two-loop one-gap resonator; sam-
ples of 5 l were contained in a borosilicate capillary tube
(0.64-mm inner diameter  0.84-mm outer diameter; VitroCom
Inc.). For LDAO, a second spectrumwas recordedwith the sam-
ple containing 30% (w/w) sucrose solution. The spectra were
recorded using 2-milliwatt microwave power and 1-G field
modulation at 100 kHz.
Structure and Oligomeric Population of VDAC2
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Four-pulse DEER experiments (27) at Q band were con-
ducted at 80 K on a Bruker ELEXSYS 580 spectrometer fitted
with a Bruker EN5107D2 resonator. The protein concentration
during the DEER experiments was maintained at or below 200
M. 20 l of spin-labeled protein reconstituted in LDAO or
bicelles containing 20% (v/v) glycerol were loaded into a boro-
silicate capillary tube (1.4-mm inner diameter  1.7-mm outer
diameter; VitroCom) and subsequently flash-frozen in liquid
nitrogen. A 36-ns -pump pulse was set at the maximum
absorption spectra, and the observer /2 (16-ns) and  (32-ns)
pulses were positioned 50MHz (17.8 G) up-field. Distance dis-
tributions were obtained from the raw dipolar evolution time
using the program LongDistances (available at the Hubbell
Laboratory Web site). A dipolar evolution function (DEF) was
obtained after applying an exponentially decaying background
function (using a dimensionality of 3) to correct for random
intermolecular dipolar interactions. The DEF was fit to obtain
interspin distance distributions (Fig. 7, B and C).
In addition to the distribution of distances between interact-
ing spins, the average number of interacting spins in a molecu-
lar entity, nm, can be determined according to Equation 1 (28),
nm  1  	ln	1 	 
/C (Eq. 1)
where
 is the “depth ofmodulation” (shown in Fig. 7,B andC),
and C is a constant that depends on the pump pulse profile, the
resonator, and the spectral line shape of the nitroxide spin label
(28). In the present experiments, C was determined using dou-
ble cysteine mutants of T4 lysozyme (N68C/T109C and
T109C/V131C) known to be quantitatively labeled with R1 as
judged by determination of free thiols after the labeling reaction
using a 4,4-dithiodipyridine assay (26). From the depth of
modulation and using nm  2, C is obtained from Equation 1;
the values obtained from the two T4 lysozyme mutants agreed
to within 1%. From the experimentally determined depth of
modulation and C, the value of nm for VDAC2 in LDAO or
bicelles can be determined.
Cross-linking Experiments—Disulfide bonds between single-
cysteine mutants were induced with the oxidizing reagent
dichloro(1,10-phenanthroline)Cu(II). zfVDAC2 mutants were
diluted to 15 M in buffer containing 150 mM NaCl, 20 mM
TrisHCl (pH 8.0), 5 mM DTT, and 0.1% LDAO. The oxidizing
reaction was performed with 5 mM dichloro(1,10-phenanthro-
line)Cu(II) at 4 °C for 2min and subsequently quenchedwith 10
mM EDTA and 10mMN-ethylmaleimide. The results were ana-
lyzed on 12% SDS-polyacrylamide gels stainedwith a Coomassie-
based InstantBlue reagent (Expedeon).
RESULTS
Protein Purification and Lipid Bilayer Conductance—Native
recombinant zfVDAC2 protein with a His tag fused to the C
terminus was prepared using a two-step column purification
that consisted of 1) solubilized inclusion bodies that were
applied to a Talon metal affinity column and eluted with 150
mM imidazole and 2) concentrated protein that was refolded
and applied to a Superdex 200 column to remove aggregation
and obtain a homogenous protein population (Fig. 2, A and B).
Purified zfVDAC2 protein was inserted in planar lipid bilayers,
where it exhibited a single channel conductance of 4.2  0.5
nanosiemens at 10 mV in 1 M KCl (open state; Fig. 2C). As the
applied voltage was increased to 30 mV, the channel pre-
sented distinct gating behavior between the open and closed
states with a conductance of 1.7  0.2 nanosiemens (Fig. 2C).
This behavior is in good agreement with recordings from
VDAC1 isolated from rats (29) and indicates that zfVDAC2,
from our preparation, forms active channels. To further under-
stand the functional aspects of ion andmetabolite trafficking as
well as the relation of zfVDAC2 to previously reportedVDAC1,
we pursued a high resolution structure of zfVDAC2.
Structural Overview—Optimized crystals of zfVDAC2 belong
to the trigonal space group P3221 with one molecule per asym-
metric unit. The structure was determined by molecular
replacement using the original mVDAC1 coordinates (Protein
Data Bank code 3EMN) as a search model. The only part of the
model that requiredmanual rebuilding following themolecular
replacement procedure was the loop between -strands 1 and
2. The model was ultimately refined from merged data to a
resolution of 2.8 Å with an R-free of 24.6% and an R-work of
28.2% (Table 1). 282 of the 283 amino acids of zfVDAC2 were
assigned alongwith sixwatermolecules and one copy of LDAO.
Further details regarding the crystallization and structure
determination can be found under “Experimental Procedures.”
A refined electron density map is shown in Fig. 3C.
The structure of zfVDAC2 is similar to that of mVDAC1
(Protein Data Bank code 3EMN), forming a -barrel composed
of 19 -strands (Fig. 3). All of the strands exhibit an antiparallel
pattern with the exception of strands 1 and 19, which associate
in a parallel manner to seal the barrel. The maximal height and
FIGURE 2. Functional characterization of zfVDAC2. A, size exclusion chro-
matography of zfVDAC2. The dashed box represents a non-aggregated
homogenous population of protein used for further characterization. B, 12%
SDS-polyacrylamide gel stained with Coomassie Brilliant Blue showing a pure
sample of zfVDAC2. C, electrophysiology recordings of zfVDAC2 in
diphytanoyl phosphatidylcholine bilayers in 10 mM TrisHCl (pH 7.4), 1 M KCl, 5
mM CaCl2. Total point histograms at each applied voltage were plotted to
calculate the conductance (G) of the open and closed state. mAU, milliabsor-
bance units.
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width of the -barrel are 35 and 40 Å, respectively. The correct
orientation of the protein within the outer membrane of the
mitochondria is still debated, with multiple studies producing
conflicting results on the endogenous position of the N and C
termini (30–32); however, a recent study has shown the C ter-
minus to reside in the IMS (33). The N terminus of the protein
forms a distorted -helix that is aligned nearly parallel to the
plane of the membrane, causing a partial narrowing of the pore
(Fig. 3). The pore forms a large pathway that traverses the entire
length of the protein. There have now been a number of studies
confirming that this conformation probably resides in the
“open” state of the channel (11, 12).
A structural alignment between the crystal structure of
zfVDAC2 and mVDAC1 (Protein Data Bank code 3EMN)
showed a root mean square deviation of 0.98 Å (Fig. 4A). The
well aligned structures, including the N-terminal segment,
indicate that these proteins share many similar properties and
FIGURE 3. Overall structure of zfVDAC2. Shown are cartoon representations of zfVDAC2 viewed perpendicular to the membrane plane (A) and in the
membrane plane (B). The protein backbone is rainbow-colored from the N terminus (blue) to the C terminus (red). A 2Fo  Fc map contoured at 1.5
 is displayed
in a blue wire frame with the zfVDAC2 model shown in sticks (C).
TABLE 1
Crystallography statistics for zfVDAC2
Data collection
Space group P3221
Cell dimensions
a, b, c (Å) 72.47, 72.47, 177.95
, ,  (degrees) 90, 90, 120
Resolution (Å) 51.29–2.701
Rsym or Rmerge 0.08 (0.76)
a
I/
I 12.99 (1.95)
Completeness (%) 97.98 (97.3)
Redundancy 3.5 (3.4)
Refinement
Resolution (Å) 50–2.8
No. of reflections 53,149
Rwork/Rfree 24.55/28.22 (31.23/35.34)
No. of atoms 2151
Protein 2133
Ligand/ion 12
Water 6
B-Factors
Protein 51.0
Ligand/ion 58.3
Water 24.4
Ramachandran favored (%) 94
Ramachandran outliers (%) 0.71
Root mean square deviations
Bond lengths (Å) 0.004
Bond angles (degrees) 0.87
a Values in parentheses are for the highest resolution shell.
FIGURE 4. Superposition of zfVDAC2 and VDAC1. A, zfVDAC2 in blue and
mVDAC1 (Protein Data Bank code 3EMN) in red were aligned with a C root
mean square deviation of 0.98 Å. There is a large displacement (12 Å) in the
loop between -strands 1 and 2. B, an IMS view of the loop between -strands
1 and 2, including zfVDAC2 in blue, mVDAC1 in red, hVDAC1 (Protein Data
Bank code 2JK4) in green, and a representative NMR conformer of hVDAC1
(Protein Data Bank code 2K4T) in salmon.
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functions. The sole exception is a large displacement (12Å) of
the loop between strands 1 and 2 (Fig. 4B). Further comparison
using Columbic electrostatic calculations (Fig. 5) revealed a
continuous electronegative patch on the cytosolic lip of
mVDAC1 extending from the C terminus of the protein (19)
and within the loops connecting 1 to 2, 3 to 4, and 5 to
6. In zfVDAC2, the loop connecting 1 to 2 is electroposi-
tive, disrupting the electronegative continuity. In addition,
there are a number of other subtle differences. Residues 61–65
in -strand 3 contain four positive residues in zfVDAC2
(KYKRS) as opposed to two positive residues in mVDAC1
(KYRWT); residues 280–282, at the C terminus of the protein,
contain two negative residues in zfVDAC2 (Glu-Leu-Glu) as
opposed to one inmVDAC1 (Glu-Phe-Gln); andGlu-36, which
resides in mVDAC1 in the mobile loop connecting -strands 1
and 2, is substituted to an Ala in zfVDAC2. Additional hydro-
phobicity analysis did not show any significant difference
between the two isoforms.
Dimer Interface—The oligomeric organization of VDAC
has been strongly correlated with its physiological function.
Numerous studies have demonstrated thatVDACcan achieve a
number of oligomeric populations, depending on the cell’s
environment, includingmonomers, dimers, trimers, tetramers,
hexamers, and evenhigher order oligomers (34).More recently,
this arrangement has been shown to be dynamic and further
influenced by the lipidic environment (35). As was done with
hVDAC1 (5), a zfVDAC2 dimer was constructed using crystal
symmetry operators. zfVDAC2 forms crystals of a space sym-
metry group P3221, which leads to three distinct zfVDAC2
symmetry-related interfaces. The most extensive surface, with
a buried surface area of 554 Å2 and a solvation free energy gain
of 
G  14.9 kcal/mol, is formed by buried hydrophobic res-
idues in strands 17 (Arg-252 and Leu-251), 18 (Leu-259,
Leu-257, and Ile-255), 19 (Leu-281, Leu-279, Leu-277, and
Leu-275), 1 (Val-31, Leu-29, and Val-27), and 3 (Val-54, Ser-
52, Asp-50, Thr-49, and Ser-47) (Fig. 6).
To confirm the dimer interface of zfVDAC2 in solution and
the relative abundance of zfVDAC2 oligomers, we generated a
cysteine-less construct by replacing the endogenous cysteine
residue with alanine (C127A) and subsequently engineered a
cysteine at position 232, which is theN-terminal residue of16.
This mutant was then spin-labeled with 1-oxyl-2,2,5,5-tetra-
methylpyrroline-3-methyl methanethiosulfonate reagent to
generate an R1 side chain, and the interspin distance distribu-
tion was measured using DEER spectroscopy in LDAO and in
lipidic bicelles. The DEER experiment measures the dipolar
interaction between unpaired electrons in the range of 17–70Å
(27) and thus can be used to detect the presence of homodimers
or higher oligomers in a solution of singly labeled proteins. Res-
idue 232 was selected for this study because modeling of the R1
side chain at site 232 in the crystallographic dimer shown in Fig.
6 suggests a distance between R1 labels of 31 Å (Fig. 7A),
which is well within the range of interspin distance that can be
reliably measured with DEER spectroscopy.
In the DEER experiment, magnetic interactions between
randomly distributed spins in different molecular entities give
rise to an exponentially decaying “background” signal (red
traces in the left-hand panels of Fig. 7, B and C). The experi-
mental DEER signals (black and cyan traces in the left-hand
panels of Fig. 7, B and C) deviate from the background at short
evolution times, unequivocally demonstrating the presence of
specific oligomers in solutions of both LDAO and bicelles.
Removal of the background signal from the raw data gives the
corresponding DEFs (right-hand panels of Fig. 7, B and C),
FIGURE 5. Electrostatic potentials of zfVDAC2 and mVDAC1. Electrostatic potentials for zfVDAC2 (top row) and mVDAC1 (bottom row) are shown. A, a view
from the IMS. There is an elongated electronegative patch extending from the C terminus of mVDAC1 through the loops of -strands 1– 6, which is interrupted
by positive charges in zfVDAC2 (dashed green circle). B, a side view. C, a view from the cytosolic side.
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which can be fit to obtain a probability distribution of interspin
distances (Fig. 7D). In LDAO, the distance distribution is broad
with a full width at half-height of nearly 20Å,which exceeds the
width anticipated from a distribution of R1 rotamers (34) and
suggests flexibility in the region of 16. The broad distribution
may also arise from heterogeneity regarding the relative orien-
tation of each molecule in the dimer. However, some of the
localmaxima in the broad distribution could arise fromdistinct
rotamers of R1. The median of the distribution is 30.5 Å, close
to that determined frommodeling of R1 in the crystallographic
dimer.
In bicelles, the median of the distribution is 32.4 Å (the most
probable distance is 30.3), again close to that expected from the
crystallographic dimer. However, there is a small population
near 55Å (arrow in Fig. 7D). The shape of the distribution is not
well determined due to the limited data collection time of 2.5
s, but a detectable population at long distance is required to fit
the data. A distance in this range cannot correspond to any
possible homodimer but must originate from higher order
oligomers.
The depth of modulation of the DEF (
; Fig. 7, B and C) is
4% for VDAC2 232R1 in either LDAO or bicelles, compared
with 10% for the doubly labeled T4 lysozyme pairs used for
determination of the constantC under identical conditions (see
“Experimental Procedures”). The low depth of modulation
could be due to incomplete labeling of the protein and/or due to
a small fraction of protein in oligomeric form (28). Because
labeling was found to be quantitative (see “Experimental Pro-
cedures”), it is concluded that only a small fraction of the pro-
tein exists in oligomeric form, consistent with recent spectros-
copy studies on hVDAC1 (35).
The distance distribution for 232R1 in LDAO clearly sup-
ports the formation of a homodimer.Within the context of this
model, the fraction of VDAC2 in dimer form, fd, can be esti-
mated from themodulation depth of theDEER signal according
to Refs. 24 and 25 (fd  n 1 ln(1 
)/C, which gives18%.
The depth of modulation for VDAC2 232R1 in bicelles is
larger than for the protein in LDAO (compare delta values in
panels B and C of Fig. 7), which indicates a higher fraction of
total oligomeric species (40%). The larger depth of modula-
tion arises due to the existence of higher order oligomers (indi-
cated by the 55 Å population in the distance distribution) and
possibly a larger value for fd. An increase in the oligomeric
population in bicelles compared with LDAO micelles is in
agreement with previous studies, which reported that the per-
centage of dimer is influenced by detergent or lipidic environ-
ments (35).
To obtain information on the relative mobility of the 232R1
side chain in LDAO and bicelles, CW EPR spectra were
recorded for the protein in the two environments. In both cases,
the spectra show a dominant component reflecting restricted
mobility of the R1 side chain (Fig. 7E, top spectra, i), and a
second component reflecting higher mobility (m). The two
spectral components can arise from slow exchange (microsec-
FIGURE 6. zfVDAC2 dimer. A symmetry-related dimer of zfVDAC2 is presented in a transparent space-filling model on top of a cartoon representation (same
coloring as in Fig. 3). The expanded view shows the interaction site composed of residues from strands 1, 3, and 17–19 presented in stick representations.
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ond tomillisecond time scale) between protein conformational
substates or from rotameric equilibria of R1 (36). It has been
shown that stabilizing osmolytes, such as sucrose, shift protein
conformational equilibria but have little effect on rotameric
equilibria of R1. For 232R1, the addition of sucrose shifts the
relative population toward the more immobilized state, sug-
gesting that the two components arise from slow (microsecond
to millisecond) exchange between conformational substates
differing in structure at, or in the vicinity of, the N-terminal
region of 16 (Fig. 7E, bottom spectra).
To further validate the data obtained by DEER, we employed
cross-linking experiments of single-cysteine mutants in an
effort to better define the dimer interface in solution. We gen-
erated three cysteine mutants that were part of the putative
dimer interface close to the cytoplasmic side of VDAC at posi-
tions Val-27, Asp-50, and Ser-52 and another set of three
mutants close to the IMS at positions Leu-251, Ile-255, and
Leu-257 (Figs. 6 and 8). These mutants were designed in loop
regions and on -strands at S–S distance ranges of 3.7–11.1 Å.
In addition, two cysteine mutants were generated at sites that
should reside outside of the putative dimer interface at posi-
tions Thr-83 and Gln-196 (Fig. 8A). Upon the addition of
dichloro(1,10-phenanthroline)Cu(II), significant cross-linking
was observed at all six sites that are part of the putative dimer
interface (Fig. 8, B and C), indicative of disulfide formation
between monomeric proteins as opposed to the control sites
that did not display appreciable cross-linking (Fig. 8D).
DISCUSSION
In recent years, there has been a vast increase in structural
and functional understanding of VDAC1, but VDAC2 and -3
have been understudied. zfVDAC2 is a good structural model
for mammalian VDAC2 due to a high degree of sequence
homology (e.g. 83.0% identity and 93.0% similarity) between
zfVDAC2 and hVDAC2 with no sequence gaps (Fig. 1 shows a
zfVDAC2 alignment against selected mammalian VDAC
sequences). Most of the minor sequence differences reside in
the exposed loop regions where the transmembrane segments
remain conserved (Fig. 9, top row). Interestingly, mammalian
VDAC2s have a small 11-amino acidN-terminal extension that
is not present in zfVDAC2.However, thisN-terminal extension
was shown not to be essential in mediating VDAC2-specific
properties of the channel, such as tBid-induced cytochrome c
release (37).Most of theseminor sequence differences reside in
the exposed loop regions where the transmembrane segments
remain conserved (Fig. 9, top row). In total, zfVDAC is a good
model for mammalian VDAC2.
VDAC2 has a number of unique and specific protein-inter-
acting partners, including the proapoptotic protein BAK (13),
the ryanodine receptor (16), and erastin and tubulin (38). A
logical assumption is that these specific interactions would be
governed by structural differences. However, a structural com-
parison between VDAC1 and -2 reveals few differences on a
positional (Fig. 9, bottom row) or electrostatic basis (Fig. 5). The
FIGURE 7. Interspin distance measurements of zfVDAC2 232R1. A, cartoon representation of zfVDAC2 232R1 showing the expected distance based on
modeling of R1 on the zfVDAC2 structure. Models of the R1 side chain at site 232 are shown as stick representations. The black dashed line shows the expected
interspin distance in the crystallographic dimer. B, left, raw data (black) and exponentially decaying background signal (magenta) arising from random
intermolecular distances in LDAO. For analysis, the raw data were truncated beyond 2.6 s (vertical dashed line) to suppress the artifact caused by pulse overlap.
Right, background-corrected DEF of zfVDAC2 232R1 reconstituted in LDAO. The fit of the DEF is shown in red. 
, “depth of modulation” see “Experimental
Procedures.” C, left, raw data (cyan) and exponentially decaying background signal (magenta) of DEER data in bicelles. The raw data were truncated beyond 2.6
s (vertical dashed line) to suppress artifact. Right, background-corrected DEF of zfVDAC2 232R1 reconstituted in bicelles. D, distance distributions of zfVDAC2
232R1 reconstituted in LDAO and bicelles are shown in black and cyan, respectively. The vertical black bar indicates the expected distance from modeling the
R1 side chain at site 232 shown in A. E, top spectra, EPR signals of 232R1 in LDAO (black) and bicelles (cyan). Bottom spectra, EPR spectra of osmolyte
perturbations for residue 232R1 in LDAO recorded in buffer (black) and in buffer containing 30% sucrose (red). Spectral intensities corresponding to relatively
immobile (i) and mobile states (m) of R1 are indicated.
Structure and Oligomeric Population of VDAC2
MAY 2, 2014 • VOLUME 289 • NUMBER 18 JOURNAL OF BIOLOGICAL CHEMISTRY 12573
 at U
B
M
 B
ib
lio
th
ek
 G
ro
ssh
ad
ern
 o
n
 A
p
ril 8
, 2
0
2
0
h
ttp
://w
w
w
.jb
c.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
sole exceptions are large displacements of the loop between
strands 1 and 2 (amino acid sequence 32–40) and the loop
connecting -strand 5 and -strand 6 (amino acid sequence
88–95) as well as a change in the electrostatic properties on the
cytosolic lip of VDAC. Indeed, differences between VDAC1
and VDAC2 accounting for the VDAC2-specific tBid-induced
cytochrome c release were previously mapped to the N-termi-
nal two-thirds, namely amino acids 13–188 (39). The loop con-
necting -strand 1 and -strand 2 is extended 12 Å away from
the pore in the zfVDAC2 structure as comparedwithmVDAC1
(Protein Data Bank code 3EMN). In the hVDAC1 x-ray struc-
ture (Protein Data Bank code 2JK4), this loop occupies a posi-
tion quite similar to that in the zfVDAC2, and the NMR struc-
ture of hVDAC1 has this loop even farther away from the
mVDAC1 position (Fig. 4B). Interestingly, there is an amino
acid divergence at position 36 located at the apex of this mobile
loop. For VDAC1, there is a highly conserved Glu, but in
VDAC2 the residue is primarily an Ala or a Cys. To date, this
residue, as far as we know, has not been subjected to functional
analysis.
The loop connecting -strands 5 and 6 in the human x-ray
structure is located 13 Å internally from the position in
mVDAC1 and zfVDAC2 x-ray structures. In the NMR model,
this loop resides in themiddle of these two positions. In the case
of zfVDAC2, this loop is pushed away due to the presence of a
symmetry-related molecule.
It would seem that loop displacements between -strands 1
and 2 and-strands 5 and 6, as observed here, would not suffice
to explain the vast phenotypic differences between isoforms.
However, the dynamic and electrostatic properties of these
loops could play a key role in establishing protein-protein inter-
actions and generate protein complexes or modulate gating
properties and thus alter the function of VDACs. Indeed, bind-
ing of partner proteins was shown to vary substantially between
VDAC isoforms, with compelling evidence that VDAC2 has a
greater repertoire of binding partners (40–42).
FIGURE 8. Cross-linking experiments validate the dimer interface. A, cartoon representation of the zfVDAC2 putative dimer with sites of cysteine mutations
displayed in spheres, differently colored by position. B, 12% SDS-PAGE for zfVDAC2 single-cysteine mutants close to the cytosolic side. C, 12% SDS-PAGE for zfVDAC2
single-cysteine mutants close to the IMS. D, 12% SDS-PAGE of non-cross-linking single-cysteine mutants at positions outside of the putative dimer interface. Black box,
monomeric zfVDAC2; red box, dimeric forms. MWM, molecular weight markers. Cu-oP, dichloro(1,10-phenanthroline)Cu(II) Groupings of images from different parts
of the same gels are marked by vertical lines.
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Another aspect of VDAC physiology that has major implica-
tions, in particular for apoptotic events, is the protein’s oligo-
meric state. Current research has strongly implicated a dimeric
organization of hVDAC1 by analysis of crystal packing (5, 7),
chemical cross-linking (43), and fluorescence cross-correlation
spectroscopy (35). However, these studies have been lacking for
VDAC2.
Using crystallographic symmetry operators, we identified a
parallel dimer interface for zfVDAC2 that is virtually identical
to the one suggested for hVDAC1 with a buried surface area of
554 Å2. The interface is formed by strands 17, 18, 19, 1,
and 3 (Figs. 6 and 8). Here we show that 18% of the protein
exists in a dimeric form in solution, as demonstrated by DEER
spectroscopy for a singly R1-labeled mutant of zfVDAC2
reconstituted in LDAO; similar dimers exist in bicelles, appar-
ently along with higher order oligomers (Fig. 7B). Remarkably,
previous fluorescence cross-correlation spectroscopy studies
done by Betaneli et al. (35) on hVDAC1 reconstituted in giant
unilamellar vesicles showed a 15% dimer population, compa-
rable with that observed here for zfVDAC2 in LDAO.
The interspin distance distributions centered on 30 Å
observed in DEER are consistent with the interspin distance
expected frommodeling of the R1 side chain in the x-ray struc-
ture presented here, but the broad distributions indicate signif-
icant protein flexibility. The main probability distributions for
VDAC2 232R1 in LDAO and bicelles are similar but not iden-
tical, showing that the structure of the dimer in both environ-
ments is similar.
The 55 Å population for the protein in bicelles, but not in
LDAO detergent micelles, cannot arise from a homodimer. A
possible oligomeric configuration could be drawn from crystal
packing analysis ofmVDAC1 crystals originating in bicelles (7).
This structure reveals amore elaborate hexameric arrangement
mimicking the native oligomeric packing observed in EM (44)
and atomic force microscopy (45) images of the outer mito-
chondria membrane. Intramolecular distances between side
chain 232R1 in this hexamer identify a likely origin for both the
30 Å and 55 Å populations (Fig. 10).
Comparison of the CW EPR spectra of residue 232R1 in
LDAO and bicelles shows an increase in the relative population
of amoremobile state in LDAO (Fig. 7C), and osmolyte pertur-
bation indicates that the two-component spectra probably arise
from multiple conformational substates in equilibrium. Thus,
the small differences that do exist in the distance distributions
for LDAO and bicelles may be due to differences in conforma-
tional flexibility of the protein at or near residue 232R1.
The cross-linking experiments strongly support the validity
of the suggested dimer interface in zfVDAC2. The two cysteine
mutants designed outside of the dimer interface displayed no
cross-linking, whereasmutants in the dimer interface displayed
distinct levels of cross-linking. The highest levels of cross-link-
FIGURE 9. Mapping the sequence diversity in VDAC isoforms. The sequence diversity between zfVDAC2 and hVDAC2 (top row) is shown utilizing a cartoon
representation of the zfVDAC2 structure and the sequence diversity between hVDAC1 and hVDAC2 (bottom row) is shown utilizing a schematic representation
of the hVDAC1 structure. The views displayed from left to right are a side view (A), a 180° rotated side view (B), and a cytosolic view (C). Blue, sequence identity;
green, sequence similarity; red, unconserved sequence substitutions.
FIGURE 10. Interspin distances of mVDAC1 hexamer at position 232. A
cartoon representation of mVDAC1 232R1 shows the expected distances
based on modeling of R1 on the mVDAC1 structure. Models of the R1 side
chain at site 232 are shown in spherical representations. The black dashed line
shows the expected interspin distance in the crystallographic hexamer. Inter-
spin distances of 70 Å are outside the range that can be reliably determined
with the DEER data recorded in this study and thus are not shown.
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ing were observed for mutants in long flexible loop regions
(D50C with S–S located 11.1 Å apart and S52C with an S–S
distance of 6.8 Å and for an internal mutant located in the
cytosolic side of1 (V27C), which is the closest cysteinemutant
in this set of cross-linking experiments (S–S distance of only 3.7
Å). The other threemutants on themitochondrial IMS side that
displayed lower cross-linking efficiencies were designed in rigid
-strands or just at the interface between short loops and 17
and 18 situated at relatively long S-S distance ranges of 6.4–
8.9 Å.
Although the present study advances our structural under-
standing in the VDAC field, in particular VDAC2, there are still
many unanswered questions that will need to be addressed.
Perhaps the varied phenotype is not purely structural but
depends on different affinities to partner proteins, expression
patterns, subcellular localization of the distinct isoforms, or dif-
ferences in the intrinsic flexibility of functionally important
structural elements between the different isoforms. There is
plenty of evidence for different physiological roles of the three
isoforms, but the search for the underlying mechanisms has to
be further explored. The structural characterization of VDAC2,
however, provides blueprints to test many hypotheses and
identifies a loop between strands 1 and 2 as a plausible dynamic
structural element, as judged by changes in its relative position
in structures of different VDAC isoforms, and identifies an area
with a change in the electrostatic surface potential between
zfVDAC2 and mVDAC1.
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is required for truncatedBID-inducedmitochondrial apoptosis by recruit-
ing BAK to the mitochondria. EMBO Rep. 10, 1341–1347
42. Palaniappan, K. K., Hangauer,M. J., Smith, T. J., Smart, B. P., Pitcher, A. A.,
Cheng, E. H., Bertozzi, C. R., and Boyce, M. (2013) A chemical glycopro-
teomics platform reveals O-GlcNAcylation of mitochondrial voltage-de-
pendent anion channel 2. Cell Rep. 5, 546–552
43. Geula, S., Naveed, H., Liang, J., and Shoshan-Barmatz, V. (2012) Struc-
ture-based analysis of VDAC1 protein: defining oligomer contact sites.
J. Biol. Chem. 287, 2179–2190
44. Mannella, C. A. (1982) Structure of the outer mitochondrial membrane:
ordered arrays of porelike subunits in outer-membrane fractions from
Neurospora crassamitochondria. J. Cell Biol. 94, 680–687
45. Hoogenboom, B. W., Suda, K., Engel, A., and Fotiadis, D. (2007) The
supramolecular assemblies of voltage-dependent anion channels in the
native membrane. J. Mol. Biol. 370, 246–255
Structure and Oligomeric Population of VDAC2
MAY 2, 2014 • VOLUME 289 • NUMBER 18 JOURNAL OF BIOLOGICAL CHEMISTRY 12577
 at U
B
M
 B
ib
lio
th
ek
 G
ro
ssh
ad
ern
 o
n
 A
p
ril 8
, 2
0
2
0
h
ttp
://w
w
w
.jb
c.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
Habilitation thesis
“Targeting cardiac arrhythmia by enhancing mitochondrial Ca2+ uptake” Johann Schredelseker
Appendix  3:  Wilting  F.,  et  al.  (2020)  The antiarrhythmic
compound  efsevin  directly  modulates  voltage-dependent
anion channel 2 by binding to its inner wall and enhancing
mitochondrial Ca2+ uptake, Br J Pharmacol.
Wilting F., Kopp R., Gurnev P.A., Schedel A., Dupper N. J., Kwon O., Nicke A.,
Gudermann T., and Schredelseker J. (2020) The antiarrhythmic compound efsevin
directly modulates voltage-dependent anion channel 2 by binding to its inner wall and
enhancing mitochondrial Ca2+ uptake, Br J Pharmacol. doi: 10.1111/bph.15022
75
R E S E A R CH P A P E R
The antiarrhythmic compound efsevin directly modulates
voltage-dependent anion channel 2 by binding to its inner wall
and enhancing mitochondrial Ca2+ uptake
Fabiola Wilting1 | Robin Kopp1 | Philip A. Gurnev2 | Anna Schedel1 |
Nathan J. Dupper3 | Ohyun Kwon3 | Annette Nicke1 | Thomas Gudermann1,4 |
Johann Schredelseker1
1Walther Straub Institute of Pharmacology and
Toxicology, Faculty of Medicine, LMU Munich,
Munich, Germany
2Section on Molecular Transport, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, National
Institutes of Health, Bethesda, Maryland
3Department of Chemistry and Biochemistry,
University of California Los Angeles, Los
Angeles, California
4Deutsches Zentrum für Herz-Kreislauf-
Forschung (DZHK), Partner Site Munich Heart
Alliance (MHA), Munich, Germany
Correspondence
Johann Schredelseker, Walther Straub
Institute of Pharmacology and Toxicology,
LMU Munich, Munich 80336, Germany.
Email: johann.schredelseker@lmu.de
Funding information
Deutsche Forschungsgemeinschaft, Grant/
Award Number: SCHR 1471/1-1; U.S. National
Institute of Health, Grant/Award Number:
R01GM071779
Background and Purpose: The synthetic compound efsevin was recently identified
to suppress arrhythmogenesis in models of cardiac arrhythmia, making it a promising
candidate for antiarrhythmic therapy. Its activity was shown to be dependent on the
voltage-dependent anion channel 2 (VDAC2) in the outer mitochondrial membrane.
Here, we investigated the molecular mechanism of the efsevin–VDAC2 interaction.
Experimental Approach: To evaluate the functional interaction of efsevin and
VDAC2, we measured currents through recombinant VDAC2 in planar lipid bilayers.
Using molecular ligand-protein docking and mutational analysis, we identified the
efsevin binding site on VDAC2. Finally, physiological consequences of the efsevin-
induced modulation of VDAC2 were analysed in HL-1 cardiomyocytes.
Key Results: In lipid bilayers, efsevin reduced VDAC2 conductance and shifted the
channel's open probability towards less anion-selective closed states. Efsevin binds
to a binding pocket formed by the inner channel wall and the pore-lining N-terminal
α-helix. Exchange of amino acids N207, K236 and N238 within this pocket for ala-
nines abolished the channel's efsevin-responsiveness. Upon heterologous expression
in HL-1 cardiomyocytes, both channels, wild-type VDAC2 and the efsevin-insensitive
VDAC2AAA restored mitochondrial Ca2+ uptake, but only wild-type VDAC2 was sen-
sitive to efsevin.
Conclusion and Implications: In summary, our data indicate a direct interaction of
efsevin with VDAC2 inside the channel pore that leads to modified gating and results
in enhanced SR-mitochondria Ca2+ transfer. This study sheds new light on the func-
tion of VDAC2 and provides a basis for structure-aided chemical optimization of
efsevin.
Abbreviations: CPVT, catecholaminergic polymorphic ventricular tachycardia; DPhPC, 1,2-diphytanoyl-sn-glycero-3-phosphatidylcholine; hVDAC2, human voltage-dependent anion channel 2;
IRES, internal ribosome entry site; MCU, mitochondrial calcium uniporter; MOI, multiplicity of infection; mVDAC2, mouse voltage-dependent anion channel 2; OMM, outer mitochondrial
membrane; PO, open probability; RuR, ruthenium red; shRNA, short hairpin RNA; SR, sarcoplasmic reticulum; VDAC, voltage-dependent anion channel; zVDAC2, zebrafish voltage-dependent
anion channel 2.
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1 | INTRODUCTION
Cardiovascular diseases represent the primary cause of death and
hospitalization worldwide (Benjamin et al., 2018). Especially, Car-
diac arrhythmias are difficult to treat due to major side effects of
common antiarrhythmic drugs. It is thus a major focus of cardiova-
scular research to identify novel, safer therapies for cardiac
arrhythmia.
Using a chemical suppressor screen on the zebrafish cardiac
arrhythmia model tremblor (Ebert et al., 2005; Langenbacher
et al., 2005), we have previously identified the synthetic compound
efsevin, a dihydropyrrole carboxylic ester compound, which potently
restored rhythmic cardiac contractions in otherwise fibrillating
zebrafish embryonic hearts (Shimizu et al., 2015). We further demon-
strated efficacy of efsevin in translational models for catecholaminer-
gic polymorphic ventricular tachycardia (CPVT; Schweitzer
et al., 2017). Here, efsevin reduced episodes of tachycardia in vivo in
CPVT mice and suppressed arrhythmogenic events in induced pluripo-
tent stem cell-derived cardiomyocytes from a CPVT patient
(Schweitzer et al., 2017). These findings make efsevin a promising lead
structure for human antiarrhythmic therapy.
In a pull-down assay with immobilized efsevin, the outer mito-
chondrial membrane (OMM) voltage-dependent anion channel
2 (VDAC2) was identified as the primary molecular target of efsevin
(Shimizu et al., 2015). Voltage-dependent anion channels are large
pore-forming proteins in the outer mitochondrial membrane. They
represent the main pathway for ions and metabolites over the outer
mitochondrial membrane. Three isoforms of voltage-dependent
anion channels are expressed in vertebrates out of which VDAC2
was described to have a specific role in the heart. While a global
knockout of VDAC2 in mice is embryonically lethal (Cheng, Sheiko,
Fisher, Craigen, & Korsmeyer, 2003), a conditional heart-specific
VDAC2 knockout mouse was reported to develop post-natal cardiac
defects and to die shortly after birth (Raghavan, Sheiko, Graham, &
Craigen, 2012). In cardiomyocytes, VDAC2 was described to inter-
act with the ryanodine receptor (RyR; Min et al., 2012) and to
modulate cytosolic Ca2+ signals (Shimizu et al., 2015; Subedi
et al., 2011). In arrhythmic tremblor zebrafish embryos, efsevin
induced a restoration of rhythmic cardiac contractions. Transient
knock-down of VDAC2 abolished the efsevin induced phenotype
restoration while overexpression of VDAC2 recovered it. In cultured
cells, efsevin enhanced uptake of Ca2+ into mitochondria. A direct
link between the enhanced mitochondrial Ca2+ uptake and efsevin's
anti-arrhythmic properties was established by two lines of experi-
ments: (a) Pharmacological inactivation of mitochondrial Ca2+ uptake
by Ru360, an inhibitor of the mitochondrial Ca2+ uniporter (MCU),
abolished efsevin's protective effect in CPVT cardiomyocytes and
(b) kaempferol, an activator of the mitochondrial Ca2+ uniporter,
reduced arrhythmogenic Ca2+ signals comparable to efsevin
(Schweitzer et al., 2017).
However, biophysical and structural determinants of the
efsevin–VDAC2 interaction have remained unexplored. It is still
unclear whether efsevin directly interacts with the VDAC2 peptide
and thereby modulates the electrophysiological properties of the
channel or if the observed effects require a yet unidentified pro-
tein partner. To address this issue, we expressed and purified
recombinant zebrafish VDAC2 (zVDAC2) protein and inserted it
into planar lipid bilayers. We found a pronounced effect of efsevin
on channel gating and opening probability, indicating a direct effect
of efsevin on the channel. To analyse the structural basis of the
efsevin VDAC2 interaction, we performed computational protein-
ligand docking using the crystal structure of zVDAC2
(Schredelseker et al., 2014). VDAC2 is formed by a barrel-like
structure consisting of 19 antiparallel β-sheets (β-sheets 1-19) and
an N-terminal α-helix lining the inner channel wall (Schredelseker
et al., 2014). We identified an efsevin binding site located in a
groove between the inner channel wall and the pore-lining α-helix
and formed by hydrogen bonds and hydrophobic interactions
between efsevin and the zVDAC2 peptide. Replacement of three
residues (N207, K236 and N238) from this binding site with ala-
nines (zVDAC2AAA) resulted in a complete loss of efsevin sensitiv-
ity. To evaluate the physiological consequence of the observed
efsevin-induced biophysical changes in VDAC2, we heterologously
expressed wild-type zVDAC2 and the efsevin-insensitive
zVDAC2AAA mutant in cultured HL-1 cardiomyocytes. We demon-
strate that the observed changes in zVDAC2 electrophysiology
translate into enhanced mitochondrial Ca2+ uptake and thereby
explain the antiarrhythmic effect of efsevin. Our data provide novel
insights into VDAC2 function and provide a basis for structure-
aided chemical optimization of efsevin as a lead structure for the
development of novel antiarrhythmic drugs.
What is already known
• The synthetic compound efsevin suppresses
arrhythmogenesis in cardiac arrhythmia models.
• Efsevin binds to the mitochondrial voltage-dependent
anion channel anion channel 2 (VDAC2).
What this study adds
• Efsevin binds into a pocket formed by the channel wall
and the pore-lining helix.
• Efsevin facilitates VDAC2 gating into a less anion-
selective state and enhances Ca2+ flux.
What is the clinical significance
• Identification of mode of action and binding
pocket allows for future structure aided-drug
optimization.
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2 | METHODS
2.1 | Expression and purification of zVDAC2
Expression and purification of zVDAC2 were performed as previ-
ously described (Schredelseker et al., 2014) with minor modifica-
tions: Histidine-tagged zVDAC2 was purified on an Äkta pure
chromatography system using a HisPrep FF 16/10 column. After
refolding dialysis, size exclusion chromatography was performed on
a HiLoad 16/600 Superdex200 pg column equilibrated with
150-mM NaCl, 1-mM DTT, 0.1% LDAO, and 20-mm Tris-HCl
(pH = 8.0). Integrity of the purified zVDAC2 was confirmed by
SDS-PAGE analysis on a 12% gel.
2.2 | Planar lipid bilayer recordings
Painted planar lipid bilayers were formed on an Ionovation Bilayer
Explorer lipid bilayer set-up across a 120-μm diameter opening with
1,2-diphytanoyl-sn-glycero-3-phosphatidylcholine (DPhPC) dissolved
in n-decane at 12.5 mgml−1. Both chambers were filled with 1-M KCl,
5-mM CaCl2, and 10-mM Tris-HCl (pH = 7.2) To facilitate insertion,
purified zVDAC2 was inserted into lipidic bicelles (Ujwal, 2012). After
formation of a stable bilayer, zVDAC2 containing bicelles were added
to the cis chamber. After insertion of a channel, the membrane was
clamped to 0 mV, and 10 s pulses to test potentials from −60 mV to
+60 mV were applied. The signal was sampled at 10 kHz and filtered
at 2 kHz. Efsevin (50-μM stock in recording solution) was added to
the cis chamber to a final concentration of 8 μM. Data analysis was
performed using Nest-o-Patch (Dr. V. Nesterov, https://sourceforge.
netq/projects/nestopatch/).
zVDAC2 ion selectivity was measured using folded planar mem-
branes formed from opposition of two monolayers made of 5 mgml−1
solution of DPhPC in pentane, as described (Rostovtseva, Gurnev,
Chen, & Bezrukov, 2012). Recordings were performed in the buffer
described above. Channel insertion was achieved by adding zVDAC2
in a 2.5% Triton X-100 solution to the cis compartment while stirring.
After single channel was inserted in symmetrical solutions, the cis side
was perfused with Tris-HCl (pH 7.2) buffer solution to achieve 0.2-M
KCl. The exact KCl concentration of 0.2 M in the cis compartment
after perfusion was verified at the end of each selectivity experiment
using a conductivity meter CDM230 (Radiometer analytical). Ion
selectivity of zVDAC2 conductance states was calculated from the
reversal potential (Vrev). Permeability ratio between Cl
−, and K+, I−/I+,
was calculated according to the Goldman–Hodgkin–Katz equation
(Hille, 2001):
I−=I+ = 1−
Vrev
kBT
e
 lnatrans
acis
 !
 1+
Vrev
kBT
e
 lnatrans
acis
 !
−1
,
where kB, T, and e have their usual meaning of Boltzmann constant,
absolute temperature, and electron charge, and KCl solution activities
were acis = 0.144 for 0.2-M KCl and atrans = 0.604 for 1-M KCl,
respectively (Lide, 2006).
2.3 | Molecular docking
The three-dimensional (3D) structure of efsevin was generated
using MarvinSketch (v15.1.9, ChemAxon) and saved in the .pdb for-
mat. The crystal structure of zVDAC2 was obtained from the
Research Collaboratory for Structural Bioinformatics Protein Data
Bank (PDB ID: 4BUM). Gasteiger charges and hydrogens were
added to protein and ligand using AutoDockTools (v1.5.6; Morris
et al., 2009), and AutoDock Vina was used to perform the molecu-
lar docking simulations (Trott & Olson, 2010). The term “indepen-
dent docking experiment” used in this text refers to independent
software runs of AutoDock Vina. Each run starts from a random
conformation that is independent from the previous one and yields
nine likely conformations. To determine the best hypothetical bind-
ing mode of efsevin on zVDAC2, the flexible form of efsevin was
first docked to the rigid zVDAC2 structure. After 15 iterative dock-
ings with a grid centred to ensure coverage of the entire channel,
analysis of 135 binding conformations showed that the binding site
with the lowest binding energy was found in the region between
the inner channel wall and the highly flexible N-terminal α-helix.
Since zVDAC2 might undergo conformational changes upon binding
of efsevin, the side chains facing the potential binding site were
kept flexible for subsequent dockings (N19, Y22, F24, N207, R218,
K236, N238, L242 and L262). The grid box was narrowed to
24 Å × 20 Å × 20 Å to cover this region. After additional 15 itera-
tive dockings with flexible side chains, the best binding poses were
selected based on the predicted binding affinities. Interactions were
analysed with LigPlot+ (Laskowski & Swindells, 2011).
2.4 | Molecular cloning
To introduce N207A, K236A and N238A into pQE60-zVDAC2
for recombinant expression and purification construct pQE60-
zVDAC2AAA was created by two mutagenesis PCR reactions using
pQE60-zVDAC2 (Schredelseker et al., 2014) as a template. The two
PCR fragments were fused by overlap extension PCR and the
resulting product was ligated into pQE60-zVDAC2 with PstI
and NheI.
For the creation of pCClc-CMV-zVDAC2-IRES-nlsEGFP for virus
production and following transduction of zVDAC2 into HL-1 cells,
eGFP with a nuclear localization signal (nls-eGFP) together with an
internal ribosome entry site (IRES) was PCR-amplified from p3E-IRES-
nlsEGFPpA (Kwan et al., 2007) and subcloned into pCS2+ containing
the zVDAC2 open reading frame (Shimizu et al., 2015). The
zVDAC2-IRES-nlsEGFP construct was fused into pCCLc-CMV using
the In-Fusion HD Cloning Kit (TaKaRa).
For the creation of pCClc-CMV-zVDAC2AAA-IRES-nlsEGFP,
zVDAC2 was exchanged for zVDAC2AAA in pCS2+-zVDAC2 (Shimizu
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et al., 2015) by PCR amplification of the zVDAC2AAA open reading
frame from PQE60-zVDAC2AAA following ligation with BamHI and
ClaI. The open reading frame of zVDAC2AAA was PCR-amplified from
pCS2+-zVDAC2AAA fused to the IRES PCR-amplified from pCClc-
CMV-zVDAC2-IRES-nlsEGFP by SOE PCR and the resulting fragment
was fused into pCClc-CMV-zVDAC2-IRES-nlsGFP using the In-Fusion
HD Cloning Kit (TaKaRa).
2.5 | Production of lentiviruses
Recombinant lentiviruses were produced in HEK 293T cells. Briefly,
cells at 40% confluency were cotransfected with pCCLc-CMV-
zVDAC2-IRES-nlsEGFP or pCCLc-CMV-zVDAC2AAA-IRES-nlsEGFP
together with pCMVΔ8.91 (coding for gag, pol, rev) and pCAGGS-
VSV-G at a 5:5:1 ratio using TransIT®-293 (Mirus). Cells were induced
with 10-mM sodium butyrate on the following day. The supernatant
containing the virus was collected on Day 3 after transfection, filtered
through a 0.45-μm syringe filter, and stored at −80C. Viral titres
were determined using the Lenti-X™ qRT-PCR Titration Kit (Takara).
2.6 | HL-1 culture and creation of cell lines
HL-1 cells were cultured as described previously (Claycomb
et al., 1998). Briefly, HL-1 cells were grown on fibronectin (0.02%)
/ gelatin (10 μgml−1) coated flasks in Claycomb medium sup-
plemented with 10% FBS, 100 μgml−1 penicillin/streptomycin,
0.1-mM norepinephrine, and 2-mM L-glutamine. Stable knockdown
of the endogenous mVDAC2 in HL-1 cardiomyocytes was per-
formed by lentiviral transduction with shLenti2.4G-mVDAC2 or
shLenti2.4G-Ctrl as described previously (Subedi et al., 2011) In
brief, HL-1 cells were transduced in serum-free Claycomb medium
with lentivirus at a multiplicity of infection (MOI) of 30 in the pres-
ence of 8 μgml−1 polybrene. Three days after transduction, cells
were selected with 2 μgml−1 puromycin for 10 days and cultured
for additional three passages. For overexpression of zVDAC2 and
zVDAC2AAA, transduction was performed as described above using
a MOI of 25. After 4 days, nlsEGFP-positive cells were selected by
FACS sorting on a BD FACS Aria III.
2.7 | SR-mitochondria Ca2+ transfer
Fluorescence-based measurements of mitochondrial Ca2+ were per-
formed as previously described (Schweitzer et al., 2017). In brief, HL-1
cells (RRID:CVCL_0303) were plated in 96-well plates 1 day prior to
the experiment. To monitor mitochondrial Ca2+, cells were stained
with Rhod-2, AM (Thermo Fisher, Darmstadt, Germany) and perme-
abilized using digitonin. Mitochondrial Ca2+ was constantly monitored
in a fluorescence plate reader (Infinite® 200 PRO multimode reader,
Tecan, Maennedorf, Switzerland), and SR Ca2+ release was induced by
superfusion with 10-mM caffeine.
2.8 | Metabolic stability assay
Efsevin (10 mM in DMSO) was co-incubated with human liver micro-
somes at 37C at an initial concentration of 1 μM. The reaction was
initiated by addition of 1-mM NADPH; 0, 5, 10, 30, and 60 minutes
after starting the reaction, small aliquots were transferred into ice-
cold acetonitrile and centrifuged at 16000× g for 10 min. Superna-
tants were analysed by LC–MS/MS. Experiments were performed as
contract research at 3D BioOptima Co., Ltd., Suzhuo, China.
2.9 | Data and statistical analysis
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analysis
in pharmacology (Curtis et al., 2018). zVDAC2 channels were inserted
into lipid bilayers and measured before and after addition of efsevin in
recording solution, thus leading groups of equal size. In some instances,
membranes ruptured during the recording explaining smaller sample size
for recordings with efsevin. The recording before efsevin addition
served as a control. Since efsevin was the only drug investigated and
was added in measuring solution, randomization and blinding were not
applied. All traces were equally analysed for predefined parameters like
average current or open state to exclude operators bias. For Ca2+
uptake experiments on HL-1 cardiomyocytes, wells were randomly
assigned to control, efsevin and ruthenium red (RuR) group to generate
groups of equal size. Wells were microscopically inspected after the
experiment, and those in which cells have detached were excluded from
the analysis. No data transformation or outlier removal was performed,
and all traces were equally analysed for maximum response by a
predefined script to exclude operators bias. Since nature and magnitude
of the effects of efsevin on zVDAC2 were unknown before the experi-
ment and not predictable, a sample size evaluation was not feasible.
Statistical analysis was only performed for sample sizes >5 from
independent experiments (i.e. individual insertions in lipid bilayers, indi-
vidual runs of computational docking, and individual cultures of HL-1
cardiomyocytes), and the obtained data were used for statistical analysis
without normalization and outlier removal. Statistical analysis was per-
formed using Prism 7 (GraphPad Software, San Diego, USA). Data are
presented as mean ± SEM of n individual experiments (no technical rep-
licates). Normality of data was determined by Shapiro–Wilk test. Tests
for statistical significance were conducted as indicated and where
unpaired student's t-test for comparison of two groups with normal dis-
tribution of data, Mann Whitney U test for comparison of two groups
with non-normal distribution of data, and Kruskal-Wallis test with
Dunn's post hoc test for multigroup comparison with non-normal data
distribution. Statistical significance of P < .05 is indicated as *.
2.10 | Materials
Efsevin was synthesized as described before (Henry et al., 2014).
Protein purification was performed on an Äkta pure, and all Äkta
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material was purchased from GE Healthcare, Munich, Germany;
LDAO was obtained from VWR, Darmstadt, Germany. The lipid
bilayer set-up and all consumables including 1,2-diphytanoyl-sn-
glycero-3-phosphatidylcholine (DPhPC) were purchased from
Ionovation, Osnabrück, Germany. Ruthenium red and caffeine used
for the HL-1 Ca2+ uptake assay were purchased from Sigma-Aldrich
(Munich, Germany). Plasmids pCCLc-CMV, pCMVΔ8.91 and
pCAGGS-VSV-G were obtained as a gift from Dr. Donald Kohn,
University of California Los Angeles, USA; plasmid shLenti2.4G-
mVDAC2 and shLenti2.4G-Ctrl were generously provided by
Dr. Yeon Soo Kim from Inje University, Gimhae, South Korea. HL-1
cardiomyocytes were obtained as a gift from Dr. William Claycomb,
Louisiana State University, New Orleans, USA; Claycomb medium
and all cell culture supplies were obtained from Sigma-Aldrich
(Munich, Germany).
2.11 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), PHARMACOLOGY.
3 | RESULTS
3.1 | Efsevin reduces currents through zVDAC2
Recombinant zVDAC2 protein was purified from Escherichia coli as
previously described (Schredelseker et al., 2014) and inserted into
diphytanoylphosphatidylcholine (DPhPC) planar lipid bilayers. Cur-
rents were measured in response to 10 s test pulses to potentials
from −60 to +60 mV in 1-M KCl. As shown in Figure 1a, typical aver-
age currents of 41 ± 3pA were recorded at 10 mV, where the channel
almost exclusively resides in its open state (Colombini, 1989;
Schredelseker et al., 2014). VDAC-typical flattening of the current–
voltage relationship (I–V curve) was observed starting at approxi-
mately ±30 mV (Figure 1b), where the channel starts gating until
finally being preferentially in its closed state at potentials above
+50 mV or below −50 mV (Figure 1a,b). The observed I–V curve for
zVDAC2 translates into a bell-shaped conductance–voltage
F IGURE 1 Effects of efsevin on zVDAC2 currents in planar lipid bilayers. (a) Typical current recordings from zVDAC2 inserted into painted
planar DPhPC lipid bilayers in 1-M KCl in response to 10 s test pulses from 0 to 10, 40, and 50 mV, respectively, under control conditions (left)
and after addition of 8-μM efsevin (right) to the same channel. Gating between three major states open (o), closed1 (c1) and closed2 (c2) and few
subconductance states can be observed (pulse protocol in shown in grey). (b) Current–voltage relationship of average zVDAC2 currents before
(n = 9 individual channels, black circles) and after addition of efsevin (n = 6 individual channels, red triangles, Unpaired Student's t-test).
(c) Conductance–voltage relationship of zVDAC2 before (n = 9 individual channels, black circles) and after addition of efsevin (n = 6 individual
channels, red triangles, Unpaired Student's t-test)
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relationship that is characteristic of VDACs (Figure 1c). Strikingly,
addition of 8-μM efsevin destabilized the channel's high conductance
state and dramatically reduced currents through zVDAC2 by about
50% across all voltages.
3.2 | Efsevin reduces zVDAC2 open probability
and shifts the channel towards closed states
Since efsevin profoundly reduced average zVDAC2 conductance,
we further analysed the biophysical properties of zVDAC2 single
channel currents to dissect the effects of efsevin on single channel
conductance versus open probability of the channel. VDAC has
been shown to undergo voltage-dependent gating between an
anion-selective high-conductance state, referred to as the classical
open state and several cation-selective low-conductance states,
referred to as closed states (Colombini, 1989; Guardiani
et al., 2018; Menzel et al., 2009; Mertins et al., 2012). Under
control conditions, we observed gating of the channel between the
classical open state with a conductance 4.2 ± 0.2 ns and two
closed states with conductances of 2.0 ± 0.1 ns for closed state
1 and 1.2 ± 0.04 ns for closed state 2 (Figure 2a,b). Efsevin shifts
the channel mainly into closed states 1 and 2 with only a few
scarce openings of the channel into the open state, already at low
potentials. Conductances of the three states remained comparable
to control conditions (open: 4.1 ± 0.1 ns; closed1: 2.1 ± 0.2 ns;
closed2: 1.0 ± 0.04 ns; Figure 2b). The shift towards the closed
states becomes most obvious when plotting the open probability
(PO) of the channel against voltage (Figure 2c). Interestingly, at the
physiologically relevant low potentials of ±30 mV
(Lemeshko, 2006; Porcelli et al., 2005), the apo-form of the chan-
nel resides mainly in the open state, while the efsevin-bound form
is preferentially closed (Figure 2d). The VDAC closed states were
previously defined as more cation-selective compared to the open
state (Tan & Colombini, 2007; Zachariae et al., 2012). We there-
fore measured the ion selectivity of the dominant states, the open
F IGURE 2 Effects of efsevin on zVDAC2 conductance and open probability (PO). (a) Representative recordings of zVDAC2 in a painted
lipid bilayer under control conditions (upper trace) and after addition of 8-μM efsevin (lower trace) at potentials where typical gating behaviour
between the three states is observed, that is, very low/high potentials under control conditions and moderate potentials after addition of
efsevin. Currents through the open and two distinct closed states of the channel are indicated by dashed lines. (b) Addition of 8-μM efsevin
does not change the conductance of the three distinct conductance states of zVDAC2 (n = 12 individual channels for control and 6 individual
channels after addition of efsevin). (c) Analysis of the open probability (PO) of zVDAC2 shows a significant shift of the channel towards the
closed states across all voltages after addition of efsevin (n = 12 for control and n = 6 for efsevin, Mann–Whitney U test). (d) Representative
conductance histograms from recordings of zVDAC2 with and without efsevin at 30 mV and 60 mV show a shift of the channel from the
classical open state to the closed states. (e,f) Current–voltage plots for the open and the efsevin-induced closed state 1 obtained from
zVDAC2 in a folded lipid bilayer using a 0.2-M to 1-M KCl gradient reveal a shift in the reversal potential (Vrev). (f ) Quantitative analysis of
selectivity measurements reveals a significant reduction in anion selectivity for the efsevin-induced closed state 1 (n = 6 for control, n = 5 for
efsevin, Unpaired Student's t- test)
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state of the apo-form and closed state 1 of the efsevin-bound
channel using salt gradient conditions (0.2-M [cis] vs. 1-M [trans]
KCl) and found a change in the Cl− to K+ permeability ratio I−/I+
from 2.38 ± 0.13 for the open state to 1.71 ± 0.14 for the
efsevin-bound closed state 1 (Figure 2e,f). In conclusion, our data
indicate that efsevin binding facilitates channel closure and induces
a shift of zVDAC2 towards the less anion-selective low conduc-
tance states.
3.3 | Molecular docking reveals an efsevin binding
site between the inner channel wall and the pore-
lining N-terminal α-helix
To identify the interaction between efsevin and zVDAC2 at the
molecular level, we performed protein-ligand docking using AutoDock
Vina (Trott & Olson, 2010). By docking the flexible form of efsevin
into the rigid crystal structure of zVDAC2 (Schredelseker et al., 2014),
a binding pocket formed between the inner channel wall and the N-
terminal α-helix of zVDAC2 repeatedly showed the lowest binding
energies in 15 independent dockings yielding 135 conformations
(Figures 3a and S1). To further investigate molecular interactions
between zVDAC2 and efsevin within this pocket, we performed sub-
sequent docking simulations in which residues facing this binding site
were made flexible. We identified multiple conformations with bind-
ing affinities below −8.0 kcalmol−1 in which the dihydropyrrole of the
efsevin core with the ethoxycarbonyl and phenyl substituents was
always interacting with residues in the channel wall, while the p-tolyl
substituent of the sulphonamide group faces the lumen of the pore
and interacts with the hinge region of the N-terminal α-helix. Interac-
tions of efsevin with zVDAC2 were identified with residues F18, N19,
Y22, G23, F24 and M26 in the N-terminal α-helix and with residues
N207, L208, A209, R218, F219, G220, K236, V237, N238, L242,
G244 and L262 in the β-barrel, whereof asparagine 207, lysine
236 and asparagine 238 were the most prominent interaction part-
ners. Hydrogen bonds and hydrophobic interactions with these three
amino acids were present in the majority of conformations
(Figure 3b). Figure 3c,d shows one representative conformation in
which efsevin is held in place by N207, K236 and N238 in the channel
wall and interacts with the α-helix through hydrophobic interactions
with residues F18, N19, Y22, G23 and F24. To finally investigate
translatability of the docking results to the human channel, we created
F IGURE 3 Predicted binding site of efsevin on zVDAC2 obtained by molecular docking. (a) Side view of the channel (pdb: 4bum, light brown)
displays a binding pocket (red) for efsevin (light blue) located in the interspace between the inner channel wall and the N-terminal pore-lining α-
helix. (b) Analysis of 25 different molecular dockings (rows) reveals interactions between efsevin and 18 amino acid rests of zVDAC2 (columns)
through hydrogen bonds (blue) and hydrophobic interactions (yellow). Residues with the most interactions (N207 in β-sheet 14, K236, and N238
in β-sheet 16 of the barrel) are boxed in red. (c) Detailed view of one representative docking with efsevin binding to the channel through
hydrogen bonds between the most prominent amino acids highlighted in (b) and efsevin. (d) Surface representation of residues forming
hydrophobic interactions in the conformation shown in (c) reveals a cavity that accommodates the p-tolyl group of efsevin on the hinge of the
flexible N-terminal α-helix. Nitrogen is shown in blue, oxygen in red, and sulfur in yellow
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a model of human VDAC2 (hVDAC2) by homology modelling using
SWISS-MODEL (Waterhouse et al., 2018) since no experimentally
determined structure for hVDAC2 is currently available. In eight out
of 10 independent docking experiments, the conformation with the
lowest binding energy was found in the same binding pocket like in
zVDAC2 indicating that this binding pocket is conserved among spe-
cies (Figure S2).
3.4 | Elimination of residues N207, K236 and
N238 abolishes the efsevin sensitivity of zVDAC2
To confirm the predicted efsevin binding site by mutational analysis,
we created a zVDAC2 mutant in which residues N207, K236 and
N238 were substituted by alanine residues, zVDAC2N207A/K236A/N238A
(zVDAC2AAA). Lipid bilayer recordings of this mutant showed that it
forms a functional channel with a similar conductance–voltage rela-
tionship, single channel conductance and PO compared to wild-type
zVDAC2 (Figure S3). Most strikingly however, the channel was insen-
sitive to efsevin, demonstrated by comparable values for the
conductance–voltage relationship, single channel conductance and PO
before and after addition of efsevin (Figure 4).
3.5 | Efsevin mediates SR-mitochondria Ca2+
transfer by binding to the N207/K236/N238 binding
site
To evaluate if the observed efsevin-induced electrophysiological
changes can explain the enhanced mitochondrial Ca2+ uptake
observed previously for HeLa cells and HL-1 cardiomyocytes
(Schweitzer et al., 2017; Shimizu et al., 2015), we developed a heterol-
ogous expression system for zVDAC2. To this aim, we created a stable
HL-1 cardiomyocyte line in which the endogenous mouse VDAC2
(mVDAC2) was knocked down by stable expression of shRNA (Subedi
et al., 2011; Figure S4) and overexpressed shRNA-insensitive zVDAC2
constructs by lentiviral transduction. Ca2+ uptake into mitochondria
upon caffeine-induced Ca2+ release from the sarcoplasmic reticulum
(SR) was then measured in permeabilized Rhod-2 stained cells (Figure
5). In line with previous experiments, knock-down of the endogenous
mVDAC2 eliminated transfer of Ca2+ from the sarcoplasmic reticulum
into mitochondria (Subedi et al., 2011). While wild-type HL-1
cardiomyocytes displayed maximum ΔF/F0 values of 0.14 ± 0.02 that
were enhanced to 0.38 ± 0.03 by 10-μM efsevin, shRNA-expressing
cells displayed ΔF/F0 max values of 0.04 ± 0.03, which were indistin-
guishable from those obtained from cells treated with the mitochon-
drial Ca2+ uptake blocker ruthenium red (RuR; ΔF/F0
max = 0.06 ± 0.02) or efsevin (ΔF/F0 max = 0.06 ± 0.01, not significant).
Though lack of VDAC2 was previously described to induce apoptosis
and we can thus not rule out downstream effects induced by
mVDAC2 knock down in these cells, the shmVDAC2 cell line was sta-
ble for the time of our experiments and thus suitable for heterologous
overexpression experiments. Overexpression of zVDAC2 completely
restored sarcoplasmic reticulum-mitochondria Ca2+ transfer to ΔF/F0
max = 0.14 ± 0.02, which was sensitive to modulation by efsevin
(ΔF/F0 max = 0.34 ± 0.02). Strikingly, zVDAC2
AAA likewise restored
mitochondrial Ca2+ uptake to levels indistinguishable from wild-type
zVDAC2 (ΔF/F0 max = 0.15 ± 0.02) but was insensitive to treatment
with efsevin (ΔF/F0 max = 0.16 ± 0.02). These data strongly indicate
that the efsevin induced changes in zVDAC2 electrophysiology
account for the enhanced mitochondrial Ca2+ uptake in
cardiomyocytes.
4 | DISCUSSION
Here, we describe the efsevin–zVDAC2 interaction at a biophysical
and structural level. Efsevin was previously shown to enhance mito-
chondrial Ca2+ uptake and to be a powerful modulator of cardiac
rhythmicity and a potent suppressor of cardiac arrhythmia. Efsevin
suppresses arrhythmogenesis in both, models for Ca2+ overload and
models for inherited arrhythmias like catecholaminergic polymorphic
F IGURE 4 Effects of efsevin on conductance, and open probability (PO) of zVDAC2
AAA in lipid bilayers. (a) Conductance–voltage relation of
zVDAC2AAA in painted bilayer recordings reveals a comparable shape before and after addition of 8-μM efsevin. (b) No differences in single
channel conductance for open and closed states of zVDAC2AAA were observed after addition of efsevin. (c) Finally, in zVDAC2AAA, efsevin was
unable to induce the reduction of PO observed for wild-type zVDAC2 (n = 4 individual channels for control and 3 individual channels after
addition of efsevin)
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ventricular tachycardia. In a murine model for CPVT, efsevin signifi-
cantly reduced episodes of ventricular tachycardia, while no adverse
effects of efsevin were observed after up to 8 days of continuous
treatment. VDAC2, which was previously described as an essential
component of the mitochondrial Ca2+ uptake machinery of the heart
(Subedi et al., 2011), was identified as the primary target of efsevin
(Shimizu et al., 2015). These findings make VDAC2-mediated mito-
chondrial Ca2+ uptake a promising therapeutic target for the devel-
opment of a novel class of antiarrhythmic drugs with efsevin as a
lead candidate. However, efsevin was identified in a chemical screen
using 168 newly synthesized diversity-oriented compounds (Shimizu
et al., 2015) without further compound optimization. In our HL-
1-based sarcoplasmic reticulum-mitochondria Ca2+ transfer assay,
efsevin showed a half-maximal activity at 2.2 μM (Figure S5A). Pre-
liminary results on efsevin's pharmacokinetics show that it is
hydrolysed rapidly in liver microsomes (Figure S5B). Furthermore,
binding of efsevin to other targets, including VDAC isoforms 1 and
3, was never tested. Thus, its unknown selectivity, the low stability
of efsevin and the relatively high EC50 value indicate the need for
chemical optimization of the compound before further preclinical
and clinical studies are performed. In this study, we present a
molecular model of the efsevin binding site on zVDAC2 and thereby
provide a basis for structure-based drug optimization in future
experiments.
When discussing VDAC2 as a potential drug target for cardiac
arrhythmia, it should be noted that the transfer of Ca2+ from the sar-
coplasmic reticulum into mitochondria is most likely a specialized role
of VDAC2 in cardiomyocytes, presumably accomplished by a func-
tional or even physical coupling to the ryanodine receptor (Min
et al., 2012; Shimizu et al., 2015; Subedi et al., 2011) and might be less
relevant or maybe accomplished by other VDAC isoforms in other cell
types. In fact, VDAC1 was previously reported to promote Ca2+ trans-
fer from the endoplasmic reticulum into mitochondria in non-excitable
cells through coupling to the IP3 receptor (De Stefani et al., 2012;
Rapizzi et al., 2002; Szabadkai et al., 2006). It is thus conceivable that
despite the ubiquitous expression of VDACs in the body, efsevin-
mediated effects are most pronounced or even limited to
cardiomyocytes due to the specialized role of VDAC2 in this tissue.
This effect might also explain the lack of major side effects that were
observed previously in translational models (Schweitzer et al., 2017).
However, future studies are needed to evaluate the role of the
efsevin-mediated effects on other VDAC2-mediated effects like
F IGURE 5 Sarcoplasmic reticulum (SR)-mitochondria Ca2+ transfer upon heterologous expression of zVDAC2 and zVDAC2AAA in HL-1
cardiomyocytes. (a) Representative recordings of mitochondrial Ca2+ upon application of 10-mM caffeine to induce SR calcium release from
permeabilized HL-1 cardiomyocytes. Traces from control conditions (black), recordings in the presence of 10-μM ruthenium red to block
mitochondrial Ca2+ uptake (RuR, grey) and in the presence of 10-μM efsevin (red) are shown for native HL-1 cells (native), cells transduced with
shRNA targeting the endogenous mouse mVDAC2 (shmVDAC2), and cells overexpressing zVDAC2 and zVDAC2AAA, respectively. (b) Statistical
analysis of SR-mitochondria Ca2+ transfer experiments. While native HL-1 cardiomyocytes showed an efsevin-sensitive uptake of Ca2+ into
mitochondria (n = 21 for control, n = 7 for RuR, and n = 18 for efsevin), this uptake was abolished upon knock-down of the endogenous mVDAC2
(shmVDAC2, n = 24 for control, n = 8 for RuR, n = 15 for efsevin). Subsequent heterologous expression of zVDAC2 (shmVDAC2, n = 21 for
control, n = 7 for RuR, n = 15 for efsevin) and zVDAC2AAA (shmVDAC2AAA, n = 18 for control, n = 6 for RuR, n = 18 for efsevin) revealed
restoration of SR-mitochondria Ca2+ transfer. However, only zVDAC2 but not zVDAC2AAA was sensitive to efsevin (Kruskal–Wallis test with
Dunn's post hoc test)
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apoptosis or regulation of bioenergetics (for a review, see Naghdi &
Hajnóczky, 2016). Furthermore, although VDAC2 was identified as
the primary target of efsevin and efsevin-induced antiarrhythmic
effects were shown to depend on VDAC2 (Shimizu et al., 2015), inter-
action of efsevin with other VDAC isoforms were never investigated.
Given a high sequence conservation of the residues involved in
VDAC2 binding identified in this study, it is conceivable that efsevin
binds to VDAC isoforms 1 and 3. This effect might be less relevant
during short-term treatment of mice and fish but might have long-
term impacts on, for example, bioenergetics and thus needs to be
investigated in future studies.
Using computational docking on the crystal structure of zVDAC2,
we identified a binding pocket formed by the inner channel wall and
the N-terminal helix. The putative binding site was confirmed by
replacing three prominent residues inside the pocket by alanines
which resulted in insensitivity of the channel to efsevin in lipid bila-
yers. It is of note that we used a C-terminal His6-tag for purification
of the channel for subsequent bilayer experiments which is not pre-
sent in the structure used for computational docking. It is thus con-
ceivable that the His6-tag interferes with efsevin and promotes
effects seen in bilayer experiments. However, the His6-tag is located
approximately 25 Å away from the proposed binding site on the
opposed mouth of the channel making interference unlikely. Further-
more, we evaluated the proposed binding site by heterologous
expression of zVDAC2 without the C-terminal His6-tag in HL-1
cardiomyocytes and found that efsevin sensitivity of the channel was
again promoted through the proposed binding site. To prove translat-
ability of the results obtained from zVDAC2, we created a homology
model of hVDAC2 using zVDAC2 as a template and found that the
lowest bind energy was calculated in the same pocket in eight out of
10 individual docking experiments. The mammalian channel includes
additional 11 amino acids on the N-terminus of the channel. Unfortu-
nately, no homologous structures of this additional sequence have
been resolved so far, and coordinates for homology modelling are
missing. It is thus again conceivable that the additional N-terminus in
mammalian channels could interfere with efsevin binding. However, in
HL-1 cardiomyocytes, we observe very similar effects of efsevin on
native cells expressing the endogenous mVDAC2, which includes the
N-terminal extension and heterologously expressed zVDAC2.
Although these data do not rule out the possibility that efsevin pro-
motes its effects on the two distinct channels differently, it argues
against it.
Our data indicate that efsevin binds to the inner wall of the β-
barrel in close proximity to the N-terminal α-helix and thereby affects
channel conductance and gating. Although still not fully resolved, vari-
ous models were proposed to explain gating of VDACs. Almost all
models include a role of the N-terminal α-helix ranging from relatively
small movements of the helix inside the barrel (Mertins et al., 2012;
Shuvo, Ferens, & Court, 2016) to a large movement that place the
helix outside of the barrel, which then collapses to induce channel clo-
sure (Choudhary et al., 2010; Zachariae et al., 2012). Furthermore, a
fixation of the helix inside the pore through disulfate bridges was
reported as a possible mechanism to regulate channel gating by redox
sensing (Okazaki et al., 2015; Reina et al., 2016). Our data identified a
binding pocket for efsevin located in a groove between the N-terminal
α-helix and the inner channel wall. In all our predicted binding confor-
mations, efsevin is bound to the channel wall through hydrogen bonds
provided by N19, N207, R218, K236 or N238 plus additional hydro-
phobic interactions and interacts with a binding pocket located on the
hinge of the α-helix. Interestingly, one of the residues in the channel
wall, K236, was previously reported to form a hydrogen bond with
F18 in the α-helix (Ujwal et al., 2008), a residue that interacts with
efsevin upon efsevin binding. It is thus conceivable that efsevin inter-
feres with the interaction between the barrel and the helix in zVDAC2
and consequently affects the movement of the α-helix required to
modulate the channel. However, it should be noted that the binding
of efsevin might induce a conformational change in the channel, which
is not considered in our docking model. Further experimental and
computational investigations, like molecular dynamics simulations and
determination of the ligand-bound VDAC2 structure are thus needed
to clarify the exact mode of gating and ion conduction through the
channel in the presence and absence of efsevin.
Using an electrophysiological approach, we found efsevin-
promoted gating of zVDAC2. Already at low potentials, the channel
preferentially gates into the two closed states and only rarely returns
to the open state. We demonstrate that the efsevin-induced low con-
ducting states display less anion selectivity compared to the open
state which translates into a higher Ca2+ flux and consequently into
higher Ca2+ uptake into mitochondria in cardiomyocytes. This is in line
with previous experimental (Tan & Colombini, 2007) and computa-
tional (Zachariae et al., 2012) studies, which have shown the closed
states of VDAC to be more cation-selective. The observed shift from
the open to the closed states is especially relevant at low potentials
ranging from −40 to +40 mV. Though it is still under debate whether
a membrane potential difference exists over the outer mitochondrial
membrane, modelling data suggest a potential of approximately −20
to −27 mV (Lemeshko, 2006) and a study based on pH measurements
suggests a potential of approximately −40 mV (Porcelli et al., 2005).
This most likely explains the enhanced Ca2+ uptake into mitochondria
seen in the presence of efsevin. The data presented in this study are
thus in agreement with the concept of increased Ca2+ flux upon chan-
nel closure.
In this study, we present a binding pocket in zVDAC2 and an
associated biophysical mechanism, namely, a modification of voltage
gating and a shift towards the cation-selective closed states. VDACs
were previously suggested as promising drug targets mainly because
of their prominent role in apoptosis (for a review, see Magrì, Reina, &
De Pinto, 2018). However, it remained unclear whether the role of
VDAC in apoptosis was directly associated with the channel's gating
behaviour or rather with a modified interaction with partner proteins
such as hexokinase or members of the Bcl-2 family. In this study, we
present evidence that the efsevin-induced change in gating facilitates
transfer of Ca2+ from the SR into mitochondria. Interestingly, we
never observed an involvement of the drug in apoptosis, neither in
this study nor in previous studies (Schweitzer et al., 2017; Shimizu
et al., 2015) despite a previously identified isoform-specific role for
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VDAC2 in apoptosis through recruitment of Bax (Lauterwasser
et al., 2016; Ma et al., 2014). Efsevin could thus serve as a tool to dis-
sect these functions in future studies.
Taken together, we provide functional and structural data that
explains the interaction between zVDAC2 and its modulator efsevin
on a molecular basis. Our data provide new insights into VDAC2 func-
tion as well as a basis for computer-aided design of optimized com-
pounds that could serve as research compounds and therapeutics for
cardiac arrhythmia.
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VISUAL ABSTRACT
Schweitzer, M.K. et al. J Am Coll Cardiol Basic Trans Science. 2017;2(6):737–47.
HIGHLIGHTS
 Fast transfer of Ca2D from the
sarcoplasmic reticulum into mitochondria
in cardiomyocytes can be enhanced by the
MiCUps efsevin, targeting the VDAC2, and
kaempferol, targeting the MCU.
 Enhancing sarcoplasmic
reticulum-to-mitochondria Ca2D transfer
with MiCUps suppresses arrhythmogenic
Ca2D events and spontaneous action
potentials in cardiomyocytes from a
mouse model of CPVT.
 In vivo treatment of CPVT mice with
MiCUps reduces episodes of ventricular
tachycardia after adrenergic stimulation.
 In induced pluripotent stem cell-derived
cardiomyocytes from a CPVT patient, both
MiCUps reduce arrhythmogenic Ca2D events.
 Our data establish fast mitochondrial
Ca2D uptake as a promising candidate
structure for pharmacological treatment
of human cardiac arrhythmia.
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SUMMARY
Cardiovascular disease-related deaths frequently arise from arrhythmias, but treatment options are limited due
to perilous side effects of commonly used antiarrhythmic drugs. Cardiac rhythmicity strongly depends on
cardiomyocyte Ca2þ handling and prevalent cardiac diseases are causally associated with perturbations in
intracellular Ca2þ handling. Therefore, intracellular Ca2þ transporters are lead candidate structures for novel
and safer antiarrhythmic therapies. Mitochondria and mitochondrial Ca2þ transport proteins are important
regulators of cardiac Ca2þ handling. Here, the authors evaluated the potential of pharmacological activation of
mitochondrial Ca2þ uptake for the treatment of cardiac arrhythmia. To this aim, the authors tested substances
that enhance mitochondrial Ca2þ uptake for their ability to suppress arrhythmia in a murine model for ryanodine
receptor 2 (RyR2)-mediated catecholaminergic polymorphic ventricular tachycardia (CPVT) in vitro and in vivo
and in induced pluripotent stem cell-derived cardiomyocytes from a CPVT patient. In freshly isolated cardio-
myocytes of RyR2R4496C/WT mice efsevin, a synthetic agonist of the voltage-dependent anion channel 2 (VDAC2)
in the outer mitochondrial membrane, prevented the formation of diastolic Ca2þ waves and spontaneous action
potentials. The antiarrhythmic effect of efsevin was abolished by blockade of the mitochondrial Ca2þ uniporter
(MCU), but could be reproduced using the natural MCU activator kaempferol. Both mitochondrial Ca2þ uptake
enhancers (MiCUps), efsevin and kaempferol, significantly reduced episodes of stress-induced ventricular
tachycardia in RyR2R4496C/WT mice in vivo and abolished diastolic, arrhythmogenic Ca2þ events in human
iPSC-derived cardiomyocytes. These results highlight an immediate potential of enhanced mitochondrial
Ca2þ uptake to suppress arrhythmogenic events in experimental models of CPVT and establish MiCUps as
promising pharmacological tools for the treatment and prevention of Ca2þ-triggered arrhythmias such as CPVT.
(J Am Coll Cardiol Basic Trans Science 2017;2:737–47) ©2017 TheAuthors. PublishedbyElsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
C
ardiovascular diseases remain the leading
cause of death worldwide (1). Approximately
one-half of all cardiovascular deaths are
attributed to severe cardiac arrhythmia (2). Cardiac
rhythmicity critically depends on precisely regulated
Ca2þ oscillations in cardiomyocytes (3), and cardiac
arrhythmia is frequently associated with perturba-
tions of cellular Ca2þ handling (4,5). Most currently
used antiarrhythmic drugs target receptors and chan-
nels in the cell membrane (sarcolemma) to block the
propagation of arrhythmic events along the myocar-
dium but do not restore defective intracellular Ca2þ
handling. Due to their modulatory effects on the
cardiac action potential, these drugs often show
pro-arrhythmic side effects. Therefore, intracellular
Ca2þ transporters are candidate structures for novel
and safer antiarrhythmic therapies.
Mitochondria occupy approximately 30% of the
cardiomyocyte volume (6,7) and closely interact with
the sarcoplasmic reticulum (SR) to absorb Ca2þ, which
is released from the SR into the cytosol through car-
diac ryanodine receptors (RyR2) (8,9). For that,
mitochondria are equipped with a regulated network
of Ca2þ transporters. While the mitochondrial calcium
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uniporter (MCU) has been identified as the main route
for Ca2þ import in the inner mitochondrial membrane
(10–12), the voltage-dependent anion channel 2
(VDAC2) in the outer mitochondrial membrane has
only recently been shown to be a major part of the
Ca2þ transport route from the SR into mitochondria
(13–15). In addition to the 2 pore-forming channels,
the mitochondrial Ca2þ uptake complex is regulated
by several auxiliary subunits such as the essential
MCU regulator EMRE or the mitochondrial Ca2þ up-
take proteins MICU1 and -2 (16,17). While it is gener-
ally accepted that a slow and moderate rise of
mitochondrial Ca2þ triggers enhanced energy produc-
tion under higher workload (18), the immediate role of
mitochondria in shaping cellular Ca2þ signals on a beat-
to-beat level remains a matter of debate (19,20). Mito-
chondria have been demonstrated to be regulators of
cardiac rhythmicity (21,22), but their potential to serve
as therapeutic targets has not been evaluated so far.
The synthetic compound efsevin has been newly
identified to activate VDAC2 and to enhance mito-
chondrial Ca2þ uptake (15). Using efsevin, we demon-
strated that cardiac rhythmicity in zebrafish embryos
can be critically modulated by enhancing mitochon-
drial Ca2þ uptake (15).
This study evaluated the translational potential of
pharmacological activation of mitochondrial Ca2þ
uptake for the prevention and treatment of cardiac
arrhythmia. To this end, we used 2 models of cate-
cholaminergic polymorphic ventricular tachycardia
(CPVT), exemplifying a Ca2þ-triggered arrhythmia.
CPVT manifests in early adolescence and is character-
ized by episodes of life-threatening ventricular
tachycardia upon catecholaminergic stimulation
after physical exercise or emotional stress. The
RyR2R4496C/WT mouse harbors an R4496C mutation in
the SR Ca2þ release channel RyR2, homologous to the
human R4497C mutation, which is associated with
CPVT (23) and displays a CPVT phenotype (24). We
show that activating mitochondrial Ca2þ uptake
suppresses arrhythmia in RyR2R4496C/WT car-
diomyocytes in vitro and in RyRR4496C/WT mice in vivo.
Finally, we demonstrate that activating mitochondrial
Ca2þ uptake is likewise efficient in blocking arrhyth-
mogenesis in induced pluripotent stem cell (iPSC)-
derived cardiomyocytes from a CPVT patient hetero-
zygous for a different RyR2 mutation (RyR2S406L).
METHODS
ISOLATION OF CARDIOMYOCYTES. Isolation of ven-
tricular cardiomyocytes from heterozygous knock-in
RyR2R4496C/WT mice (24) was performed using a
Langendorff perfusion-based enzymatic digestion
protocol (25) with minor modifications. Only
excitable, rod-shaped, quiescent cells were used for
experiments.
HUMAN iPSC-BASED MODEL. iPSCs from a skin
biopsy from a CPVT patient carrying the RyR2S406L/WT
mutation and from a healthy donorwere differentiated
into spontaneously beating explants (26,27) and
enzymatically dissociated into single cardiomyocytes.
Ca2D IMAGING. Ca2þ transients, spontaneous dia-
stolic Ca2þ waves, and Ca2þ sparks were measured in
cardiomyocytes loaded with Fluo-4 acetoxymethyl
ester (AM) (Thermo Fisher Scientific, Darmstadt,
Germany), using confocal microscopy in line scan
mode. Cells were paced by extracellular electrodes at
0.5 Hz.
ELECTROPHYSIOLOGY. Action potentials were
recorded in current clamp mode, using the perforated
patch-clamp technique. Cells were paced by repetitive,
depolarizing intracellular current injections at 0.5 Hz,
followed by a 60-s pause to detect potentially pro-
arrhythmic events during this diastolic phase.
cAMP ACCUMULATION ASSAY. For evaluation of
intracellular cAMP levels, cardiomyocytes were
labeled with 3H-labeled adenine to measure accu-
mulation of [3H]cAMP over 15 min.
IN VIVO ARRHYTHMIA TESTING. Drugs were admin-
istered to RyR2R4496C/WT mice 8 to 12 weeks of age
through osmotic minipumps, and subsequently,
electrocardiography recordings were performed
under light isoflurane anesthesia, to monitor ven-
tricular tachycardia after bolus injection of epineph-
rine/caffeine (epi/caff). All animal procedures were
performed in accordance with national and European
ethical regulations (directive 2010/63/EU) and
approved by the responsible government agency
(BMWFW-66.010/0012-WF/V/3b/2015).
MITOCHONDRIAL Ca2D UPTAKE. Mitochondrial Ca2þ
uptake in response to 10mM caffeine to open RyR2was
measured in Rhod-2 AM-loaded permeabilized HL-1
cardiomyocytes (28) on a fluorescence 96-well plate
reader. The Ca2þ chelator 1,2-bis(o-aminophenoxy)
ethane-N,N,N0,N0-tetraacetic acid (BAPTA) (1 mM)
was used to restrict Ca2þ to the low micrometer range
around RyR clusters (8,29).
STATISTICAL ANALYSIS. Data are mean  standard
error of the mean. Normality of data was determined
by Shapiro-Wilk test, and respective tests for statis-
tical significance were conducted as indicated. Post
hoc tests were Dunn’s test for Kruskal-Wallis tests
and Tukey’s multiple comparisons test for ANOVA.
Significance for contingency tables was calculated
using Fisher’s exact test.
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Please see the detailed Methods in the
Supplemental Appendix.
RESULTS
EFSEVIN REDUCES ARRHYTHMOGENIC Ca2D WAVES
IN RyR2R4496C/WT CARDIOMYOCYTES. The triggers
for arrhythmia originating from imbalanced cellular
Ca2þ homeostasis, such as CPVT, are intracellular
Ca2þ waves during diastole, which arise from an
increased SR Ca2þ leak through RyR2 (30). We there-
fore recorded diastolic Ca2þ waves in freshly isolated
ventricular cardiomyocytes from RyR2R4496C/WT mice
and their wild-type (WT) littermates. Under control
conditions (vehicle), neither WT cardiomyocytes nor
RyR2R4496C/WT cells showed spontaneous Ca2þ waves
within 90 s after preceding electrical stimulation at
0.5 Hz. However, unlike WT cells, RyR2R4496C/WT
cardiomyocytes displayed pronounced spontaneous,
diastolic Ca2þ waves after stimulation with the cate-
cholamine isoproterenol (ISO) (Figures 1A to 1C).
Strikingly, application of 15 mM efsevin significantly
reduced the number of cells displaying such Ca2þ
waves and the average number of Ca2þ waves per
FIGURE 1 Efsevin Reduces Diastolic Ca2þ Waves and Spontaneous Action Potentials in RyR2R4496C/WT Cardiomyocytes
(A) Confocal line scans across the long axis of freshly isolated cardiomyocytes from wild-type and RyR2R4496C/WT mice loaded with Fluo-4 AM
to measure intracellular Ca2þ. Images show line scans, and graphs depict fluorescence intensity plots. Cells were stimulated at 0.5 Hz for 30 s
to reach steady state conditions (last 5 Ca2þ transients are shown) before pulsing was stopped and the diastolic phase was recorded for 90 s to
screen for spontaneous diastolic Ca2þ waves. (B) While wild-type cells never showed a significant frequency of spontaneous diastolic Ca2þ
waves, 25 of 68 RyR2R4496C/WT cardiomyocytes showed waves, which could be significantly reduced to 2 of 45 cells (p < 0.001, Fisher’s
exact test) by addition of 15 mM efsevin. (C) Average number of Ca2þ waves per minute was significantly enhanced from 0 in vehicle-treated
RyR2R4496C/WT cardiomyocytes to 0.46  0.09 waves/min in cells treated with 1 mM ISO (p < 0.001, Kruskal-Wallis test). Addition of 15 mM
efsevin reduced the number of waves/minute to 0.07  0.05 to levels indistinguishable from untreated cells (p ¼ 0.578). (D) Patch clamp
recordings from RyR2R4496C/WT cardiomyocytes showed an increase in spontaneous action potentials after superfusion with ISO, which were
eliminated by addition of 15 mM efsevin. (E) Quantitative analysis of patch clamp recordings revealed a significant increase of spontaneous
diastolic action potentials (APs) from 1.12  0.62 APs/min under vehicle (Veh.) to 5.76  2.45 APs/min after superfusion with ISO (p ¼ 0.018,
Friedman test, n ¼ 15) and a significant reduction to 0.58  0.34 APs/min when simultaneously treated with ISO and efsevin (p ¼ 0.011).
**p < 0.01; ***p < 0.001. ISO ¼ isoproterenol.
Schweitzer et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 6 , 2 0 1 7
Mitochondrial Ca2+ Uptake in Arrhythmia D E C E M B E R 2 0 1 7 : 7 3 7 – 4 7
740
minute in RyR2R4496C/WT cardiomyocytes to levels of
unstimulated RyR2R4496C/WT cells and WT cells.
Notably, in contrast to previous data from unstimu-
lated cells (15), efsevin did not exert any significant
effects on the amplitude and kinetics of electrically
evoked Ca2þ transients under ISO stimulation
(Supplemental Figure 1).
EFSEVIN REDUCES SPONTANEOUS ACTION POTENTIALS IN
RyR2R4496C/WT CARDIOMYOCYTES. Cardiac arrhythmia
is triggered when Ca2þwaves activate the sarcolemmal
sodium–calcium exchanger, leading to a transient
depolarizing sodium inward current and finally spon-
taneous action potentials (31), which can propagate
along the myocardium. Hence, we recorded
spontaneous action potentials in patch-clamped
RyR2R4496C/WT cardiomyocytes. We observed a signif-
icant increase in the frequency of spontaneous action
potentials after cells were superfused with 1 mM ISO.
Subsequent treatment with 15 mM efsevin effectively
reduced these spontaneous depolarizations to base-
line levels (Figures 1D and 1E). Notably, efsevin did not
exert any effects on the resting membrane potential
and amplitude of electrically evoked action potentials
under ISO stimulation but caused a significant change
of the repolarization phase (Supplemental Figure 1),
namely a prolongation of the action potential duration
at 50% repolarization (APD50) but not at 90%
repolarization (APD90). To evaluate whether this ef-
fect seen on the fast, inactivating mouse action po-
tential (32) could lead to QT prolongation in human
cells, we recorded action potentials from human iPSC-
derived cardiomyocytes in the presence of efsevin and
found no changes in APD50 and APD90 compared to
vehicle-treated cells (Supplemental Figures 2A and
2B). Furthermore, efsevin did not inhibit hERG chan-
nel activity in a heterologous expression system at
relevant concentrations (Supplemental Figure 2C).
THE ANTIARRHYTHMIC EFFECT OF EFSEVIN IS MEDIATED
BY MITOCHONDRIAL Ca2D UPTAKE. We next investi-
gated the mechanism of efsevin’s antiarrhythmic ef-
fect. To exclude the possibility that efsevin directly
blocks catecholaminergic stimulation by ISO, we
measured cAMP accumulation in efsevin-treated
RyR2R4496C/WT cardiomyocytes. Stimulation by ISO
induced a significant increase in cellular cAMP, which
was blocked by the beta-adrenoreceptor blocker pro-
pranolol. Addition of efsevin alone did not increase or
decrease cellular cAMP concentrations, and addition
of efsevin to stimulated cells had no effect on the ISO-
induced cAMP increase, indicating that efsevin does
not influence beta-adrenergic signaling in car-
diomyocytes (Figure 2).
Efsevin significantly enhanced transfer of Ca2þ
from the SR into mitochondria in a Ca2þ uptake assay
in permeabilized cultured HL-1 cardiomyocytes.
Mitochondrial Ca2þ was measured after addition of 10
mM caffeine to open RyR2s in the presence of the
Ca2þ chelator BAPTA to restrict Ca2þ released from
RyRs to the low micrometer range around RyR clus-
ters (8,29) (Figure 3A). The efsevin-sensitive Ca2þ
transfer between the SR and mitochondria was
blocked by addition of the MCU blocker ruthenium
red. To test whether the enhanced SR–mitochondria
Ca2þ transfer was directly responsible for the reduc-
tion of diastolic Ca2þ wave frequency in RyR2R4496C/
WT cardiomyocytes, we assessed whether blocking of
mitochondrial Ca2þ uptake abolished the antiar-
rhythmic effect of efsevin. We measured
catecholamine-induced Ca2þ waves in RyR2R4496C/WT
myocytes under simultaneous blockade of mito-
chondrial Ca2þ uptake, using the MCU inhibitor
Ru360 (Figure 3B). We observed a moderately higher
Ca2þ wave frequency under all conditions, consistent
with the idea that mitochondrial Ca2þ uptake pre-
vents Ca2þ wave formation. Most strikingly, the abil-
ity of efsevin to suppress the ISO-induced increase in
Ca2þ wave frequency was abolished in the presence of
Ru360, indicating that the suppression of diastolic
Ca2þ waves by efsevin is solely mediated by enhanced
mitochondrial Ca2þ uptake.
FIGURE 2 Efsevin Does Not Affect Beta-Adrenergic
Stimulation in RyR2R4496C/WT Cardiomyocytes
cAMP accumulation in freshly isolated RyR2R4496C/WT
cardiomyocytes was measured in response to different stimuli.
Efsevin had no effect on cellular cAMP levels (p>0.999, Kruskal-
Wallis test), whereas ISO induced a significant increase in cellular
cAMP (p < 0.001). This increase could be blocked using the
beta-adrenoreceptor blocker propranolol (prop) (p ¼ 0.036),
although efsevin had no effect on the ISO-induced increase in
cellular cAMP (p ¼ 0.999), indicating that efsevin neither acti-
vates nor blocks thebeta-adrenergic system in cardiomyocytes.
*p < 0.05; ***p < 0.001. Abbreviations as in Figure 1.
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We next tested if enhancing mitochondrial Ca2þ
uptake was a general pharmacological approach to
suppress arrhythmogenic events or if it is limited to a
specific effect of efsevin on VDAC2. To this purpose,
we used another activator of mitochondrial Ca2þ up-
take, the natural plant flavonoid kaempferol, which
was reported to directly activate MCU in the inner
mitochondrial membrane (33,34). Indeed, kaempferol
increased SR–mitochondria Ca2þ transfer, comparable
to efsevin (Figure 3D). To evaluate the antiarrhythmic
potential of kaempferol, we measured diastolic Ca2þ
waves in kaempferol-treated RyR2R4496C/WT car-
diomyocytes under ISO to induce catecholaminergic
stimulation. Strikingly, 10 mM kaempferol completely
eliminated ISO-induced arrhythmogenic Ca2þ waves
in RyR2R4496C/WT cardiomyocytes (Figure 3E).
It was previously reported that enhanced mito-
chondrial Ca2þ uptake in cardiomyocytes restricts
diffusion of Ca2þ inside the cytosol (13) and thereby
prevents propagation of cytosolic Ca2þ signals under
conditions of Ca2þ overload (15). Because an
enhanced RyR-mediated Ca2þ leak was reported to
be the mechanism responsible for arrhythmogenesis
in CPVT (35–37), we recorded Ca2þ sparks from
RyR2R4496C/WT cardiomyocytes (Figure 4). We
observed an increase in Ca2þ spark frequency and
amplitude after treatment with ISO, consistent with
previous work (36), thus explaining the enhanced
Ca2þ wave frequency under catecholaminergic stim-
ulation. Strikingly, the SR leak in cells treated with
ISO together with efsevin was reduced compared to
that in cells treated with ISO alone, as indicated by a
decrease in Ca2þ spark frequency and amplitude.
Also, we found removal of cytosolic Ca2þ was
accelerated under efsevin stimulation, leading to a
reduction of full width and full duration of Ca2þ
sparks. Together, these effects explain the suppres-
sive effect of efsevin on propagating Ca2þ waves.
MiCUps REDUCE EPISODES OF STRESS-INDUCED
VENTRICULAR TACHYCARDIA IN VIVO. To assess
the potency of both of the mitochondrial Ca2þ uptake
enhancers (MiCUps), efsevin and kaempferol, to sup-
press arrhythmia in vivo, we administered efsevin and
kaempferol to RyR2R4496C/WT mice, using implantable
osmotic minipumps. All mice recovered well from
surgery, and their behavior was grossly normal.
Treated mice showed no signs of discomfort, stress, or
abnormal behavior. After 3 days, efsevin and kaemp-
ferol showed no effect on electrocardiography (ECG)
parameters such as the interval between atrial
and ventricular depolarization (PR), the interval
between ventricular depolarization and subsequent
repolarization (QT), or conduction of ventricular
FIGURE 3 Efsevin Acts Through Mitochondrial Ca2þ Uptake
(A) Representative recordings of mitochondrial Ca2þ in permeabilized HL-1 cardiomyocytes.
Superfusion with caffeine induced a rapid uptake of Ca2þ into mitochondria (black trace),
which was enhanced by 15 mM efsevin and blocked by 10 mM RuR (gray trace). (B) Quantifi-
cation of peak mitochondrial fluorescence showed a significant increase in mitochondrial
Ca2þ uptake in cells treatedwith efsevin fromDF/F0¼0.140.03 (n¼ 10) to0.500.07
(n¼ 19, p < 0.001, ANOVA). (C) 15 mM efsevin reduces spontaneous propagating waves in
RyR2R4496C/WT cardiomyocytes under ISO influence from 0.36 0.16 waves/min (n¼ 15) to
0 (black bars) (n¼ 21, p ¼ 0.035, Kruskal-Wallis test). In the presence of 8 mM of the
mitochondrial Ca2þ uptake blocker Ru360, vehicle-treated cells showed 0.07 0.04
waves/min (n¼ 29), which increased to 0.63 0.16 under ISO influence (n¼ 21, p< 0.001)
but could not be blocked with efsevin as shown by an indistinguishable value of 0.62 0.12
waves/min under ISO influence together with efsevin (gray bars) (n¼ 62, p ¼ 0.354
compared to that with ISO). (D) 10 mM of the MCU activator kaempferol significantly
increasedmitochondrial Ca2þ uptake after SRCa2þ release fromDF/F0¼0.160.04 (n¼ 9)
to 0.55 0.05 (n¼ 10, p < 0.001, ANOVA) Ca2þ uptake was inhibited by 50 mM RuR
(gray bars). (E) Treatment of RyR2R4496C/WT cardiomyocytes with 10 mM kaempferol
completely eliminated ISO-induced spontaneous diastolic Ca2þ waves from 0.19 0.04
waves/min (n¼ 49) to 0 (n¼ 45; p < 0.001, Mann-Whitney U test). *p < 0.05;
***p < 0.001. DF/F0 ¼ change in fluorescence over baseline fluorescence; MCU ¼
mitochondrial Ca2þ uniporter; RuR¼ ruthenium red; SR¼ sarcoplasmic reticulum.
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depolarization (QRS) and basal heart rate (Figures 5A
and 5B). To activate their adrenergic response, we
injected mice with a bolus of 2 mg/kg epinephrine and
120 mg/kg caffeine (epi/caff). The epi/caff injection
induced a significant increase in heart rate in all 3
groups, but no differences were observed between
vehicle-treated mice and mice treated with MiCUps.
Most strikingly, both of the MiCUps significantly
reduced episodes of bidirectional ventricular tachy-
cardia under catecholaminergic stimulation. Injection
of epi/caff provoked bidirectional ventricular tachy-
cardia in all vehicle-treated control animals (n ¼ 11)
but only in 6 of 10 mice treated with efsevin and 6 of 11
mice treated with kaempferol (Figures 5D and 5E).
Comparable results were obtained from mice treated
with efsevin for 8 days (Supplemental Figure 3).
MiCUps REDUCE ARRHYTHMOGENIC Ca2D WAVES IN
iPSC-DERIVED CARDIOMYOCYTES FROM A CPVT
PATIENT. In order to evaluate the translational po-
tential of MiCUps for the treatment of CPVT, we used a
human cell-based arrhythmia model for CPVT. Human
iPSC-derived cardiomyocytes from a CPVT patient
heterozygous for the RyR2S406L mutation associated
with CPVT (26) were used to record arrhythmogenic
Ca2þ waves, whereas cells obtained from a healthy 32-
year-old female without history of cardiac disease
served as control. In accordance with the CPVT
phenotype, where patients show a normal ECG pattern
under baseline conditions, only few untreated cells
displayed Ca2þ waves (Figure 6), whereas beta-
adrenergic stimulation induced by ISO led to a signif-
icant increase in diastolic Ca2þ waves in RyR2S406L/WT
cells but did not induce Ca2þ waves in control cells.
Treatment of RyR2S406L cells with either efsevin or
kaempferol significantly reduced the number of cells
displaying Ca2þ waves and the average frequency of
Ca2þ waves per minute to baseline levels.
DISCUSSION
MITOCHONDRIA AS DRUG TARGETS. Mitochondria
occupy approximately 30% of the cardiomyocyte
volume (6,7). Although their crucial roles in ATP syn-
thesis, regulation of respiratory rate, and apoptosis are
well understood, mitochondrial contributions to car-
diac Ca2þ handling are still under debate. While it is
generally accepted that a gradual and moderate rise in
mitochondrial Ca2þ enhances energy production (18),
the role of a low-affinity/high-conductance, fast
mitochondrial Ca2þ uptake remains unclear. Different
experimental approaches suggest an immediate role
for this uptake in the regulation of cardiomyocyte
bioenergetics (38), contraction (39), and rhythmicity
(15,21), but the potential of this rapid mitochondrial
Ca2þ uptake mechanism to serve as a drug target in
cardiovascular disease has not been sufficiently eval-
uated. Itwas proposed that inhibition ofMCUbyRu360
ameliorates myocardial damage after ischemia reper-
fusion injury in rats, presumably by inhibiting depo-
larization of mitochondria and following opening of
the mitochondrial permeability transition pore (40).
FIGURE 4 Efsevin Reduces Intracellular Ca2þ Spark Frequency, Amplitude, and
Cytosolic Ca2þ Clearance Leading to a Restriction of Individual Ca2þ Sparks
(A) Representative line scan confocal images from RyR2R4496C/WT cardiomyocytes show
spontaneous Ca2þ sparks. (B) Treatment with ISO induced a higher spark frequency and
amplitude and accelerated cytosolic Ca2þ removal (taudecay) leading to narrower
(full width) and shorter (full duration) sparks. Administration of efsevin reduced Ca2þ
spark frequency (p ¼ 0.049, Kruskal Wallis test) and amplitude (p < 0.001, Kruskal
Wallis test) and limited spatial (p < 0.001, Kruskal Wallis test) and temporal (p ¼ 0.002,
Kruskal Wallis test) expansion of Ca2þ sparks. *p < 0.05; **p < 0.01; ***p < 0.001.
Abbreviations as in Figure 1.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 6 , 2 0 1 7 Schweitzer et al.
D E C E M B E R 2 0 1 7 : 7 3 7 – 4 7 Mitochondrial Ca2+ Uptake in Arrhythmia
743
However, in healthy myocardium, the role of fast
mitochondrial Ca2þuptake remains elusive. Regarding
arrhythmia, protective (22) as well as pro-arrhythmic
(41) effects of activated mitochondria were discussed.
We have recently identified the novel compound
efsevin, which binds to the outer mitochondrial
membrane VDAC2, enhances mitochondrial Ca2þ up-
take, and restores rhythmic cardiac contractions in a
zebrafish model for Ca2þ-induced cardiac arrhythmia
(15). Here we show that enhancing mitochondrial Ca2þ
uptake by using MiCUps efficiently suppresses
arrhythmia in a murine and a human model of CPVT
in vitro and in vivo. Our results establish pharmaco-
logical activation of rapid mitochondrial Ca2þ uptake
as a novel preventive and therapeutic strategy against
CPVT. We have previously shown that efsevin sup-
presses arrhythmia in cellular models for Ca2þ over-
load induced by high extracellular Ca2þ (15). Thus, due
to their potent role of suppressing arrhythmogenic
Ca2þ waves in both Ca2þ overload (15) and CPVT, it is
conceivable that MiCUps may also be applied in other
more common forms of Ca2þ-induced cardiac ar-
rhythmias. These include arrhythmias in the setting of
heart failure, which are triggered by cellular Ca2þ
overload or atrial fibrillation, also linked to imbalances
in cardiomyocyte Ca2þ handling (5). This study serves
as a proof-of-principle, holding great promise for
additional indications.
OPTIMIZED MiCUps. Our work shows that enhancing
mitochondrial Ca2þ uptake efficiently reduces
arrhythmia in experimental models of CPVT. In order
to develop MiCUps toward human therapeutics,
several steps of optimizationmust be taken. Candidate
compounds need to be optimized to achieve a high
affinity MiCUp with low side effects and suitable
pharmacokinetics for application in human subjects.
We show that the antiarrhythmic effect can be ach-
ieved by activation of at least 2 distinct target proteins
within the mitochondrial Ca2þ uptake complex: efse-
vin, targeting VDAC2 in the outer mitochondrial
membrane, and kaempferol, targeting MCU in the
FIGURE 5 MiCUps Reduce Episodes of Ventricular Tachycardia in RyR2R4496C/WT Mice
Three-lead surface ECGs from RyR2R4496C/WT mice receiving efsevin or kaempferol through an osmotic minipump are shown. After a baseline
ECG was recorded, mice were injected with epi/caff as an adrenergic stimulus. Basic parameters of the ECG like PR (A), QT (B), and QRS (C)
intervals were comparable between the vehicle-treated group and both of the MiCUp-treated groups at baseline and after epi/caff challenge
(Kruskal-Wallis test). (D) Heart rate increased upon administration of epi/caff in all 3 groups but remained unaffected by the administration
of MiCUps (Kruskal-Wallis test). (E) Examples of a normal ECG recording and a recording showing bidirectional ventricular tachycardia.
(F) Episodes of bidirectional ventricular tachycardia were recorded in 11 of 11 vehicle-treated mice but were significantly reduced to 6 of 10 in
mice with efsevin and 6 of 11 in mice with kaempferol (p ¼ 0.035, Fisher’s exact test). *p < 0.05. ECG ¼ electrocardiography; epi/caff ¼
epinephrine/caffeine; MiCUp ¼ mitochondrial calcium uptake enhancer.
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inner membrane. Suppression of arrhythmia is
thus attributable to enhanced mitochondrial Ca2þ up-
take and is independent of the molecular target
protein within the fast mitochondrial Ca2þ uptake
complex. Our work thus establishes the entire
protein complex as a pharmacological target structure
and allows for future optimization of this therapeutic
concept through novel compounds and targets. Apart
from VDAC2 and MCU, the auxiliary MCU regulators
MICU1 and -2, MCUb, EMRE, and MCUR1 (16,17) may
serve as future candidate targets.
SIDE EFFECTS. Mitochondrial Ca2þ uptake proteins
such as VDAC2 and MCU are ubiquitously expressed.
Regarding a therapeutic application, it is thus impor-
tant to evaluate potential side effects of a MiCUp-
based therapy. It is important to note that we did not
observe any adverse effects of MiCUps in mice treated
with efsevin or kaempferol for 3 to 8 consecutive days.
Furthermore, kaempferol was previously used in ani-
mal experiments, and no adverse effects, even after up
to 1 year of treatment or at high doses, were observed
(42–44). However, further long-term experiments and
large animal studies are needed to further evaluate
safety of a MiCUp-based therapy. Although we did not
observe changes in cytosolic Ca2þ in our experiments,
long-term effects of enhanced mitochondrial Ca2þ
uptake on a potential redistribution of cellular Ca2þ in
the heart and other organs must be evaluated.
Furthermore, because an enhanced mitochondrial
Ca2þ uptake was observed to activate mitochondrial
metabolism and reactive oxygen species production,
special focus should be directed toward side effects
related to changes in cellular bioenergetics.
Common side effects of actual antiarrhythmic drugs
like Naþ, Kþ, and Ca2þ channel blockers include
FIGURE 6 MiCUps Reduce Spontaneous Ca2þ Waves in Human iPSC-derived Cardiomyocytes
Confocal line scans of iPSC-derived human cardiomyocytes from a CPVT patient (RyR2S406L/WT) and a healthy individual are shown (control).
(A) Confocal line scans across iPSC-derived human cardiomyocytes loaded with Fluo-4 AM to measure intracellular Ca2þ and intensity plots
show that stimulation with ISO does not induce spontaneous, diastolic Ca2þ waves in control cells but induced waves in RyR2S406L/WT
cardiomyocytes. These waves can be blocked with either 15 mM efsevin (upper right panel) or 10 mM kaempferol (lower right panel).
(B) Quantitative analysis revealed a significant reduction in the number of RyR2S406L/WT cells showing ISO-induced Ca2þ waves upon
treatment with MiCUps, to a level comparable to that of unstimulated cells (asterisks denote significance compared to RyR2S406L/WT þISO
by Fisher’s exact test). (C) Quantification of waves/min reveal a significant reduction from 3.78  0.72 waves/min in RyR2S406L/WT car-
diomyocytes treated with ISO to levels indistinguishable from control after treatment with efsevin (0.15  0.15; p < 0.001 compared to
ISO: p ¼ 0.884 compared to vehicle, Kruskal-Wallis test) or kaempferol, respectively (0.21  0.14, p < 0.001 compared to ISO; p ¼ 0.980
compared to vehicle, Kruskal-Wallis test). ***p < 0.001. CPVT ¼ catecholaminergic polymorphic ventricular tachycardia; iPSC ¼ induced
pluripotent stem cell; other abbreviations as in Figure 1.
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changes in cardiac electrophysiology like deceleration
of cardiac de- or repolarization, the latter often
expressed as a prolonged QT interval. We observed an
effect of efsevin on the repolarization phase of the
action potential in mice (Supplemental Figure 1),
namely a prolongation of APD50 but not APD90.
However, whereas repolarization in mice is carried
mainly by fast potassium currents (Ito, IK, slow), the
human action potential displays a pronounced plateau
phase, and phase 3 repolarization is carried predomi-
nantly by the delayed Kþ currents IKr and Iks (32). To
rule out the possibility that the observed prolongation
of APD50 by efsevin in mice could be relevant for hu-
man therapy, we showed that efsevin does not influ-
ence action potential duration in human iPSC-derived
cardiomyocytes and does not block hERG activity. It is
thus conceivable that efsevin has a direct impact on
the fast repolarizing currents in mice but does not in-
fluence the human action potential. Most importantly,
however, we did not observe effects of MiCUp
administration on ECG parameters like PR, QT, and
QRS interval and heart rate in mice treated with
MiCUps. Because MiCUps target intracellular struc-
tures to suppress the generation of ectopic de-
polarizations and do not influence the cardiac action
potential, they might be less prone to severe side ef-
fects like, for example, the typical pro-arrhythmic ef-
fects observed with class I or III antiarrhythmic drugs.
However, the murine repertoire of ion channels gov-
erning the cardiac action potential of mice varies from
the human one, and additional experiments in other
mammalian species are needed to solve this issue.
CONCLUSIONS
Common antiarrhythmic drugs aim at inhibiting
expansion of ectopic activity and display perilous side
effects. Because major arrhythmias are often associ-
ated with imbalanced intracellular Ca2þ homeostasis
(3–5), intracellular Ca2þ transporters are attractive
candidates for newer and safer therapies. Here we
show that enhancing mitochondrial Ca2þ uptake by
pharmacological agonists of the mitochondrial Ca2þ
uptake proteins VDAC2 and MCU efficiently
suppresses arrhythmia in amurine and a humanmodel
for CPVT. Our data establish MiCUps as attractive
compounds for a novel preventive and therapeutic
strategy to treat Ca2þ-triggered cardiac arrhythmias.
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